{"title":"Farmaci e Sciroppi per la Tosse Secca e Grassa","description":"\u003cp\u003eRimedi per la tosse secca e per quella grassa: sedativi della tosse a base di destrometorfano, mucolitici ed espettoranti con acetilcisteina e carbocisteina, sciroppi vegetali con miele e piantaggine, pastiglie balsamiche e caramelle. Formati per adulti e per bambini. Spedizione veloce in 24\/48 ore.\u003c\/p\u003e","products":[{"product_id":"sciroppo-tre-azioni-tosse-e-mal-di-gola-150ml-dr-tili","title":"Syrup Three Actions cough and sore throat 150ml Dr.Tili","description":"\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Made_in_Italy.png?v=1668012159\" alt=\"Supplement made in Italy\" width=\"125\" height=\"125\" style=\"float: none;\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Made_in_Italy.png?v=1668012159\" data-mce-style=\"float: none;\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg height=\"125\" width=\"125\" alt=\"gluten-free supplement\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_glutine_480x480.png?v=1668012159\" data-mce-fragment=\"1\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_glutine_480x480.png?v=1668012159\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg height=\"125\" width=\"125\" alt=\"lactose-free supplement\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_lattosio_480x480.png?v=1668012159\" data-mce-fragment=\"1\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_lattosio_480x480.png?v=1668012159\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg height=\"125\" width=\"125\" alt=\"vegan supplement\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ingredienti_vegani_480x480.png?v=1668012159\" data-mce-fragment=\"1\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ingredienti_vegani_480x480.png?v=1668012159\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eFood supplement based on high-titration phytotherapeutic extract of snail slime, grindella, thyme, poppy, sundew and propolis. Contributes to \u003cstrong\u003eclear the airways\u003c\/strong\u003e, \u003cstrong\u003ecalm dry or wet cough\u003c\/strong\u003e and others \u003cstrong\u003edissolve and eliminate phlegm\u003c\/strong\u003e. \u003cstrong\u003eAlso suitable for children\u003c\/strong\u003e thanks to the addition of honey which gives it an excellent flavour.\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003esnail slime\u003c\/strong\u003e owes his \u003cstrong\u003eexpectorant and fluidizing properties\u003c\/strong\u003e to high viscosity mucins and certain enzymes contained therein. The former can form a \u003cstrong\u003eprotective film on the mucous membranes\u003c\/strong\u003e, reducing contact with irritants. The latter are capable of \u003cstrong\u003ebreak the bonds between the molecules that make up mucus\u003c\/strong\u003e, reducing its viscosity. Snail slime extract is a remedy for dry coughs, oily coughs and sore throats that can help thin bronchial mucus and eliminate it thanks to its properties. \u003cstrong\u003enatural mucolytic and antitussive properties\u003c\/strong\u003e. \u003c\/p\u003e\n\u003cp\u003eIndicated in case of: wet cough, dry cough, catarrh, sore throat.\u003c\/p\u003e\n\u003cp\u003eI \u003cstrong\u003epoppy flowers\u003c\/strong\u003e contain a large amount of \u003cstrong\u003ealkaloids, mucilages and anthocyanins\u003c\/strong\u003e. These have excellent \u003cstrong\u003edecongestant and expectorant properties\u003c\/strong\u003e which help to naturally eliminate phlegm and calm coughs.\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003eDrosera\u003c\/strong\u003e it is an insectivorous plant whose name means \"dewy, covered with dew\". For this reason it is often called \u003cstrong\u003eSun Dew\u003c\/strong\u003e. In fact, the sundew has real colored tentacles on the leaves. These secrete tiny drops of sugary, viscous and shiny mucilage. Drosera was already used in ancient times as \u003cstrong\u003eremedy for respiratory tract infections\u003c\/strong\u003e, for \u003cstrong\u003ecalm the cough\u003c\/strong\u003e e \u003cstrong\u003edissolve phlegm\u003c\/strong\u003e. They are recognized \u003cstrong\u003ebronchosedative properties\u003c\/strong\u003e, \u003cstrong\u003edecongestants\u003c\/strong\u003e ed \u003cstrong\u003eexpectorants\u003c\/strong\u003e \u003cstrong\u003enatural\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003ePropolis\u003c\/strong\u003e it is mostly composed of resins, balms and waxes. Rich in flavonoids and polyphenols, it also has a high content of mineral salts and B vitamins. Thanks to the composition of caffeic acid and flavonoids, propolis has \u003cstrong\u003enatural anti-inflammatory properties\u003c\/strong\u003e. Excellent in case of \u003cstrong\u003einflamed mucous membranes\u003c\/strong\u003e e \u003cstrong\u003ediseases of the upper respiratory tract\u003c\/strong\u003e. Propolis is also very useful in case of seasonal allergies.\u003cbr\u003eIt is indicated in cases of: burning throat, inflamed mucous membranes, colds and seasonal allergies.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy should you use Tre Azioni Cough and Sore Throat Syrup 150ml Dr.Tili? What is it for?\u003c\/h3\u003e\u003cp\u003eFood supplement based on snail slime, grindella, thyme, poppy, sundew and propolis, useful for promoting the functionality of the respiratory tract; It helps to calm dry or wet coughs and to thin and eliminate phlegm. Formulated with honey, also suitable for children.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Dr.Tili Tre Action Cough and Sore Throat Syrup 150ml contain?\u003c\/h3\u003e\u003cp\u003eFructose syrup. Purified water. Eucalyptus honey (15%). Snail extract. Thyme leaf e.f. (thymus vulgaris L.). Propolis resin d.e. tit. 8-12% in galangin. Grindelia flowering herb (grindelia robusta nut.) d.e. d\/e 4:1. Drosera flowering herb (Drosera rotundifolia l.) d.e. d\/e 4:1. Strawberry flavour. Preservatives: sodium benzoate and potassium sorbate. Acidifier: citric acid. \u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eMEDIA ANALYSIS\u003c\/h2\u003e\n\u003ch3\u003eWhat does Dr.Tili Tre Action Cough and Sore Throat Syrup 150ml contain?\u003c\/h3\u003e\u003cp\u003eSnail extract: 1800 mg.\u003c\/p\u003e\u003cp\u003eGrindella d.e.: 400 mg.\u003c\/p\u003e\u003cp\u003eThyme fluid extract: 600 mg.\u003c\/p\u003e\u003cp\u003ePoppy d.e.: 265 mg.\u003c\/p\u003e\u003cp\u003eDrosera d.e.: 265 mg.\u003c\/p\u003e\u003cp\u003ePropolis d.e.: 400 mg.\u003c\/p\u003e\u003cp\u003eof which galangin 40 mg.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Tre Azioni Cough and Sore Throat Syrup 150ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003eWe recommend a spoonful of Dr.Tili Tre Azioni Cough and Sore Throat Syrup 3\/4 times a day (away from meals) pure or diluted in herbal teas, juices, milk or other drinks. Shake before use.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Tre Azioni Cough and Sore Throat Syrup 150ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003eSupplements are not intended as substitutes for a varied, balanced diet and a healthy lifestyle.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Dr.Tili Tre Action Cough and Sore Throat Syrup 150ml stored?\u003c\/h3\u003e\u003cp\u003eDrinkable food preparation to be stored in a cool, dry place (with a temperature below 30°) and not exposed to sunlight. Once opened, keep in the refrigerator and consume within 30 days.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Tre Azioni Cough and Sore Throat Syrup 150ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003e150ml\u003c\/p\u003e","brand":"Tilab","offers":[{"title":"Default Title","offer_id":40207819636851,"sku":"974015873","price":16.9,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/tilab-srl-sciroppo-tre-azioni-tosse-e-mal-di-gola-150ml-dr-tili-farmacia-dottor-tili-1213792882.jpg?v=1767123790"},{"product_id":"fluibron-aerosol-20-fiale-15-mg-2-ml","title":"Fluibron Aerosol 20 vials 15mg\/2ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTreatment of secretion disorders in acute and chronic bronchopulmonary diseases.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 ml of sterile solution contains: Active ingredient: Ambroxol hydrochloride 750 mg. A single-dose container contains 15 mg of ambroxol hydrochloride. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSodium chloride, water for injections.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Severe hepatic and\/or renal alterations. First three months of pregnancy (see par. 4.6) \u003ci\u003ePediatric population\u003c\/i\u003e The medicine is contraindicated in children under 2 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003e Pediatric population\u003c\/i\u003e FLUIBRON must not be used in children under 2 years of age due to safety concerns (paragraph 4.8). Adults and children over 5 years of age: one single-dose container, 2 times a day. Children aged 2 to 5 years: half a container or a single-dose container, 1-2 times a day. Do not exceed the recommended doses. Do not use for prolonged treatments. After a short period of treatment without appreciable results, consult your doctor. \u003cu\u003eMethod of administration\u003c\/u\u003e The solution can be administered using normal aerosol therapy devices. It can also be diluted in distilled water in the ratio 1:1. To use, carry out the following operations: 1) Flex the single-dose container in both directions. 2) Detach the single-dose container from the strip first at the top and then in the center. 3) Open the single-dose container by rotating the flap in the direction indicated by the arrow. 4) By exerting moderate pressure on the walls of the single-dose container, release the medicine in the prescribed quantity and introduce it into the nebulizer ampoule. 5) If half the dose is used, the container can be closed as indicated in the information leaflet. The closed container must be stored at a temperature between 2°C and 8°C (in the refrigerator) and the remaining quantity must be used within 12 hours of first opening.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSingle-dose containers must be stored inside the protective bag, protected from light. If half the dose is used, the closed container should be stored at a temperature between 2°C and 8°C (in the refrigerator) and used within 12 hours.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003ePediatric population\u003c\/u\u003e \u003c\/i\u003e Mucolytics can induce bronchial obstruction in children under 2 years of age. In fact, the drainage capacity of bronchial mucus is limited in this age group, due to the physiological characteristics of the respiratory tract. They should therefore not be used in children under 2 years of age (see section 4.3). Since inhaling aerosols too deeply can cause an irritating cough, you should try to inhale and exhale normally during inhalation. In particularly sensitive patients, pre-warming the inhaled product to body temperature may be recommended. For patients suffering from bronchial asthma it is advisable to use a bronchial spasmolytic before inhalation. Fluibron should be administered with caution in patients with peptic ulcers. Cases of serious skin reactions such as erythema multiforme, Stevens-Johnson syndrome (SJS)\/toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP) have been reported associated with the administration of ambroxol. If symptoms or signs of progressive skin rash are present (sometimes associated with blisters or mucosal lesions), treatment with ambroxol should be stopped immediately and a doctor should be consulted. The majority of these cases can be explained by the severity of the patient's underlying disease and\/or concomitant therapy. Additionally, during the early phase of Stevens-Johnson syndrome or TEN, patients may experience nonspecific flu-like prodromes such as fever, muscle aches, rhinitis, cough, and sore throat. Because of these misleading, nonspecific flu-like prodromes, symptomatic treatment with cough-and-cold medications may be instituted. Therefore, if new lesions of the skin or mucous membranes appear, it is necessary to immediately consult your doctor and discontinue treatment with ambroxol hydrochloride as a precaution. In the presence of mild or moderate renal insufficiency, Fluibron should be used only after consulting your doctor. As with any medicinal product with hepatic metabolism followed by renal elimination, accumulation of ambroxol metabolites generated in the liver may occur in severe renal insufficiency.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFollowing the administration of ambroxol, the concentrations of antibiotics (amoxicillin, cefuroxime, erythromycin) in bronchopulmonary secretions and saliva are increased. No interactions with other medicinal products have been observed.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt the recommended doses the medicine is normally well tolerated. The following side effects were observed during therapy with ambroxol hydrochloride, with the frequencies: Very common ≥1\/10 Common ≥1\/100 and \u003c1\/10 Uncommon ≥1\/1,000 and \u003c1\/100 Rare ≥1\/10,000 and \u003c1\/1,000 Very rare \u003c1\/10,000 Not known not known (the frequency cannot be estimated based on available data)\u003c\/p\u003e\n\u003cp\u003eImmune System Disorders - Adverse reaction: Hypersensitivity reactions. Frequency: Rare.\u003c\/p\u003e\n\u003cp\u003eImmune System Disorders - Adverse Reaction: Anaphylactic reactions, including anaphylactic shock, angioedema and pruritus. Frequency: Not known.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Adverse reaction: Dysgeusia (e.g. alteration of the sense of taste). Frequency: Common.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Adverse reaction: Headache. Frequency: Rare.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Adverse reaction: Hypoesthesia of the oral cavity and pharynx. Frequency: Common.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Adverse reaction: Bronchial obstruction. Frequency: Not known.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Adverse reaction: Nausea. Frequency: Common.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Adverse reaction: Vomiting, diarrhea, dyspepsia and abdominal pain, dry mouth. Frequency: Uncommon.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Adverse reaction: Dry throat. Frequency: Not known.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Adverse reaction: Rash, urticaria. Frequency: Rare.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Adverse reaction: Serious cutaneous adverse reactions (including erythema multiforme, Stevens-Johnson syndrome\/toxic epidermal necrolysis and acute generalized exanthematous pustulosis). Frequency: Not known.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at \u003cu\u003ehttp:\/\/www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetta-reazione-avversa\u003c\/u\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known cases of overdose with Fluibron for inhalation use. The symptoms observed in cases of accidental overdose and\/or in cases of errors in administration of the medicinal product are consistent with the expected side effects of ambroxol hydrochloride at recommended doses and may require symptomatic treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAmbroxol hydrochloride crosses the placental barrier. Animal studies have not shown any direct or indirect harmful effects on pregnancy, embryonic\/foetal development, parturition or postnatal development. Clinical studies and extensive clinical experience after the 28th week of pregnancy have shown no evidence of harmful effects on the fetus. However, it is recommended that you observe the usual precautions regarding the use of medicines during pregnancy. Particularly during the first trimester, the use of Fluibron is not recommended. Ambroxol hydrochloride is secreted into breast milk. Although no side effects on infants are expected, the use of Fluibron is not recommended in breastfeeding mothers.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere is no evidence of effects on the ability to drive or use machines.\u003c\/p\u003e","brand":"Chiesi","offers":[{"title":"Default Title","offer_id":40207824420979,"sku":"024596153","price":16.15,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/chiesi-farmaceutici-spa-fluibron-aerosol-20-fiale-15-mg-2-ml-farmacia-dottor-tili-1213792734.webp?v=1767126819"},{"product_id":"vicks-vaporub-unguento-inalante-50-g","title":"Vicks Vaporub Inhalant Ointment 50 g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBalsamic treatment for diseases of the upper respiratory tract.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of ointment contains: \u003ci\u003eactive ingredients\u003c\/i\u003e: camphor 5 g; turpentine essential oil 5 g; menthol 2.75 g; eucalyptus essential oil 1.5 g. For the complete list of excipients see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThymol, cedarwood essential oil, white petrolatum.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Children up to 30 months of age. Administration through steam inhalation is contraindicated in children under 12 years of age. Children with a history of epilepsy or febrile convulsions. Generally contraindicated during pregnancy and breastfeeding (see section 4.6).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVicks Vaporub is contraindicated in children up to 30 months of age and vapor inhalation is contraindicated in children under 12 years (see section 4.3). Children must always be supervised. Vicks Vaporub ointment can be used in two ways: \u003cb\u003e1) Topical use (\u003cu\u003eadults and children over 30 months of age\u003c\/u\u003e)\u003c\/b\u003e Apply externally by first rubbing the chest, throat and back for 3 - 5 minutes and then spreading a thick layer on the chest. Repeat the treatment 2 times a day, one in the evening before going to sleep. Do not rub more than twice a day on the front of the chest, neck and back. Wear loose clothing to facilitate inhalation of vapours. \u003cb\u003e2) Inhalations (\u003cu\u003eadults and children over 12 years of age\u003c\/u\u003e)\u003c\/b\u003e Dissolve 2 teaspoons (2x5 ml) in half a liter of hot (not boiling) water and aspirate the released steam for a time not exceeding 10 minutes. To avoid the risk of serious burns, do not heat the mixture a second time or heat the mixture during inhalation (see section 4.4). Do not heat in the microwave. Do not exceed the recommended doses. The duration of treatment should not exceed 3 days. \u003ci\u003eTHE PRODUCT MUST NOT BE INGESTED\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUse the product according to the instructions. For external use only. Do not apply on wounds, abrasions and mucous membranes. Do not ingest or apply directly into the nostrils, eyes, mouth or face. Do not make a tight bandage. Do not use with hot compress or any type of heat. This product contains terpene derivatives which, in excessive doses, can cause neurological disorders such as seizures in infants and children. If symptoms persist, consult your doctor. The product should be used with caution or under medical suggestion by patients who present: • hypersensitivity reactions to perfumes or solvents; • convulsions or epilepsy (it is contraindicated in children with a history of epilepsy or febrile convulsions, see section 4.3); • Marked hypersensitivity of the respiratory tract including those conditions such as asthma and chronic obstructive pulmonary disease (COPD) as it can cause bronchospasm in these patients Inhalations: In order to avoid the risk of serious burns, do not use boiling water to prepare inhalations. Do not heat the mixture in the microwave and do not heat it again during and after use (see also section 6.6). The treatment must not be prolonged for more than 3 days due to the risks associated with the accumulation of terpene derivatives, such as \u003ci\u003ecamphor, cineol, niaouli, wild thyme, terpineol, terpine, citral, menthol and essential oils of pine needle, eucalyptus and turpentine\u003c\/i\u003e (due to their lipophilic properties the rate of metabolism and disposal is not known) in tissues and the brain, in particular neuropsychological disorders. A higher than recommended dose should not be used to avoid an increased risk of adverse drug reactions and disorders associated with overdose (see section 4.9). The product is flammable, it must not be brought near flames.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVicks Vaporub must not be used concomitantly with other products (medicines or cosmetics) containing terpene derivatives, regardless of the route of administration (oral, rectal, cutaneous, nasal or inhalation).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects may occur with the use of the medicine. Such effects may occur with the following frequency categories: Very common (≥1\/10) Common (≥1\/100; \u003c1\/10) Uncommon (≥1\/1,000; \u003c1\/100) Rare (≥1\/10,000; \u003c1\/1,000) Very rare (\u003c1\/10,000) Not known (frequency cannot be predicted from the available data). \u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e Not known: erythema or heat erythema (redness and sensation of heat in the skin caused by camphor and menthol, which have rubefacient effects), skin irritation, allergic dermatitis, itching. \u003cb\u003eImmune system disorders\u003c\/b\u003e Not known: hypersensitivity, symptom of respiratory allergy (dyspnea and cough). If such events occur, treatment should be suspended and the necessary clinical measures adopted. \u003cb\u003eEye pathologies\u003c\/b\u003e Not known: eye irritation (following topical use or inhalation). \u003ci\u003eSystemic pathologies and conditions relating to the administration site\u003c\/i\u003e: Due to the recommended route of administration, systemic exposure is very low and no undesirable effects due to systemic exposure have been observed. Not known: burns at the application site. Other adverse events may be linked to improper use of the product (ingestion), in this regard see paragraph 4.9. \u003cb\u003e \u003cu\u003ePediatric population\u003c\/u\u003e \u003c\/b\u003e Due to the presence of camphor, turpentine essential oil, menthol and eucalyptus essential oil and in case of non-compliance with the recommended doses there may be a risk of convulsions in children and infants. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: http:\/\/www.agenziafarmaco.gov.it\/content\/comesegnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn case of accidental oral intake or incorrect administration in newborns and children there may be a risk of neurological disorders. If necessary, administer appropriate symptomatic treatment in specialized treatment centers. Overdose can cause skin irritation. \u003cu\u003eImproper use\u003c\/u\u003e: Ingestion of the ointment may cause gastrointestinal symptoms such as vomiting and diarrhea. Treatment is symptomatic. Acute poisoning has been observed following significant accidental intake with nausea, vomiting, abdominal pain, headache, dizziness, feeling hot\/hot flashes, convulsions, respiratory depression and coma. Patients with severe gastrointestinal or neurologic symptoms of poisoning should be observed and treated symptomatically. Do not induce vomiting. A) Topical administration: in the event of application of an excessive dose topically, skin irritation reactions may rarely occur. In this case, remove the excess product with a paper towel and administer, if necessary, an adequate therapy for such reactions. B) Inhalation: the symptoms and treatment are the same as in case of accidental ingestion. C) Accidental ingestion: the symptoms are mainly due to the presence of camphor. These include gastrointestinal problems such as nausea, vomiting and diarrhea. In the event of significant overdose, effects on the central nervous system are possible, such as ataxia, convulsions and respiratory depression. Treatment must be symptomatic and gastric lavage can be performed if necessary. In the presence of serious symptoms of poisoning at a gastrointestinal or neurological level, the patient must immediately consult his doctor for appropriate therapeutic measures.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003cu\u003ePregnancy\u003c\/u\u003e \u003c\/b\u003e There are no or limited data available on the use of camphor, turpentine essential oil, menthol, eucalyptus essential oil in pregnant women. There are no clinical data relating to the use of the components of Vicks Vaporub during pregnancy. Camphor is able to cross the placenta but there is no data on the other components. Animal studies do not indicate harmful effects, direct or indirect, on pregnancy, embryonic\/foetal development, parturition or postnatal development (see section 5.3). However, Vicks Vaporub is not recommended during pregnancy and in women of childbearing potential who are not using contraceptive measures. The use of the drug during pregnancy should only take place after consulting your doctor. \u003cb\u003e \u003cu\u003eBreastfeeding\u003c\/u\u003e \u003c\/b\u003e There is insufficient information on the excretion of camphor, turpentine essential oil, menthol, eucalyptus essential oil in breast milk. There are no clinical data relating to the use of the components of Vicks Vaporub during breastfeeding. Vicks Vaporub should not be used during breastfeeding. The product, applied to the mother's chest during breastfeeding, poses a potential risk of apneic reflex in the breast-fed infant.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVicks Vaporub does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Procter \u0026 Gamble","offers":[{"title":"Default Title","offer_id":40207831629939,"sku":"021625064","price":11.02,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/procter-gamble-vicks-vaporub-unguento-inalante-50-g-farmacia-dottor-tili-1254211152.jpg?v=1786731971"},{"product_id":"isomar-spray-acqua-di-mare-e-acido-ialuronico-100ml","title":"Isomar Spray Sea Water and Hyaluronic Acid 100ml","description":"\u003cp\u003e\u003cspan style=\"text-align: justify;\" data-mce-style=\"text-align: justify;\"\u003eIsomar Spray is an isotonic and sterile solution based on \u003cstrong\u003eCinque Terre sea water and hyaluronic acid,\u003c\/strong\u003e for daily nose and ear hygiene. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eIsomar Spray Sea Water and Hyaluronic Acid is a solution suitable for \u003cstrong\u003ecolds, bronchitis, sinusitis, asthma, allergies\u003c\/strong\u003e generally also from pollen and for those who work in closed environments in the presence of dust. Indispensable for those who have suffered \u003cstrong\u003enasal interventions and for those who snore during sleep\u003c\/strong\u003e(acute and chronic bronchopathies).\u003c\/p\u003e\n\u003cp\u003eIsomar Daily Hygiene Spray is particularly recommended in pediatric age, starting from the first year of age, in pregnant women and during the breastfeeding period. With its characteristic \u003cstrong\u003efluidizing action\u003c\/strong\u003e it can be\u003cstrong\u003e used daily to increase the humidity of the nasal mucosa\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eIn children who have not yet fully mastered blowing their nose, it promotes greater patency of the nostrils. In adults it allows better drainage of nasal mucus. With its physiological action it is the \u003cstrong\u003eoptimal product for prolonged and frequent use for both children and adults\u003c\/strong\u003e. \u003c\/p\u003e\n\u003cp\u003eWith the \u003cstrong\u003ealternative nebulizer\u003c\/strong\u003e is indicated for \u003cstrong\u003eear cleaning and washing\u003c\/strong\u003e. It prevents the formation of earwax plugs and the accumulation of unwanted particles which could cause hearing problems. \u003cstrong\u003eIt also helps keep the auditory canal clear\u003c\/strong\u003e in the subjects \u003cstrong\u003ehearing aid wearers\u003c\/strong\u003e. The nebulization feature prevents any overpressure on the tympanic membrane.\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e2 nose and ear nebulizers.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy use Isomar Spray Sea Water and Hyaluronic Acid 100ml? What is it for?\u003c\/h3\u003e\u003cp\u003eSterile isotonic solution based on sea water and hyaluronic acid, indicated for the daily hygiene of the nose and ears; thanks to its fluidifying and hydrating action on the nasal mucous membranes, it is useful as an adjuvant in case of colds, sinusitis and allergies, and is also indicated in pediatric age from the first year of life, during pregnancy and during breastfeeding.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Isomar Spray Sea Water and Hyaluronic Acid 100ml contain?\u003c\/h3\u003e\u003cp\u003eIsotonic sea water.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Isomar Spray Sea Water and Hyaluronic Acid 100ml?\u003c\/h3\u003e\u003cp\u003eFor the nose: one\/two 2-second sprays per nostril. We recommend using it in a vertical position, to allow the product to flow out evenly and to obtain over 300 sprays.\u003cbr\u003eFor the ear: spray once\/twice. It can be used several times a day.\u003cbr\u003eFor those who practice underwater disciplines: use regularly before and after diving. Humidifies the nasal mucosa dried out by the mask or the compressed air from the cylinders.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Isomar Spray Sea Water and Hyaluronic Acid 100ml?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWarnings\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003ePressurized container. Protect from sunlight and do not expose to temperatures above 50°C. Do not burn or pierce even after use.\u003cbr\u003eUse the product only for its intended use.\u003cbr\u003eKeep out of reach of children.\u003cbr\u003eFailure to check the integrity of the product could alter its functional characteristics.\u003cbr\u003eDo not use after the expiry date.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Isomar Spray Sea Water and Hyaluronic Acid 100ml?\u003c\/h3\u003e\u003cp\u003e100ml spray bottle, with 2 nose and ear sprays.\u003c\/p\u003e","brand":"Euritalia Pharma","offers":[{"title":"Default Title","offer_id":40207831728243,"sku":"906059427","price":13.3,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/euritalia-pharma-div-coswell-isomar-spray-acqua-di-mare-e-acido-ialuronico-100ml-farmacia-dottor-tili-1213793058.jpg?v=1767128351"},{"product_id":"grintuss-pediatric-sciroppo-bambini-180g","title":"Grintuss Pediatric Children's Syrup 180g","description":"\u003cp\u003eGrintuss Pediatric is one \u003cstrong\u003esyrup for dry and wet cough\u003c\/strong\u003e based on Honey and molecular complexes of Grindelia, Plantain and Helichrysum. \u003cspan data-mce-fragment=\"1\"\u003eGrintuss Pediatric is \u003c\/span\u003eindicated for the treatment of coughs, both dry and oily, moles \u003cstrong\u003echildren from 1 year of age\u003c\/strong\u003e.\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eThe composition of Grintuss Pediatric based on honey and natural extracts is indicated for \u003cstrong\u003ecough therapy in children during the cold winter period\u003c\/strong\u003e. \u003c\/p\u003e\n\u003cp\u003e\u003cspan data-mce-fragment=\"1\"\u003eGrintuss \u003c\/span\u003eChildren's Syrup \u003cstrong\u003ecalms coughs and thins phlegm\u003c\/strong\u003e respecting the airways of the little ones. Grintuss indeed \u003cstrong\u003emodulates the cough without suppressing it\u003c\/strong\u003e, thus respecting its importance \u003cstrong\u003edefense role of the upper airways\u003c\/strong\u003e.\u003cbr data-mce-fragment=\"1\"\u003e\u003c\/p\u003e\n\u003cp\u003eThanks to its natural composition, Grintuss Pediatric performs a triple action: \u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMucoregulating and antitussive action\u003c\/strong\u003e: \u003cspan data-mce-fragment=\"1\"\u003eGrintuss Pediatric \u003c\/span\u003eadheres to the mucosa and limits contact with external irritating agents. It generates a barrier effect with a microfilm film that protects and respects the airways.\u003cbr\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFluidifying action\u003c\/strong\u003e: Grintuss Pediatric promotes the hydration of the mucosa and mucus, promoting their expulsion.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy should Grintuss Pediatric Syrup Children 180g be used? What is it for?\u003c\/h3\u003e\u003cp\u003eSyrup based on honey and molecular complexes of Grindelia, Plantain and Helichrysum, indicated for the treatment of dry and wet coughs in children from 1 year of age; calms coughs and promotes the fluidization of phlegm while respecting the airways of the little ones.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Grintuss Pediatric Syrup Children 180g contain?\u003c\/h3\u003e\u003cp\u003e5 ml of product contains: Poliresin plant complex 31 mg, based on polysaccharides, resins and flavonoids (LPME extractive fraction of plantain*, grindelia* and helichrysum*), honey* 1.7 g, cane sugar*, water; essential oils of lemon, sweet orange and myrtle, natural lemon aroma, gum arabic and xanthan.\u003cbr\u003e*Ingredient from organic farming\u003cbr\u003eIt does not contain preservatives and artificial sweeteners.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Grintuss Pediatric Syrup Children 180g?\u003c\/h3\u003e\u003cp\u003eChildren 1-6 years: 5 ml of syrup (one teaspoon) two to four times a day.\u003cbr\u003eChildren over 6 years: 10 ml of syrup (two teaspoons) two to four times a day.\u003cbr\u003eIt is advisable to carry out the last administration before going to bed. Shake before use. After use, close the bottle tightly.\u003cbr\u003eThe product can also be taken for prolonged periods. If after 14 days of treatment the symptoms do not resolve, it is still recommended to consult a doctor.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Grintuss Pediatric Syrup Children 180g?\u003c\/h3\u003e\u003cp\u003eDo not use if there is individual hypersensitivity or allergy to one or more components.\u003cbr\u003eIf the symptoms do not improve, it is advisable to consult your doctor.\u003cbr\u003eKeep out of reach of children.\u003cbr\u003eThe product is well tolerated. However, if you notice the appearance of an undesirable effect attributable to the product or its use, inform your doctor and\/or pharmacist and the manufacturer. In the event of a serious accident, also inform the competent authority of your country.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Grintuss Pediatric Syrup Children 180g stored?\u003c\/h3\u003e\u003cp\u003eStore at room temperature even after opening.\u003cbr\u003eValidity with intact packaging: 30 months.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Grintuss Pediatric Syrup Children 180g?\u003c\/h3\u003e\u003cp\u003e180 g bottle, contains measuring spoon.\u003c\/p\u003e","brand":"Aboca","offers":[{"title":"Default Title","offer_id":40719010136179,"sku":"927091203","price":15.16,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/aboca-spa-societa-agricola-grintuss-pediatric-sciroppo-bambini-180g-farmacia-dottor-tili-1213792516.jpg?v=1767130990"},{"product_id":"fluimucil-mucolitico-sciroppo-espettorante-600-mg-15-ml","title":"Fluimucil Mucolytic Expectorant Syrup 600 Mg-15 Ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTreatment of respiratory diseases characterized by dense and viscous hypersecretion.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg effervescent tablets\u003c\/i\u003e Each tablet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 600 mg. Excipients with known effects: aspartame, glucose, sodium. \u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg granules for oral solution \u003c\/i\u003e Each sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 600 mg. Excipients with known effects: aspartame, glucose, lactose, sorbitol. \u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg\/15 ml syrup\u003c\/i\u003e 15 ml of syrup contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 600 mg. Excipients with known effects: propylene glycol, methyl parahydroxybenzoate, propyl parahydroxybenzoate, sodium, sorbitol. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg, effervescent tablets\u003c\/i\u003e One tablet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 200 mg. Excipients with known effects: sodium, aspartame. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg, buccal tablets:\u003c\/i\u003e One tablet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 200 mg. Excipients with known effects: sorbitol, sodium, aspartame. \u003ci\u003e FLUIMUCIL MUCOLITIC 200 mg, granules for oral solution\u003c\/i\u003e One sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 200 mg. Excipients with known effects: sucrose, glucose, sunset yellow (E110), lactose. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg, granules for oral solution without sugar\u003c\/i\u003e One sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 200 mg. Excipients with known effects: sorbitol, aspartame. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg, granules for oral solution\u003c\/i\u003e One sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 100 mg. Excipients with known effects: sucrose, sunset yellow (E110).\u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg, granules for oral solution without sugar\u003c\/i\u003e One sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 100 mg. Excipients with known effects: sorbitol, aspartame. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg\/5 ml, syrup\u003c\/i\u003e A 150 ml bottle contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 3,000 g (corresponding to 100 mg\/5 ml of syrup). Excipients with known effects: ethanol, methyl parahydroxybenzoate, propylene glycol, sodium benzoate, sodium. A 200 ml bottle contains: \u003cu\u003e Active ingredient\u003c\/u\u003e: N-acetylcysteine 4,000 g (corresponding to 100 mg\/5 ml of syrup). Excipients with known effects: ethanol, methyl parahydroxybenzoate, propylene glycol, sodium benzoate, sodium. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg granules for oral solution \u003c\/i\u003e Aspartame, Orange flavor (containing glucose and lactose), Sorbitol. \u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg effervescent tablets \u003c\/i\u003e Anhydrous citric acid, Lemon flavor (containing glucose), Aspartame, Sodium bicarbonate. \u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg\/15 ml syrup 200 ml bottle\u003c\/i\u003eMethyl parahydroxybenzoate, Propyl parahydroxybenzoate, Sodium edetate, Carmellose, Sodium saccharin, Grenadine flavoring (containing propylene glycol), Strawberry flavoring (containing propylene glycol), Sorbitol, Sodium hydroxide, Purified water. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg buccal tablets\u003c\/i\u003e Anhydrous citric acid, sorbitol, mannitol, polyethylene glycol 6000, povidone, sodium bicarbonate, lemon flavouring, mandarin flavouring, aspartame, magnesium stearate, microcrystalline cellulose. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg granules for oral solution without sugar \u003c\/i\u003e Sorbitol, aspartame, orange flavouring. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg granules for oral solution\u003c\/i\u003eOrange juice granules; Orange flavor (containing glucose and lactose); saccharin; sunset yellow (E 110); Sucrose. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg effervescent tablets\u003c\/i\u003e \u003ci\u003eAnhydrous citric acid, sodium bicarbonate, lemon flavouring, aspartame.\u003c\/i\u003e \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg granules for oral solution\u003c\/i\u003eOrange juice granules; Orange flavour; Saccharin; E 110; Sucrose. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg granules for oral solution without sugar\u003c\/i\u003e Sorbitol; Aspartame; Orange flavour. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg\/5 ml syrup 150 ml bottle\u003c\/i\u003e Methyl parahydroxybenzoate, sodium benzoate, sodium edetate, sodium carboxymethyl cellulose, raspberry flavor (containing propylene glycol and ethanol), sodium saccharinate, sodium hydroxide, purified water. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg\/5 ml syrup 200 ml bottle\u003c\/i\u003e Methyl parahydroxybenzoate, sodium benzoate, sodium edetate, sodium carboxymethylcellulose, sodium cyclamate, sucralose, raspberry flavor (containing propylene glycol and ethanol), sodium saccharinate, sodium hydroxide, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Children under 2 years of age. Pregnancy and breast-feeding (see section 4.6).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eAdults\u003c\/u\u003e: 1 sachet of Mucolytic Fluimucil 200 mg granules for oral solution (with or without sugar) or 2 sachets of Mucolytic Fluimucil 100 mg (with or without sugar) 2-3 times a day. Fluimucil Mucolytic 200 mg, buccal tablets and effervescent tablets: 1 tablet 2-3 times a day. Fluimucil Mucolytic 100 mg\/5 ml, syrup: 10 ml of syrup (1 measuring spoon), equal to 200 mg of N-acetylcysteine, 2-3 times a day. Fluimucil Mucolytic 600 mg\/15 ml syrup, Fluimucil Mucolytic 600 mg effervescent tablets and Fluimucil Mucolytic 600 mg granules for solution: a 15 ml measuring spoon or an effervescent tablet or a sachet (preferably in the evening). Any dosage adjustments may concern the frequency of administration or the fractionation of the dose but must in any case be included within the maximum daily dosage of 600 mg. \u003cu\u003eChildren over 2 years old\u003c\/u\u003e: Fluimucil Mucolytic 100 mg granules for oral solution (with or without sugar): 1 sachet 2 to 4 times a day, depending on age. Fluimucil Mucolytic 100 mg\/5 ml, syrup: ½ scoop of syrup (5 ml), equal to 100 mg of N-acetylcysteine, 2 to 4 times a day depending on age. The duration of therapy is 5 to 10 days. \u003cb\u003eMethod of administration\u003c\/b\u003e \u003cu\u003eGranules for oral solution\u003c\/u\u003e: dissolve the contents of a sachet in a glass containing a little water, mixing as needed with a teaspoon. This results in a pleasant solution that can be drunk directly from the glass or, in the case of small children, given in teaspoons or in a bottle. The solution should be taken as soon as it is ready. \u003cu\u003eOral soluble tablets\u003c\/u\u003e: keep the tablet in the oral cavity until it has completely dissolved. \u003cu\u003eSyrup\u003c\/u\u003e: shake before use. Once opened, the syrup is valid for 15 days. Effervescent tablets: dissolve one tablet in a glass containing a little water, mixing as needed with a teaspoon. To facilitate the release of the tablet, we recommend tearing open the blister, using the side notches as indicated in the figure.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSachets of 100 and 200 granules for oral solution, 600 mg granules for oral solution, 200 mg granules for oral solution without sugar and 200 mg buccal tablets: store at a temperature not exceeding 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePatients suffering from bronchial asthma must be closely monitored during therapy; if bronchospasm appears, treatment with N-acetylcysteine ​​must be immediately suspended and appropriate treatment must be started. Mucolytics can induce bronchial obstruction in children under 2 years of age. In fact, the drainage capacity of bronchial mucus is limited in this age group, due to the physiological characteristics of the respiratory tract. They should therefore not be used in children under 2 years of age (see section 4.3). The use of the medicine in patients suffering from peptic ulcers or with a history of peptic ulcers requires particular attention, especially in case of simultaneous intake of other drugs with a known gastro-injurious effect. The possible presence of a sulphurous odor does not indicate alteration of the preparation but is specific to the active ingredient contained in it. The administration of N-acetylcysteine, especially at the beginning of treatment, can fluidize bronchial secretions and increase their volume at the same time. If the patient is unable to expectorate effectively, postural drainage and bronchoaspiration should be used to avoid retention of secretions. N-acetylcysteine ​​can affect histamine metabolism. Therefore, caution should be used when administering Fluimucil Mucolytic to patients with histamine intolerance, as hypersensitivity symptoms may occur. \u003ci\u003e \u003cu\u003eImportant information about some excipients\u003c\/u\u003e \u003c\/i\u003e Sodium benzoate The 100 mg\/5 ml syrup (150 ml and 200 ml) contains 15 mg of sodium benzoate for the 10 ml dose and 7.5 mg for the 5 ml dose.\u003ci\u003eParahydroxybenzoates\u003c\/i\u003e Syrups contain parahydroxybenzoates which can cause delayed allergic reactions. \u003ci\u003eSorbitol\u003c\/i\u003e The buccal tablets, 600 mg\/15 ml syrup, 600 mg granules for oral solution and 100 mg and 200 mg sugar-free granules for oral solution contain sorbitol. The sorbitol content in oral medicinal products may modify the bioavailability of other co-administered oral medicinal products. Patients with hereditary fructose intolerance should not be given these medicines. \u003ci\u003eAspartame\u003c\/i\u003e The buccal tablets, effervescent tablets, granules for oral solution 600 mg and granules for sugar-free oral solution 100 and 200 mg contain aspartame, a source of phenylalanine which may be harmful in patients with phenylketonuria. \u003ci\u003eGlucose\u003c\/i\u003e The 600 mg effervescent tablets, the 600 mg granules for oral solution and the 200 mg granules for oral solution contain glucose, patients suffering from rare problems of glucose-galactose malabsorption should not take this medicine. \u003ci\u003eSunset yellow (E110)\u003c\/i\u003e The granules for oral solution 100 mg and 200 mg contain sunset yellow (E110) which may cause allergic reactions. \u003ci\u003eSucrose\u003c\/i\u003e The granules for oral solution 100 and 200 mg contain sucrose. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. \u003ci\u003eSodium\u003c\/i\u003e The buccal tablets contain 26.9 mg sodium per tablet equivalent to 1.3% of the WHO recommended maximum daily intake of 2 g sodium for an adult. The 200 mg and 600 mg effervescent tablets contain 156.9 mg sodium per dose, equivalent to 7.8% of the WHO recommended maximum daily intake of 2 g sodium for an adult. The 100 mg\/5 ml (150 ml) syrup contains 36.7 mg of sodium per 10 ml dose, equivalent to 1.83% of the WHO recommended maximum daily intake of 2 g of sodium for an adult. The 100 mg\/5 ml (150 ml) syrup contains 18.4 mg sodium per 5 ml dose, equivalent to 0.9% of the WHO recommended maximum daily intake of 2 g sodium for an adult. The 100 mg\/5 ml (200 ml) syrup contains 38.2 mg of sodium per 10 ml dose, equivalent to 1.9% of the WHO recommended maximum daily intake of 2 g of sodium for an adult. The 100 mg\/5 ml (200 ml) syrup contains 19.1 mg sodium per 5 ml dose, equivalent to 0.9% of the WHO recommended maximum daily intake of 2 g sodium for an adult. The 600 mg\/15 ml syrup contains 98.31 mg of sodium per 15 ml dose equivalent to 4.9% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult. \u003ci\u003eLactose\u003c\/i\u003e The 600 mg granules for oral solution and the 200 mg granules for oral solution contain lactose. Patients suffering from rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. \u003ci\u003ePropylene glycol\u003c\/i\u003e The 100 mg\/5 ml syrup (150 ml and 200 ml) contains 23.4 mg of propylene glycol for the 10 ml dose and 11.7 mg for the 5 ml dose. The 600 mg\/15 ml syrup contains 168 mg of propylene glycol per dose (15 ml) equivalent to 11.2 mg\/ml. \u003ci\u003eEthanol\u003c\/i\u003e The 100 mg\/5 ml syrup (150 ml and 200 ml) contains 3.85 mg of alcohol (ethanol) in every 100 ml. The dose quantity of this medicine is equivalent to less than 1 ml of beer or 1 ml of wine. The small amount of alcohol in this medicine will not produce any noticeable effects.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDrug-drug interaction\u003c\/u\u003e. Antitussive drugs and mucolytic agents, such as N-acetylcysteine, should not be taken at the same time as the reduction of the cough reflex could lead to an accumulation of bronchial secretions. Activated charcoal can reduce the effect of N-acetylcysteine. It is advisable not to mix other drugs with the Fluimucil Mucolytic solution. The information available regarding the antibiotic-N-acetylcysteine ​​interaction refers to in vitro tests, in which the two substances were mixed, which showed a decreased activity of the antibiotic. However, as a precaution, it is recommended to take oral antibiotics at least two hours after the administration of N-acetylcysteine, excluding loracarbef. It has been shown that the simultaneous intake of nitroglycerin and N-acetylcysteine ​​causes significant hypotension and causes dilation of the temporal artery with the possible onset of headache. If the simultaneous administration of nitroglycerin and N-acetylcysteine ​​is necessary, patients should be monitored for the appearance of hypotension which can even be severe and alerted to the possible onset of headache. \u003cu\u003ePediatric population\u003c\/u\u003e Interaction studies have only been carried out in adults. \u003cu\u003eDrug-laboratory test interactions\u003c\/u\u003e N-acetylcysteine may cause interference with the colorimetric assay method for the determination of salicylates. N-acetylcysteine ​​may interfere with urine ketone testing.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSafety profile summary\u003c\/u\u003e The adverse events most frequently associated with the oral administration of N-acetylcysteine ​​are gastrointestinal in nature. Less frequently, hypersensitivity reactions including anaphylactic shock, anaphylactic\/anaphylactoid reactions, bronchospasm, angioedema, rash and pruritus have been reported. \u003cu\u003eTabular list of adverse reactions\u003c\/u\u003e The following table shows the adverse reactions listed according to the classification and frequency system: very common (≥ 1\/10), common (≥ 1\/100 to \u003c 1\/10), uncommon (≥ 1\/1,000 to \u003c 1\/100), rare (≥ 1\/10,000 to \u003c 1\/1,000), very rare (\u003c 1\/10,000) and not known (the frequency cannot be established on the basis of available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003eSystem organ class - Adverse reactions: Uncommon (≥1\/1,000; \u003c1\/100). Rare (≥1\/10,000; \u003c1\/1,000). Very rare (\u003c1\/10,000). Not known.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Adverse reactions: Hypersensitivity. Anaphylactic shock, anaphylactic\/anaphylactoid reaction.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Adverse reactions: Headache.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders - Adverse reactions: Tinnitus.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders - Adverse reactions: Tachycardia.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Haemorrhage.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Bronchospasm, dyspnoea. Bronchial obstruction.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Adverse reactions: Vomiting, diarrhea, stomatitis, abdominal pain, nausea. Dyspepsia.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Adverse reactions: Urticaria, rash, angioedema, pruritus.\u003c\/p\u003e\n\u003cp\u003eSystemic disorders and conditions relating to the administration site - Adverse reactions: Pyrexia. Edema of the face.\u003c\/p\u003e\n\u003cp\u003eDiagnostic tests - Adverse reactions: Reduced blood pressure.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDescription of some adverse reactions\u003c\/u\u003e In very rare cases, the appearance of serious skin reactions has occurred in temporal connection with the intake of N-acetylcysteine, such as Stevens-Johnson syndrome and Lyell syndrome. Although in most cases at least one other suspected drug has been identified which is more likely involved in the genesis of the aforementioned mucocutaneous syndromes, in case of mucocutaneous alterations it is advisable to contact your doctor and the intake of N-acetylcysteine ​​must be stopped immediately. Some studies have confirmed a reduction in platelet aggregation when taking N-acetylcysteine. The clinical significance of these findings has not yet been defined. \u003ci\u003eReporting of suspected adverse reactions\u003c\/i\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been found with oral administration of N-acetylcysteine. Healthy volunteers, who took a daily dose of 11.6 g of N-acetylcysteine ​​for three months, did not experience serious adverse reactions. Doses up to 500 mg NAC\/kg body weight, administered orally, were tolerated without any symptoms of intoxication. \u003ci\u003eSymptoms\u003c\/i\u003e Overdose can cause gastrointestinal symptoms such as nausea, vomiting and diarrhea. \u003ci\u003eTreatment\u003c\/i\u003e There are no specific antidotal treatments; Overdose therapy is based on symptomatic treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAlthough the teratological studies conducted with Fluimucil Mucolytic on animals have not shown any teratogenic effect, however, as with other drugs, its administration during pregnancy and during the period of breastfeeding with breast milk should only be carried out in case of actual need.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eN-acetylcysteine does not influence the ability to drive and use machines.\u003c\/p\u003e","brand":"Zambon","offers":[{"title":"Default Title","offer_id":40723405013107,"sku":"034936157","price":12.09,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/zambon-italia-srl-fluimucil-mucolitico-sciroppo-espettorante-600-mg-15-ml-farmacia-dottor-tili-1213792518.png?v=1767131129"},{"product_id":"fluimucil-mucolitico-200-mg-30-bustine-granulato-senza-zucchero","title":"Fluimucil Mucolitico 200 mg 30 Sachets Sugar-free Granules","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTreatment of respiratory diseases characterized by dense and viscous hypersecretion.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg effervescent tablets\u003c\/i\u003e Each tablet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 600 mg. Excipients with known effects: aspartame, glucose, sodium. \u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg granules for oral solution \u003c\/i\u003e Each sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 600 mg. Excipients with known effects: aspartame, glucose, lactose, sorbitol. \u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg\/15 ml syrup\u003c\/i\u003e 15 ml of syrup contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 600 mg. Excipients with known effects: propylene glycol, methyl parahydroxybenzoate, propyl parahydroxybenzoate, sodium, sorbitol. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg, effervescent tablets\u003c\/i\u003e One tablet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 200 mg. Excipients with known effects: sodium, aspartame. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg, buccal tablets:\u003c\/i\u003e One tablet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 200 mg. Excipients with known effects: sorbitol, sodium, aspartame. \u003ci\u003e FLUIMUCIL MUCOLITIC 200 mg, granules for oral solution\u003c\/i\u003e One sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 200 mg. Excipients with known effects: sucrose, glucose, sunset yellow (E110), lactose. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg, granules for oral solution without sugar\u003c\/i\u003e One sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 200 mg. Excipients with known effects: sorbitol, aspartame. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg, granules for oral solution\u003c\/i\u003e One sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 100 mg. Excipients with known effects: sucrose, sunset yellow (E110).\u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg, granules for oral solution without sugar\u003c\/i\u003e One sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 100 mg. Excipients with known effects: sorbitol, aspartame. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg\/5 ml, syrup\u003c\/i\u003e A 150 ml bottle contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 3,000 g (corresponding to 100 mg\/5 ml of syrup). Excipients with known effects: ethanol, methyl parahydroxybenzoate, propylene glycol, sodium benzoate, sodium. A 200 ml bottle contains: \u003cu\u003e Active ingredient\u003c\/u\u003e: N-acetylcysteine 4,000 g (corresponding to 100 mg\/5 ml of syrup). Excipients with known effects: ethanol, methyl parahydroxybenzoate, propylene glycol, sodium benzoate, sodium. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg granules for oral solution \u003c\/i\u003e Aspartame, Orange flavor (containing glucose and lactose), Sorbitol. \u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg effervescent tablets \u003c\/i\u003e Anhydrous citric acid, Lemon flavor (containing glucose), Aspartame, Sodium bicarbonate. \u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg\/15 ml syrup 200 ml bottle\u003c\/i\u003eMethyl parahydroxybenzoate, Propyl parahydroxybenzoate, Sodium edetate, Carmellose, Sodium saccharin, Grenadine flavoring (containing propylene glycol), Strawberry flavoring (containing propylene glycol), Sorbitol, Sodium hydroxide, Purified water. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg buccal tablets\u003c\/i\u003e Anhydrous citric acid, sorbitol, mannitol, polyethylene glycol 6000, povidone, sodium bicarbonate, lemon flavouring, mandarin flavouring, aspartame, magnesium stearate, microcrystalline cellulose. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg granules for oral solution without sugar \u003c\/i\u003e Sorbitol, aspartame, orange flavouring. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg granules for oral solution\u003c\/i\u003eOrange juice granules; Orange flavor (containing glucose and lactose); saccharin; sunset yellow (E 110); Sucrose. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg effervescent tablets\u003c\/i\u003e \u003ci\u003eAnhydrous citric acid, sodium bicarbonate, lemon flavouring, aspartame.\u003c\/i\u003e \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg granules for oral solution\u003c\/i\u003eOrange juice granules; Orange flavour; Saccharin; E 110; Sucrose. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg granules for oral solution without sugar\u003c\/i\u003e Sorbitol; Aspartame; Orange flavour. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg\/5 ml syrup 150 ml bottle\u003c\/i\u003e Methyl parahydroxybenzoate, sodium benzoate, sodium edetate, sodium carboxymethyl cellulose, raspberry flavor (containing propylene glycol and ethanol), sodium saccharinate, sodium hydroxide, purified water. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg\/5 ml syrup 200 ml bottle\u003c\/i\u003e Methyl parahydroxybenzoate, sodium benzoate, sodium edetate, sodium carboxymethylcellulose, sodium cyclamate, sucralose, raspberry flavor (containing propylene glycol and ethanol), sodium saccharinate, sodium hydroxide, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Children under 2 years of age. Pregnancy and breast-feeding (see section 4.6).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eAdults\u003c\/u\u003e: 1 sachet of Mucolytic Fluimucil 200 mg granules for oral solution (with or without sugar) or 2 sachets of Mucolytic Fluimucil 100 mg (with or without sugar) 2-3 times a day. Fluimucil Mucolytic 200 mg, buccal tablets and effervescent tablets: 1 tablet 2-3 times a day. Fluimucil Mucolytic 100 mg\/5 ml, syrup: 10 ml of syrup (1 measuring spoon), equal to 200 mg of N-acetylcysteine, 2-3 times a day. Fluimucil Mucolytic 600 mg\/15 ml syrup, Fluimucil Mucolytic 600 mg effervescent tablets and Fluimucil Mucolytic 600 mg granules for solution: a 15 ml measuring spoon or an effervescent tablet or a sachet (preferably in the evening). Any dosage adjustments may concern the frequency of administration or the fractionation of the dose but must in any case be included within the maximum daily dosage of 600 mg. \u003cu\u003eChildren over 2 years old\u003c\/u\u003e: Fluimucil Mucolytic 100 mg granules for oral solution (with or without sugar): 1 sachet 2 to 4 times a day, depending on age. Fluimucil Mucolytic 100 mg\/5 ml, syrup: ½ scoop of syrup (5 ml), equal to 100 mg of N-acetylcysteine, 2 to 4 times a day depending on age. The duration of therapy is 5 to 10 days. \u003cb\u003eMethod of administration\u003c\/b\u003e \u003cu\u003eGranules for oral solution\u003c\/u\u003e: dissolve the contents of a sachet in a glass containing a little water, mixing as needed with a teaspoon. This results in a pleasant solution that can be drunk directly from the glass or, in the case of small children, given in teaspoons or in a bottle. The solution should be taken as soon as it is ready. \u003cu\u003eOral soluble tablets\u003c\/u\u003e: keep the tablet in the oral cavity until it has completely dissolved. \u003cu\u003eSyrup\u003c\/u\u003e: shake before use. Once opened, the syrup is valid for 15 days. Effervescent tablets: dissolve one tablet in a glass containing a little water, mixing as needed with a teaspoon. To facilitate the release of the tablet, we recommend tearing open the blister, using the side notches as indicated in the figure.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSachets of 100 and 200 granules for oral solution, 600 mg granules for oral solution, 200 mg granules for oral solution without sugar and 200 mg buccal tablets: store at a temperature not exceeding 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePatients suffering from bronchial asthma must be closely monitored during therapy; if bronchospasm appears, treatment with N-acetylcysteine ​​must be immediately suspended and appropriate treatment must be started. Mucolytics can induce bronchial obstruction in children under 2 years of age. In fact, the drainage capacity of bronchial mucus is limited in this age group, due to the physiological characteristics of the respiratory tract. They should therefore not be used in children under 2 years of age (see section 4.3). The use of the medicine in patients suffering from peptic ulcers or with a history of peptic ulcers requires particular attention, especially in case of simultaneous intake of other drugs with a known gastro-injurious effect. The possible presence of a sulphurous odor does not indicate alteration of the preparation but is specific to the active ingredient contained in it. The administration of N-acetylcysteine, especially at the beginning of treatment, can fluidize bronchial secretions and increase their volume at the same time. If the patient is unable to expectorate effectively, postural drainage and bronchoaspiration should be used to avoid retention of secretions. N-acetylcysteine ​​can affect histamine metabolism. Therefore, caution should be used when administering Fluimucil Mucolytic to patients with histamine intolerance, as hypersensitivity symptoms may occur. \u003ci\u003e \u003cu\u003eImportant information about some excipients\u003c\/u\u003e \u003c\/i\u003e Sodium benzoate The 100 mg\/5 ml syrup (150 ml and 200 ml) contains 15 mg of sodium benzoate for the 10 ml dose and 7.5 mg for the 5 ml dose.\u003ci\u003eParahydroxybenzoates\u003c\/i\u003e Syrups contain parahydroxybenzoates which can cause delayed allergic reactions. \u003ci\u003eSorbitol\u003c\/i\u003e The buccal tablets, 600 mg\/15 ml syrup, 600 mg granules for oral solution and 100 mg and 200 mg sugar-free granules for oral solution contain sorbitol. The sorbitol content in oral medicinal products may modify the bioavailability of other co-administered oral medicinal products. Patients with hereditary fructose intolerance should not be given these medicines. \u003ci\u003eAspartame\u003c\/i\u003e The buccal tablets, effervescent tablets, granules for oral solution 600 mg and granules for sugar-free oral solution 100 and 200 mg contain aspartame, a source of phenylalanine which may be harmful in patients with phenylketonuria. \u003ci\u003eGlucose\u003c\/i\u003e The 600 mg effervescent tablets, the 600 mg granules for oral solution and the 200 mg granules for oral solution contain glucose, patients suffering from rare problems of glucose-galactose malabsorption should not take this medicine. \u003ci\u003eSunset yellow (E110)\u003c\/i\u003e The granules for oral solution 100 mg and 200 mg contain sunset yellow (E110) which may cause allergic reactions. \u003ci\u003eSucrose\u003c\/i\u003e The granules for oral solution 100 and 200 mg contain sucrose. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. \u003ci\u003eSodium\u003c\/i\u003e The buccal tablets contain 26.9 mg sodium per tablet equivalent to 1.3% of the WHO recommended maximum daily intake of 2 g sodium for an adult. The 200 mg and 600 mg effervescent tablets contain 156.9 mg sodium per dose, equivalent to 7.8% of the WHO recommended maximum daily intake of 2 g sodium for an adult. The 100 mg\/5 ml (150 ml) syrup contains 36.7 mg of sodium per 10 ml dose, equivalent to 1.83% of the WHO recommended maximum daily intake of 2 g of sodium for an adult. The 100 mg\/5 ml (150 ml) syrup contains 18.4 mg sodium per 5 ml dose, equivalent to 0.9% of the WHO recommended maximum daily intake of 2 g sodium for an adult. The 100 mg\/5 ml (200 ml) syrup contains 38.2 mg of sodium per 10 ml dose, equivalent to 1.9% of the WHO recommended maximum daily intake of 2 g of sodium for an adult. The 100 mg\/5 ml (200 ml) syrup contains 19.1 mg sodium per 5 ml dose, equivalent to 0.9% of the WHO recommended maximum daily intake of 2 g sodium for an adult. The 600 mg\/15 ml syrup contains 98.31 mg of sodium per 15 ml dose equivalent to 4.9% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult. \u003ci\u003eLactose\u003c\/i\u003e The 600 mg granules for oral solution and the 200 mg granules for oral solution contain lactose. Patients suffering from rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. \u003ci\u003ePropylene glycol\u003c\/i\u003e The 100 mg\/5 ml syrup (150 ml and 200 ml) contains 23.4 mg of propylene glycol for the 10 ml dose and 11.7 mg for the 5 ml dose. The 600 mg\/15 ml syrup contains 168 mg of propylene glycol per dose (15 ml) equivalent to 11.2 mg\/ml. \u003ci\u003eEthanol\u003c\/i\u003e The 100 mg\/5 ml syrup (150 ml and 200 ml) contains 3.85 mg of alcohol (ethanol) in every 100 ml. The dose quantity of this medicine is equivalent to less than 1 ml of beer or 1 ml of wine. The small amount of alcohol in this medicine will not produce any noticeable effects.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDrug-drug interaction\u003c\/u\u003e. Antitussive drugs and mucolytic agents, such as N-acetylcysteine, should not be taken at the same time as the reduction of the cough reflex could lead to an accumulation of bronchial secretions. Activated charcoal can reduce the effect of N-acetylcysteine. It is advisable not to mix other drugs with the Fluimucil Mucolytic solution. The information available regarding the antibiotic-N-acetylcysteine ​​interaction refers to in vitro tests, in which the two substances were mixed, which showed a decreased activity of the antibiotic. However, as a precaution, it is recommended to take oral antibiotics at least two hours after the administration of N-acetylcysteine, excluding loracarbef. It has been shown that the simultaneous intake of nitroglycerin and N-acetylcysteine ​​causes significant hypotension and causes dilation of the temporal artery with the possible onset of headache. If the simultaneous administration of nitroglycerin and N-acetylcysteine ​​is necessary, patients should be monitored for the appearance of hypotension which can even be severe and alerted to the possible onset of headache. \u003cu\u003ePediatric population\u003c\/u\u003e Interaction studies have only been carried out in adults. \u003cu\u003eDrug-laboratory test interactions\u003c\/u\u003e N-acetylcysteine may cause interference with the colorimetric assay method for the determination of salicylates. N-acetylcysteine ​​may interfere with urine ketone testing.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSafety profile summary\u003c\/u\u003e The adverse events most frequently associated with the oral administration of N-acetylcysteine ​​are gastrointestinal in nature. Less frequently, hypersensitivity reactions including anaphylactic shock, anaphylactic\/anaphylactoid reactions, bronchospasm, angioedema, rash and pruritus have been reported. \u003cu\u003eTabular list of adverse reactions\u003c\/u\u003e The following table shows the adverse reactions listed according to the classification and frequency system: very common (≥ 1\/10), common (≥ 1\/100 to \u003c 1\/10), uncommon (≥ 1\/1,000 to \u003c 1\/100), rare (≥ 1\/10,000 to \u003c 1\/1,000), very rare (\u003c 1\/10,000) and not known (the frequency cannot be established on the basis of available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003eSystem organ class - Adverse reactions: Uncommon (≥1\/1,000; \u003c1\/100). Rare (≥1\/10,000; \u003c1\/1,000). Very rare (\u003c1\/10,000). Not known.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Adverse reactions: Hypersensitivity. Anaphylactic shock, anaphylactic\/anaphylactoid reaction.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Adverse reactions: Headache.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders - Adverse reactions: Tinnitus.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders - Adverse reactions: Tachycardia.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Haemorrhage.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Bronchospasm, dyspnoea. Bronchial obstruction.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Adverse reactions: Vomiting, diarrhea, stomatitis, abdominal pain, nausea. Dyspepsia.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Adverse reactions: Urticaria, rash, angioedema, pruritus.\u003c\/p\u003e\n\u003cp\u003eSystemic disorders and conditions relating to the administration site - Adverse reactions: Pyrexia. Edema of the face.\u003c\/p\u003e\n\u003cp\u003eDiagnostic tests - Adverse reactions: Reduced blood pressure.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDescription of some adverse reactions\u003c\/u\u003e In very rare cases, the appearance of serious skin reactions has occurred in temporal connection with the intake of N-acetylcysteine, such as Stevens-Johnson syndrome and Lyell syndrome. Although in most cases at least one other suspected drug has been identified which is more likely involved in the genesis of the aforementioned mucocutaneous syndromes, in case of mucocutaneous alterations it is advisable to contact your doctor and the intake of N-acetylcysteine ​​must be stopped immediately. Some studies have confirmed a reduction in platelet aggregation when taking N-acetylcysteine. The clinical significance of these findings has not yet been defined. \u003ci\u003eReporting of suspected adverse reactions\u003c\/i\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been found with oral administration of N-acetylcysteine. Healthy volunteers, who took a daily dose of 11.6 g of N-acetylcysteine ​​for three months, did not experience serious adverse reactions. Doses up to 500 mg NAC\/kg body weight, administered orally, were tolerated without any symptoms of intoxication. \u003ci\u003eSymptoms\u003c\/i\u003e Overdose can cause gastrointestinal symptoms such as nausea, vomiting and diarrhea. \u003ci\u003eTreatment\u003c\/i\u003e There are no specific antidotal treatments; Overdose therapy is based on symptomatic treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAlthough the teratological studies conducted with Fluimucil Mucolytic on animals have not shown any teratogenic effect, however, as with other drugs, its administration during pregnancy and during the period of breastfeeding with breast milk should only be carried out in case of actual need.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eN-acetylcysteine does not influence the ability to drive and use machines.\u003c\/p\u003e","brand":"Zambon","offers":[{"title":"Default Title","offer_id":40731897430131,"sku":"034936106","price":11.63,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/zambon-italia-srl-fluimucil-mucolitico-200-mg-30-bustine-granulato-senza-zucchero-farmacia-dottor-tili-1213792517.webp?v=1767131148"},{"product_id":"seki-sciroppo-flacone-200ml-3-54-mg-ml","title":"Seki Syrup Bottle 200ml 3.54 mg\/ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCough suppressant.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSEKI 3.54 mg\/ml syrup \u003c\/b\u003e 100 ml contain: \u003ci\u003eactive ingredient\u003c\/i\u003e: cloperastine phendizoate 354 mg equal to cloperastine 180 mg \u003cb\u003e \u003ci\u003eexcipients with known effects\u003c\/i\u003e:\u003c\/b\u003e ethanol 30 mg, methyl parahydroxybenzoate 122 mg, propyl parahydroxybenzoate 18 mg, propylene glycol 230.4 mg, sucrose 45 mg For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSEKI 3.54 mg\/ml syrup\u003c\/b\u003e microcrystalline cellulose, sodium carmellose, polyoxyl-40-stearate, \u003cb\u003esucrose, methyl-para-hydroxybenzoate, propyl-para-hydroxybenzoate\u003c\/b\u003e, banana essence (containing \u003cb\u003eethanol, propylene glycol\u003c\/b\u003e), purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Due to the absence of studies in early childhood, the medicine is contraindicated in children under 2 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eDaily dose\u003c\/i\u003e: \u003cb\u003eADULTS:\u003c\/b\u003e 2 small glasses (\"Adults\" mark on the dispenser included in the package; one \"Adults\" mark corresponds to 7.5 ml of syrup) in the evening at bedtime; a drink in the morning, a drink in the afternoon. \u003cb\u003eCHILDREN:\u003c\/b\u003e After two years: two small glasses (\"Children\" mark on the dispenser included in the package; one \"Children\" mark corresponds to 3.75 ml of syrup) in the evening before bedtime; a drink in the morning, a drink in the afternoon. Duration of treatment: 7 days. If you do not notice appreciable results, it is advisable to consult your doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore below 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCaution is advised when using it in patients suffering from intraocular hypertension, prostatic hypertrophy or bladder obstruction. \u003ci\u003e \u003cu\u003eImportant information about some excipients\u003c\/u\u003e \u003c\/i\u003e \u003cu\u003eEthanol (contained in banana flavour)\u003c\/u\u003e This medicine contains 0.0011 ml of alcohol (ethanol) in each 3.75 ml dose (marked “Children”) and 0.0022 ml of alcohol (ethanol) in each 7.5 ml dose (marked “Adults”). The amount in one dose of this medicine is equivalent to less than 1 ml of beer or 1 of wine. The small amount of alcohol in this medicine will not produce any noticeable effects. \u003cu\u003eParahydroxybenzoates\u003c\/u\u003e This medicine contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed). \u003cu\u003ePropylene Glycol (contained in banana flavour)\u003c\/u\u003e This medicine contains 8.6 mg of propylene glycol in 3.75 ml (mark “Children”) and 17.3 mg of propylene glycol in 7.5 ml (mark “Adults”). \u003cu\u003eSucrose\u003c\/u\u003e This medicine contains 1.687 g of sucrose per 3.75 ml dose (mark “Children”) and 3.375 g of sucrose per 7.5 ml dose (mark “Adults”). To be taken into consideration in people suffering from diabetes mellitus. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. \u003cu\u003eSodium\u003c\/u\u003e This medicinal product contains less than 1 mmol sodium (23mg) per dose, i.e. essentially 'sodium-free'.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAlthough the central side effects of cloperastine are reduced, the medicine can interact with both central nervous system depressants and stimulants. No interaction studies have been conducted on humans. The concomitant use of Seki with: - alcohol, - antihistamines, - anticholinergics, - sedatives is not recommended, both in adult patients and in children. It is not known whether in pediatric age the extent of the interactions reported above is similar to that in adulthood. There is no information regarding any interactions of the drug with laboratory tests. No information is available regarding the interaction of cloperastine with food, therefore its intake during meals is not recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBelow is a table relating to the frequency of side effects: Frequency: very common (≥ 1\/10); common (≥ 1\/100, \u003c 1\/10); uncommon (≥ 1\/1000, \u003c 1\/100); rare (≥ 1\/10000, \u003c 1\/1000); very rare (\u003c 1\/10000), not known (frequency cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003eSystem organ class - Adverse reactions: Uncommon (≥1\/1,000; \u003c1\/100). Rare (≥1\/10,000; \u003c1\/1,000). Very rare (\u003c1\/10,000). Not known.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Anaphylactic\/anaphylactoid reaction.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Adverse reactions: Drowsiness, dry mouth.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Urticaria Erythema.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePediatrics\u003c\/u\u003e Clinical studies and post-marketing surveillance with cloperastine have not shown any relevant differences in the nature, frequency, severity and reversibility of adverse reactions between adult and pediatric populations. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eAdults\u003c\/u\u003e No cases of overdose have been reported in adults treated with Seki. \u003cu\u003eChildren\u003c\/u\u003e One case of overdose has been reported in a child who took a dose of 40 ml of Seki syrup. No associated adverse reactions were reported. The patient was treated with two tablespoons of activated charcoal. \u003cu\u003eTreatment of overdose\u003c\/u\u003e Gastric lavage is useful if performed within a short time of ingesting the drug. The patient must be kept calm to minimize any sign of central overexcitation: in this case the use of benzodiazepines can be useful.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e There is no information available regarding the use of Seki during pregnancy. Although toxicity studies carried out during pregnancy in animals have not shown teratogenic activity and foetotoxicity, it is good prudential practice not to take the drug in the first months of pregnancy and in the subsequent period only in case of actual need under the direct supervision of a doctor. \u003cu\u003eBreastfeeding\u003c\/u\u003e It is not known whether the medicinal product and\/or its metabolites are excreted in breast milk; Since the risk to the infant cannot be excluded, Seki must not be used during breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the product can, although rarely, cause drowsiness, those who may drive vehicles or carry out operations requiring a high degree of vigilance must be warned of this.\u003c\/p\u003e","brand":"Zambon","offers":[{"title":"Default Title","offer_id":46362954826055,"sku":"024427041","price":11.44,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/zambon-italia-srl-seki-sciroppo-flacone-200ml-3-54-mg-ml-farmacia-dottor-tili-1213792515.jpg?v=1767131245"},{"product_id":"stodal-sciroppo-omeopatico-200-ml","title":"Stodal Homeopathic Syrup 200 ml","description":"\u003cp\u003eStodal homeopathic syrup used to counteract respiratory tract diseases such as \u003cstrong\u003ebronchitis, tracheitis and laryngitis\u003c\/strong\u003e. It is indicated \u003cstrong\u003ein both adults and children\u003c\/strong\u003e, in the presence of \u003cstrong\u003epainful cough, dry cough, fatty and productive cough\u003c\/strong\u003e as a homeopathic medicine free from side effects. \u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Stodal Homeopathic Syrup 200 ml used? What is it for?\u003c\/h3\u003e\u003cp\u003eHomeopathic medicine. As required by current legislation, no specific therapeutic indications are approved for homeopathic products. Traditionally used to accompany dry or oily coughs in the presence of respiratory tract diseases (bronchitis, tracheitis, laryngitis), both in adults and children.\u003c\/p\u003e\n\u003ch2\u003eACTIVE INGREDIENTS AND EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat is the composition of Stodal Homeopathic Syrup 200 ml?\u003c\/h3\u003e\u003cp\u003eBryonia Cretica 3 CH, Cephaelis Ipecacuanha 3 CH, Dactylopius Coccus 3 CH, Drosera TM, Euspongia Officinalis 3 CH, Kalii Stibyli Tartras 6 CH, Lobaria Pulmonaria 3 CH, Pulsatilla Pratensis 6 CH, Rumex Crispus 6 CH (950 Mg Of Each Ingredient Per 100 G Of Syrup).\u003cbr data-mce-fragment=\"1\"\u003e\u003cstrong\u003eExcipients\u003c\/strong\u003e: Sucrose (6 G\/10 G), Water, 0.125 G Of Color E150 (Caramel), 0.085 G Of Preservative E210 (Benzoic Acid) And 0.340 G Of Alcohol (0.3% V\/V).\u003c\/p\u003e\n\u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003eHow to take Stodal Homeopathic Syrup 200 ml?\u003c\/h3\u003e\u003cp\u003eThe administration of Stodal syrup differs between adults and children:\u003cbr\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eAdults: a spoonful of Stodal (approximately 15 ml) 3 to 5 times a day;\u003c\/li\u003e\n\u003cli\u003eChildren: one teaspoon of Stodal (approximately 5 ml) 3 to 5 times a day.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Stodal Homeopathic Syrup 200 ml?\u003c\/h3\u003e\u003cp\u003eStodal Homeopathic Syrup 200 ml can be administered to children under 2 years of age following medical consultation. If cough persists for more than 7 days, consult your doctor.\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Stodal Homeopathic Syrup 200 ml?\u003c\/h3\u003e\u003cp\u003e200ml\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Boiron","offers":[{"title":"Default Title","offer_id":46368117948743,"sku":"802519266","price":13.58,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/boiron-srl-stodal-sciroppo-omeopatico-200-ml-farmacia-dottor-tili-1213792510.jpg?v=1767131290"},{"product_id":"levotuss-sciroppo-30-mg-5-ml-levodropropizina-200-ml","title":"Levotuss Syrup 30 mg\/5 ml Levodropropizina 200 ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic treatment of cough\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 ml of solution contains: active ingredient: levodropropizine 600 mg Excipients with known effects: sucrose, propylene glycol, methyl parahydroxybenzoate, propyl parahydroxybenzoate, sodium. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSucrose, methyl parahydroxybenzoate, propyl parahydroxybenzoate, citric acid monohydrate, sodium hydroxide, cherry flavor (containing propylene glycol), purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Administration of the drug should be avoided in patients with bronchorrhea and reduced mucociliary function (Kartagener syndrome, ciliary dyskinesia). Pregnancy and breastfeeding (see 4.6). Do not administer to children under 2 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e \u003cu\u003eAdults\u003c\/u\u003e: 10 ml of syrup up to 3 times a day at intervals of at least 6 hours. \u003cu\u003eChildren\u003c\/u\u003e: 10-20 kg 3 ml 3 times a day; 20-30 kg 5 ml 3 times a day. Treatment should be continued until the cough disappears. However, if after 2 weeks of therapy the cough is still present, it is advisable to stop treatment and ask your doctor for advice. In fact, cough is a symptom and the causal pathology should be studied and treated. \u003ci\u003ePediatric population\u003c\/i\u003e Do not administer to children under 2 years of age (see section 4.3). \u003cu\u003eMethod of administration\u003c\/u\u003e The package includes a measuring cup with notches corresponding to 3, 5 and 10 ml. To open the package you need to firmly press the cap and rotate it counterclockwise at the same time.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe observation that the pharmacokinetic profiles of levodropropizine are not markedly altered in the elderly suggests that dose corrections or modifications of the intervals between administrations may not be required in old age. In any case, in light of the evidence that sensitivity to various drugs is altered in the elderly, special caution should be used when levodropropizine is administered to elderly patients. It is advisable to use caution in patients with severe renal insufficiency (creatinine clearance below 35 ml\/min). It is also advisable to use caution in case of simultaneous intake of sedative drugs in particularly sensitive individuals (see 4.5). This medicine contains 4 g of sucrose per dose (10 ml). To be taken into consideration in people suffering from diabetes mellitus. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. This medicine contains methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reactions (possibly delayed). This medicinal product contains 22.5 mg of propylene glycol per dose (10 ml), equivalent to 2.25 mg\/ml. This medicinal product contains less than 1 mmol (23 mg) sodium per single 10 ml dose, i.e. essentially sodium-free. This medicinal product contains 41 mg sodium per 20 ml daily dose (10 ml twice a day in the adult dosage), equivalent to 2% of the WHO recommended maximum daily intake of 2 g sodium for an adult. This medicinal product contains 62 mg sodium per maximum daily dose of 30 ml (10 ml 3 times during the day in the adult dosage), equivalent to 3% of the maximum daily intake recommended by WHO which corresponds to 2 g sodium for an adult. Antitussive drugs are symptomatic and should only be used while awaiting diagnosis of the underlying cause and\/or the effect of therapy on the underlying pathology. In the absence of information on the effect of food intake on the absorption of the drug, it is advisable to take the drug between meals.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAnimal pharmacology studies have shown that levodropropizine does not enhance the pharmacological effect of substances active on the central nervous system (e.g. benzodiazepines, alcohol, phenytoin, imipramine). In animals, the product does not modify the activity of oral anticoagulants, such as warfarin, nor does it interfere with the hypoglycemic action of insulin. In human pharmacology studies, the association with benzodiazepine does not modify the EEG picture. However, it is necessary to use caution in case of simultaneous intake of sedative drugs in particularly sensitive individuals (see 4.4). Clinical studies show no interaction with drugs used in the treatment of bronchopulmonary diseases such as β\u003csub\u003e2\u003c\/sub\u003e-agonists, methylxanthines and derivatives, corticosteroids, antibiotics, mucoregulators and antihistamines.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDuring treatment with levodropropizine palpitations, tachycardia, nausea, vomiting, diarrhea, erythema may occur. Reactions reported as serious are urticaria and anaphylactic reaction. Most of the reactions that occur following the intake of levodropropizine are not serious and the symptoms resolve with the suspension of therapy and, in some cases, with specific pharmacological treatment. The adverse reactions encountered (incidence unknown) are as follows: \u003cb\u003eEye pathologies\u003c\/b\u003e: Mydriasis, bilateral blindness. \u003cb\u003eImmune system disorders\u003c\/b\u003e: Allergic and anaphylactoid reactions, eyelid edema, angioneurotic edema, urticaria. \u003cb\u003ePsychiatric disorders\u003c\/b\u003e: Nervousness, drowsiness, personality change or personality disorder. \u003cb\u003eNervous system disorders:\u003c\/b\u003e Syncope, dizziness, vertigo, tremors, paraesthesia, tonic-clonic convulsion and petit mal attack, hypoglycaemic coma. \u003cb\u003eCardiac diseases\u003c\/b\u003e: Palpitations, tachycardia, atrial bigeminy. \u003cb\u003eVascular pathologies\u003c\/b\u003e: Hypotension. \u003cb\u003eRespiratory, thoracic and mediastinal disorders:\u003c\/b\u003e Dyspnea, cough, respiratory tract edema. \u003cb\u003eGastrointestinal disorders\u003c\/b\u003e: Gastric pain, abdominal pain, nausea, vomiting, diarrhoea. \u003cb\u003e Hepatobiliary disorders\u003c\/b\u003e: Cholestatic hepatitis. \u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e: Urticaria, erythema, exanthema, pruritus, angioedema, skin reactions, glossitis and aphthous stomatitis. Epidermolysis. \u003cb\u003eMusculoskeletal system and connective tissue disorders:\u003c\/b\u003e Weakness of the lower limbs. \u003cb\u003eSystemic pathologies and conditions relating to the administration site\u003c\/b\u003e: General malaise, generalized edema, asthenia. \u003cu\u003ePediatric population\u003c\/u\u003e A case of drowsiness, hypotonia and vomiting in a newborn infant after taking levodropropizine by the nursing mother has been reported. The symptoms appeared after feeding and resolved spontaneously by suspending breastfeeding for a few feedings. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioniavverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo significant side effects have been reported after administration of the drug up to 240 mg in single administration and up to 120 mg t.i.d. for 8 consecutive days. There are known cases of overdose in children aged between 2 and 4 years. These are cases of accidental overdose, all resolved without consequences. In most cases, patients experienced abdominal pain and vomiting and in one case, after taking 600 mg of levodropropizine, the patient experienced excessive sleep and decreased oxygen saturation. In case of overdose with evident clinical manifestations, immediately institute symptomatic therapy and apply the usual emergency measures (gastric lavage, activated charcoal meal, parenteral administration of liquid, etc.), if appropriate.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTeratogenicity, reproduction and fertility studies as well as peri- and post-natal studies did not reveal specific toxic effects. However, since in toxicological studies in animals at a dose of 24 mg\/kg a slight delay in body weight gain and growth was observed and since levodropropizine is able to cross the placental barrier in rats, the use of the drug is contraindicated in women who intend to become or are already pregnant as its safety of use is not documented (see 4.3). Studies in rats indicate that the drug is found in breast milk for up to 8 hours after administration. Therefore, the use of the drug during breastfeeding is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo studies on the effects on the ability to drive and\/or use machines have been performed. However, since the product may, although rarely, cause drowsiness (see section 4.8), use with caution in patients who intend to drive vehicles or operate machinery, informing them of this possibility.\u003c\/p\u003e","brand":"Dompé","offers":[{"title":"Default Title","offer_id":46459607875911,"sku":"026752016","price":11.63,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/dompe-farmaceutici-spa-levotuss-sciroppo-30-mg-5-ml-levodropropizina-200-ml-farmacia-dottor-tili-1213792503.png?v=1767112349"},{"product_id":"fluifort-sciroppo-mucolitico-200-ml-90-mg-ml","title":"Fluifort Mucolytic Syrup 200 ml 90 mg \/ ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMucolytic, fluidifying in acute and chronic respiratory system diseases.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 ml of syrup contains: active ingredient: carbocysteine lysine salt monohydrate equal to 9 g of carbocysteine lysine salt. Excipients with known effect: sucrose, methyl parahydroxybenzoate, ethanol (contained in cherry flavouring). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSucrose, natural cherry flavor (containing ethanol), methyl parahydroxybenzoate, caramel, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Gastroduodenal ulcer. Pregnancy and breastfeeding. The drug is contraindicated in children under 2 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA graduated measuring cup is attached to the package. To open the package you need to press the cap firmly and simultaneously rotate it anti-clockwise. \u003cu\u003eAdults\u003c\/u\u003e: 15 ml 2-3 times a day or according to medical prescription. The maximum duration of therapy is up to 14 days. However, carbocysteine ​​lysine salt monohydrate can also be used for prolonged periods, according to the doctor's opinion. \u003cu\u003eChildren\u003c\/u\u003e: over 5 years: 5 ml 2-3 times a day or according to medical prescription from 2 to 5 years: 2.5 ml 2-3 times a day or according to medical prescription The maximum duration of therapy is up to 7 days. However, carbocysteine ​​lysine salt monohydrate can also be used for prolonged periods, according to the doctor's opinion. In consideration of the pharmacokinetic characteristics, the recommended dosage can be maintained even in patients with renal and hepatic insufficiency.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore at temperatures not exceeding 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMucolytics can induce bronchial obstruction in children under 2 years of age. In fact, the drainage capacity of bronchial mucus is limited in this age group, due to the physiological characteristics of the respiratory tract. They should therefore not be used in children under 2 years of age (see section 4.3). \u003cu\u003eGastrointestinal bleeding\u003c\/u\u003e Cases of gastrointestinal bleeding have been reported with the use of carbocysteine. Caution is advised in the elderly, in patients with a history of gastroduodenal ulcers, or in patients taking concomitant medications known to increase the risk of gastrointestinal bleeding. In case of gastrointestinal bleeding, the patient should discontinue treatment with carbocysteine. \u003cu\u003eAsthmatic and debilitated patients\u003c\/u\u003e: It is recommended to take specific precautions in patients with severe respiratory insufficiency, in patients with asthma and a history of bronchospasm, as well as in debilitated patients. The use of carbocysteine ​​causes a decrease in mucus viscosity and an increase in mucus removal, both through the ciliary activity of the epithelium and through the cough reflex. Therefore, increased cough and sputum is expected. The use of antitussive medicines inhibits the cough reflex and increases the risk of airway obstruction, due to an increase in the accumulation of mucus in the airways. The concomitant use of this medicinal product with cough suppressants and\/or medicinal products that inhibit bronchial secretion (e.g. anti-muscarinic medicinal products) is not recommended. There are no known phenomena of habituation or dependence. Fluifort 90 mg\/ml syrup contains sucrose. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. Fluifort 90 mg\/ml syrup contains ethanol This medicine contains 14.4 mg of alcohol (ethanol) in each dose (15 ml). The amount in 15 ml of this medicine is equivalent to less than 3 ml of beer or 1 ml of wine. The small amount of alcohol in this medicine will not produce any noticeable effects. Fluifort 90 mg\/ml syrup contains methyl parahydroxybenzoate. This medicine contains methyl parahydroxybenzoate, which is known to cause urticaria. In general, parahydroxybenzoates can cause delayed reactions, such as contact dermatitis, and rarely immediate reactions with manifestations of urticaria and bronchospasm. Fluifort 90 mg\/ml syrup does not contain gluten; therefore it can be administered to patients suffering from celiac disease. Fluifort 90 mg\/ml syrup does not contain aspartame; therefore it can be administered to patients suffering from phenylketonuria.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn controlled clinical studies, no interactions were highlighted with the most common drugs used in the treatment of upper and lower airway diseases, nor with foods or laboratory tests.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects are described according to system organ class according to MedDRA and on the basis of the frequency estimated from post-marketing experience. Frequencies are defined as follows: very common (≥1\/10); common (≥1\/100, \u003c1\/10); uncommon: (≥1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1000); very rare (\u003c1\/10,000); not known (frequency cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Not known. Adverse reaction: Skin rash, urticaria, erythema, exanthema, exanthema\/bullous erythema, pruritus, angioedema, dermatitis Stevens-Johnson syndrome, bullous dermatitis, erythema multiforme, toxic skin rash.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Not known. Adverse reaction: Abdominal pain, nausea, vomiting, diarrhea Gastrointestinal bleeding.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Not known. Adverse reaction: Dizziness.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Not known. Adverse reaction: Dyspnea.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Frequency: Not known. Adverse reaction: Redness.\u003c\/p\u003e\n\u003cp\u003eBronchial obstruction may also occur with unknown frequency with mucolytics for oral and rectal use. \u003cb\u003e \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e \u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptoms reported in case of overdose are: headache, nausea, vomiting, diarrhea, gastralgia, skin reactions, alteration of sensory systems. There is no specific antidote; it is advisable to induce vomiting and possibly perform gastric lavage followed by specific support therapy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAlthough the active ingredient is neither teratogenic nor mutagenic and has not shown negative effects on the reproductive function in animals, Fluifort must not be administered during pregnancy (see 4.3). Since no data are available regarding the passage of carbocysteine ​​lysine salt monohydrate into breast milk, use during breastfeeding is contraindicated (see 4.3).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo adverse effects of the drug on the ability to drive or use machinery have been reported.\u003c\/p\u003e","brand":"Dompé","offers":[{"title":"Default Title","offer_id":46486289973575,"sku":"023834068","price":11.63,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/dompe-farmaceutici-spa-fluifort-sciroppo-mucolitico-200-ml-90-mg-ml-farmacia-dottor-tili-1213792497.jpg?v=1767112449"},{"product_id":"fluifort-granulato-mucolitico-soluzione-orale-10-bustine-2-7g","title":"Fluifort Mucolytic Granules Oral Solution 10 Sachets 2.7g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMucolytic, fluidifying in acute and chronic respiratory system diseases.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e1 sachet of 5 g contains: active ingredient: carbocysteine lysine salt monohydrate equal to 2.7 g of carbocysteine lysine salt Excipients with known effect: aspartame For the complete list of excipients, see paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCitric acid, mannitol, povidone, natural cedar flavor, natural orange flavor, orange juice, aspartame, maltodextrin.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Gastroduodenal ulcer. Pregnancy and breastfeeding. Pediatric patients (under 11 years).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOnly 1 sachet per day. In consideration of the pharmacokinetic characteristics, the recommended dosage can be maintained even in patients with renal and hepatic insufficiency. The maximum duration of therapy is up to 14 days. However, carbocysteine ​​lysine salt monohydrate can also be used for prolonged periods, according to the doctor's opinion. Instructions for using the sachet: dissolve the contents of the sachet in about half a glass of water, mixing well.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eGastrointestinal bleeding\u003c\/u\u003e Cases of gastrointestinal bleeding have been reported with the use of carbocysteine. Caution is advised in the elderly, in patients with a history of gastroduodenal ulcers, or in patients taking concomitant medications known to increase the risk of gastrointestinal bleeding. In case of gastrointestinal bleeding, the patient should discontinue treatment with carbocysteine. \u003cu\u003eAsthmatic and debilitated patients\u003c\/u\u003e: It is recommended to take specific precautions in patients with severe respiratory insufficiency, in patients with asthma and a history of bronchospasm, as well as in debilitated patients. The use of carbocysteine ​​causes a decrease in mucus viscosity and an increase in mucus removal, both through the ciliary activity of the epithelium and through the cough reflex. Therefore, increased cough and sputum is expected. The use of antitussive medicines inhibits the cough reflex and increases the risk of airway obstruction, due to an increase in the accumulation of mucus in the airways. The concomitant use of this medicinal product with cough suppressants and\/or medicinal products that inhibit bronchial secretion (e.g. anti-muscarinic medicinal products) is not recommended. There are no known phenomena of habituation or dependence. Fluifort 2.7 g granules for oral solution does not affect low-calorie or controlled diets and can also be administered to diabetic patients. Fluifort 2.7 g granules for oral solution does not contain gluten; therefore it can be administered to patients suffering from celiac disease. Fluifort 2.7 g granules for oral solution contains a source of phenylalanine which may be harmful to patients suffering from phenylketonuria. Dissolve the contents of the sachet in about half a glass of water, mixing well.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn controlled clinical studies, no interactions were highlighted with the most common drugs used in the treatment of upper and lower airway diseases, nor with foods or laboratory tests.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects are described according to system organ class according to MedDRA and on the basis of the frequency estimated from post-marketing experience. Frequencies are defined as follows: very common (≥1\/10); common (≥1\/100, \u003c1\/10); uncommon: (≥1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1000); very rare (\u003c1\/10,000); not known (frequency cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Not known. Adverse reaction: Skin rash, urticaria, erythema, exanthema, bullous rash\/erythema, pruritus, angioedema, dermatitis. Stevens-Johnson syndrome, bullous dermatitis, erythema multiforme, toxic skin rash.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Not known. Adverse reaction: Abdominal pain, nausea, vomiting, diarrhea. Gastrointestinal bleeding.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Not known. Adverse reaction: Dizziness.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Not known. Adverse reaction: Dyspnea.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Frequency: Not known. Adverse reaction: Redness.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e \u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptoms reported in case of overdose are: headache, nausea, vomiting, diarrhea, gastralgia, skin reactions, alteration of sensory systems. There is no specific antidote; it is advisable to induce vomiting and possibly perform gastric lavage followed by specific support therapy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAlthough the active ingredient is neither teratogenic nor mutagenic and has not shown negative effects on the reproductive function in animals, Fluifort must not be administered during pregnancy (see 4.3). Since no data are available regarding the passage of carbocysteine ​​lysine salt monohydrate into breast milk, use during breastfeeding is contraindicated (see 4.3).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo adverse effects of the drug on the ability to drive or use machinery have been reported.\u003c\/p\u003e","brand":"Dompé","offers":[{"title":"Default Title","offer_id":46656331055431,"sku":"023834118","price":11.07,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/dompe-farmaceutici-spa-fluifort-granulato-mucolitico-soluzione-orale-10-bustine-2-7g-farmacia-dottor-tili-1213792486.webp?v=1767112612"},{"product_id":"fluimucil-mucolitico-600mg-10-bustine-granulato-per-soluzione-orale","title":"Fluimucil mucolytic 600mg 10 sachets granules for oral solution","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTreatment of respiratory diseases characterized by dense and viscous hypersecretion.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg effervescent tablets\u003c\/i\u003e Each tablet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 600 mg. Excipients with known effects: aspartame, glucose, sodium. \u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg granules for oral solution \u003c\/i\u003e Each sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 600 mg. Excipients with known effects: aspartame, glucose, lactose, sorbitol. \u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg\/15 ml syrup\u003c\/i\u003e 15 ml of syrup contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 600 mg. Excipients with known effects: propylene glycol, methyl parahydroxybenzoate, propyl parahydroxybenzoate, sodium, sorbitol. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg, effervescent tablets\u003c\/i\u003e One tablet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 200 mg. Excipients with known effects: sodium, aspartame. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg, buccal tablets:\u003c\/i\u003e One tablet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 200 mg. Excipients with known effects: sorbitol, sodium, aspartame. \u003ci\u003e FLUIMUCIL MUCOLITIC 200 mg, granules for oral solution\u003c\/i\u003e One sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 200 mg. Excipients with known effects: sucrose, glucose, sunset yellow (E110), lactose. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg, granules for oral solution without sugar\u003c\/i\u003e One sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 200 mg. Excipients with known effects: sorbitol, aspartame. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg, granules for oral solution\u003c\/i\u003e One sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 100 mg. Excipients with known effects: sucrose, sunset yellow (E110).\u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg, granules for oral solution without sugar\u003c\/i\u003e One sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 100 mg. Excipients with known effects: sorbitol, aspartame. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg\/5 ml, syrup\u003c\/i\u003e A 150 ml bottle contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 3,000 g (corresponding to 100 mg\/5 ml of syrup). Excipients with known effects: ethanol, methyl parahydroxybenzoate, propylene glycol, sodium benzoate, sodium. A 200 ml bottle contains: \u003cu\u003e Active ingredient\u003c\/u\u003e: N-acetylcysteine 4,000 g (corresponding to 100 mg\/5 ml of syrup). Excipients with known effects: ethanol, methyl parahydroxybenzoate, propylene glycol, sodium benzoate, sodium. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg granules for oral solution \u003c\/i\u003e Aspartame, Orange flavor (containing glucose and lactose), Sorbitol. \u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg effervescent tablets \u003c\/i\u003e Anhydrous citric acid, Lemon flavor (containing glucose), Aspartame, Sodium bicarbonate. \u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg\/15 ml syrup 200 ml bottle\u003c\/i\u003eMethyl parahydroxybenzoate, Propyl parahydroxybenzoate, Sodium edetate, Carmellose, Sodium saccharin, Grenadine flavoring (containing propylene glycol), Strawberry flavoring (containing propylene glycol), Sorbitol, Sodium hydroxide, Purified water. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg buccal tablets\u003c\/i\u003e Anhydrous citric acid, sorbitol, mannitol, polyethylene glycol 6000, povidone, sodium bicarbonate, lemon flavouring, mandarin flavouring, aspartame, magnesium stearate, microcrystalline cellulose. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg granules for oral solution without sugar \u003c\/i\u003e Sorbitol, aspartame, orange flavouring. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg granules for oral solution\u003c\/i\u003eOrange juice granules; Orange flavor (containing glucose and lactose); saccharin; sunset yellow (E 110); Sucrose. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg effervescent tablets\u003c\/i\u003e \u003ci\u003eAnhydrous citric acid, sodium bicarbonate, lemon flavouring, aspartame.\u003c\/i\u003e \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg granules for oral solution\u003c\/i\u003eOrange juice granules; Orange flavour; Saccharin; E 110; Sucrose. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg granules for oral solution without sugar\u003c\/i\u003e Sorbitol; Aspartame; Orange flavour. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg\/5 ml syrup 150 ml bottle\u003c\/i\u003e Methyl parahydroxybenzoate, sodium benzoate, sodium edetate, sodium carboxymethyl cellulose, raspberry flavor (containing propylene glycol and ethanol), sodium saccharinate, sodium hydroxide, purified water. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg\/5 ml syrup 200 ml bottle\u003c\/i\u003e Methyl parahydroxybenzoate, sodium benzoate, sodium edetate, sodium carboxymethylcellulose, sodium cyclamate, sucralose, raspberry flavor (containing propylene glycol and ethanol), sodium saccharinate, sodium hydroxide, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Children under 2 years of age. Pregnancy and breast-feeding (see section 4.6).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eAdults\u003c\/u\u003e: 1 sachet of Mucolytic Fluimucil 200 mg granules for oral solution (with or without sugar) or 2 sachets of Mucolytic Fluimucil 100 mg (with or without sugar) 2-3 times a day. Fluimucil Mucolytic 200 mg, buccal tablets and effervescent tablets: 1 tablet 2-3 times a day. Fluimucil Mucolytic 100 mg\/5 ml, syrup: 10 ml of syrup (1 measuring spoon), equal to 200 mg of N-acetylcysteine, 2-3 times a day. Fluimucil Mucolytic 600 mg\/15 ml syrup, Fluimucil Mucolytic 600 mg effervescent tablets and Fluimucil Mucolytic 600 mg granules for solution: a 15 ml measuring spoon or an effervescent tablet or a sachet (preferably in the evening). Any dosage adjustments may concern the frequency of administration or the fractionation of the dose but must in any case be included within the maximum daily dosage of 600 mg. \u003cu\u003eChildren over 2 years old\u003c\/u\u003e: Fluimucil Mucolytic 100 mg granules for oral solution (with or without sugar): 1 sachet 2 to 4 times a day, depending on age. Fluimucil Mucolytic 100 mg\/5 ml, syrup: ½ scoop of syrup (5 ml), equal to 100 mg of N-acetylcysteine, 2 to 4 times a day depending on age. The duration of therapy is 5 to 10 days. \u003cb\u003eMethod of administration\u003c\/b\u003e \u003cu\u003eGranules for oral solution\u003c\/u\u003e: dissolve the contents of a sachet in a glass containing a little water, mixing as needed with a teaspoon. This results in a pleasant solution that can be drunk directly from the glass or, in the case of small children, given in teaspoons or in a bottle. The solution should be taken as soon as it is ready. \u003cu\u003eOral soluble tablets\u003c\/u\u003e: keep the tablet in the oral cavity until it has completely dissolved. \u003cu\u003eSyrup\u003c\/u\u003e: shake before use. Once opened, the syrup is valid for 15 days. Effervescent tablets: dissolve one tablet in a glass containing a little water, mixing as needed with a teaspoon. To facilitate the release of the tablet, we recommend tearing open the blister, using the side notches as indicated in the figure.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSachets of 100 and 200 granules for oral solution, 600 mg granules for oral solution, 200 mg granules for oral solution without sugar and 200 mg buccal tablets: store at a temperature not exceeding 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePatients suffering from bronchial asthma must be closely monitored during therapy; if bronchospasm appears, treatment with N-acetylcysteine ​​must be immediately suspended and appropriate treatment must be started. Mucolytics can induce bronchial obstruction in children under 2 years of age. In fact, the drainage capacity of bronchial mucus is limited in this age group, due to the physiological characteristics of the respiratory tract. They should therefore not be used in children under 2 years of age (see section 4.3). The use of the medicine in patients suffering from peptic ulcers or with a history of peptic ulcers requires particular attention, especially in case of simultaneous intake of other drugs with a known gastro-injurious effect. The possible presence of a sulphurous odor does not indicate alteration of the preparation but is specific to the active ingredient contained in it. The administration of N-acetylcysteine, especially at the beginning of treatment, can fluidize bronchial secretions and increase their volume at the same time. If the patient is unable to expectorate effectively, postural drainage and bronchoaspiration should be used to avoid retention of secretions. N-acetylcysteine ​​can affect histamine metabolism. Therefore, caution should be used when administering Fluimucil Mucolytic to patients with histamine intolerance, as hypersensitivity symptoms may occur. \u003ci\u003e \u003cu\u003eImportant information about some excipients\u003c\/u\u003e \u003c\/i\u003e Sodium benzoate The 100 mg\/5 ml syrup (150 ml and 200 ml) contains 15 mg of sodium benzoate for the 10 ml dose and 7.5 mg for the 5 ml dose.\u003ci\u003eParahydroxybenzoates\u003c\/i\u003e Syrups contain parahydroxybenzoates which can cause delayed allergic reactions. \u003ci\u003eSorbitol\u003c\/i\u003e The buccal tablets, 600 mg\/15 ml syrup, 600 mg granules for oral solution and 100 mg and 200 mg sugar-free granules for oral solution contain sorbitol. The sorbitol content in oral medicinal products may modify the bioavailability of other co-administered oral medicinal products. Patients with hereditary fructose intolerance should not be given these medicines. \u003ci\u003eAspartame\u003c\/i\u003e The buccal tablets, effervescent tablets, granules for oral solution 600 mg and granules for sugar-free oral solution 100 and 200 mg contain aspartame, a source of phenylalanine which may be harmful in patients with phenylketonuria. \u003ci\u003eGlucose\u003c\/i\u003e The 600 mg effervescent tablets, the 600 mg granules for oral solution and the 200 mg granules for oral solution contain glucose, patients suffering from rare problems of glucose-galactose malabsorption should not take this medicine. \u003ci\u003eSunset yellow (E110)\u003c\/i\u003e The granules for oral solution 100 mg and 200 mg contain sunset yellow (E110) which may cause allergic reactions. \u003ci\u003eSucrose\u003c\/i\u003e The granules for oral solution 100 and 200 mg contain sucrose. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. \u003ci\u003eSodium\u003c\/i\u003e The buccal tablets contain 26.9 mg sodium per tablet equivalent to 1.3% of the WHO recommended maximum daily intake of 2 g sodium for an adult. The 200 mg and 600 mg effervescent tablets contain 156.9 mg sodium per dose, equivalent to 7.8% of the WHO recommended maximum daily intake of 2 g sodium for an adult. The 100 mg\/5 ml (150 ml) syrup contains 36.7 mg of sodium per 10 ml dose, equivalent to 1.83% of the WHO recommended maximum daily intake of 2 g of sodium for an adult. The 100 mg\/5 ml (150 ml) syrup contains 18.4 mg sodium per 5 ml dose, equivalent to 0.9% of the WHO recommended maximum daily intake of 2 g sodium for an adult. The 100 mg\/5 ml (200 ml) syrup contains 38.2 mg of sodium per 10 ml dose, equivalent to 1.9% of the WHO recommended maximum daily intake of 2 g of sodium for an adult. The 100 mg\/5 ml (200 ml) syrup contains 19.1 mg sodium per 5 ml dose, equivalent to 0.9% of the WHO recommended maximum daily intake of 2 g sodium for an adult. The 600 mg\/15 ml syrup contains 98.31 mg of sodium per 15 ml dose equivalent to 4.9% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult. \u003ci\u003eLactose\u003c\/i\u003e The 600 mg granules for oral solution and the 200 mg granules for oral solution contain lactose. Patients suffering from rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. \u003ci\u003ePropylene glycol\u003c\/i\u003e The 100 mg\/5 ml syrup (150 ml and 200 ml) contains 23.4 mg of propylene glycol for the 10 ml dose and 11.7 mg for the 5 ml dose. The 600 mg\/15 ml syrup contains 168 mg of propylene glycol per dose (15 ml) equivalent to 11.2 mg\/ml. \u003ci\u003eEthanol\u003c\/i\u003e The 100 mg\/5 ml syrup (150 ml and 200 ml) contains 3.85 mg of alcohol (ethanol) in every 100 ml. The dose quantity of this medicine is equivalent to less than 1 ml of beer or 1 ml of wine. The small amount of alcohol in this medicine will not produce any noticeable effects.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDrug-drug interaction\u003c\/u\u003e. Antitussive drugs and mucolytic agents, such as N-acetylcysteine, should not be taken at the same time as the reduction of the cough reflex could lead to an accumulation of bronchial secretions. Activated charcoal can reduce the effect of N-acetylcysteine. It is advisable not to mix other drugs with the Fluimucil Mucolytic solution. The information available regarding the antibiotic-N-acetylcysteine ​​interaction refers to in vitro tests, in which the two substances were mixed, which showed a decreased activity of the antibiotic. However, as a precaution, it is recommended to take oral antibiotics at least two hours after the administration of N-acetylcysteine, excluding loracarbef. It has been shown that the simultaneous intake of nitroglycerin and N-acetylcysteine ​​causes significant hypotension and causes dilation of the temporal artery with the possible onset of headache. If the simultaneous administration of nitroglycerin and N-acetylcysteine ​​is necessary, patients should be monitored for the appearance of hypotension which can even be severe and alerted to the possible onset of headache. \u003cu\u003ePediatric population\u003c\/u\u003e Interaction studies have only been carried out in adults. \u003cu\u003eDrug-laboratory test interactions\u003c\/u\u003e N-acetylcysteine may cause interference with the colorimetric assay method for the determination of salicylates. N-acetylcysteine ​​may interfere with urine ketone testing.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSafety profile summary\u003c\/u\u003e The adverse events most frequently associated with the oral administration of N-acetylcysteine ​​are gastrointestinal in nature. Less frequently, hypersensitivity reactions including anaphylactic shock, anaphylactic\/anaphylactoid reactions, bronchospasm, angioedema, rash and pruritus have been reported. \u003cu\u003eTabular list of adverse reactions\u003c\/u\u003e The following table shows the adverse reactions listed according to the classification and frequency system: very common (≥ 1\/10), common (≥ 1\/100 to \u003c 1\/10), uncommon (≥ 1\/1,000 to \u003c 1\/100), rare (≥ 1\/10,000 to \u003c 1\/1,000), very rare (\u003c 1\/10,000) and not known (the frequency cannot be established on the basis of available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003eSystem organ class - Adverse reactions: Uncommon (≥1\/1,000; \u003c1\/100). Rare (≥1\/10,000; \u003c1\/1,000). Very rare (\u003c1\/10,000). Not known.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Adverse reactions: Hypersensitivity. Anaphylactic shock, anaphylactic\/anaphylactoid reaction.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Adverse reactions: Headache.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders - Adverse reactions: Tinnitus.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders - Adverse reactions: Tachycardia.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Haemorrhage.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Bronchospasm, dyspnoea. Bronchial obstruction.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Adverse reactions: Vomiting, diarrhea, stomatitis, abdominal pain, nausea. Dyspepsia.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Adverse reactions: Urticaria, rash, angioedema, pruritus.\u003c\/p\u003e\n\u003cp\u003eSystemic disorders and conditions relating to the administration site - Adverse reactions: Pyrexia. Edema of the face.\u003c\/p\u003e\n\u003cp\u003eDiagnostic tests - Adverse reactions: Reduced blood pressure.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDescription of some adverse reactions\u003c\/u\u003e In very rare cases, the appearance of serious skin reactions has occurred in temporal connection with the intake of N-acetylcysteine, such as Stevens-Johnson syndrome and Lyell syndrome. Although in most cases at least one other suspected drug has been identified which is more likely involved in the genesis of the aforementioned mucocutaneous syndromes, in case of mucocutaneous alterations it is advisable to contact your doctor and the intake of N-acetylcysteine ​​must be stopped immediately. Some studies have confirmed a reduction in platelet aggregation when taking N-acetylcysteine. The clinical significance of these findings has not yet been defined. \u003ci\u003eReporting of suspected adverse reactions\u003c\/i\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been found with oral administration of N-acetylcysteine. Healthy volunteers, who took a daily dose of 11.6 g of N-acetylcysteine ​​for three months, did not experience serious adverse reactions. Doses up to 500 mg NAC\/kg body weight, administered orally, were tolerated without any symptoms of intoxication. \u003ci\u003eSymptoms\u003c\/i\u003e Overdose can cause gastrointestinal symptoms such as nausea, vomiting and diarrhea. \u003ci\u003eTreatment\u003c\/i\u003e There are no specific antidotal treatments; Overdose therapy is based on symptomatic treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAlthough the teratological studies conducted with Fluimucil Mucolytic on animals have not shown any teratogenic effect, however, as with other drugs, its administration during pregnancy and during the period of breastfeeding with breast milk should only be carried out in case of actual need.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eN-acetylcysteine does not influence the ability to drive and use machines.\u003c\/p\u003e","brand":"Zambon","offers":[{"title":"Default Title","offer_id":51131181891911,"sku":"034936169","price":6.9,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/zambon-italia-srl-fluimucil-mucolitico-600mg-10-bustine-granulato-per-soluzione-orale-farmacia-dottor-tili-1213792411.jpg?v=1767115690"},{"product_id":"tiocalmina-1-2g-100ml-0-1g-100ml-sciroppo-200g","title":"Tiocalmina 1.2g\/100ml + 0.1g\/100ml syrup 200g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic treatment of coughs of any nature, irritative cough and smoker's cough.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 ml of syrup contains: Active ingredients: potassium sulfoguaiacholate 1.2 g; dropropizine 0.1 g \u003cu\u003eExcipient with known effect: sucrose, ethanol and p-hydroxybenzoate.\u003c\/u\u003e For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eThe excipients are\u003c\/u\u003e: sucrose, ethanol, sweet orange essence aroma, citric acid monohydrate, methyl p-hydroxybenzoate, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. - Pregnancy - Diabetes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eChildren: 1 tablespoon 2 times a day Adults: 1 tablespoon 2 to 4 times a day Method of administration To be taken as is or diluted in your favorite drink (hot or cold) preferably between meals.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNone\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not exceed the recommended doses. After a short period of treatment without appreciable results, consult your doctor. This medicine contains \u003cu\u003esucrose\u003c\/u\u003e: Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency should not take this medicine. One dose (1 tablespoon) of this medicine administered to a child 2 years of age or older (12 kg) would result in exposure to 346 mg\/kg of ethanol which may cause an increase in blood alcohol concentration (BAC) of approximately 4.8 mg\/100 ml. Co-administration with medicines containing e.g. propylene glycol or ethanol may lead to ethanol accumulation and induce adverse effects, particularly in young children with low or immature metabolic activity.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known interactions with other medicines.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRarely reported nausea and other mild gastrointestinal disorders. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known cases of overdose.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAs a precaution, we do not recommend using the product during breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe product can cause tiredness and drowsiness, therefore particular attention must be paid when driving vehicles and operating machinery.\u003c\/p\u003e","brand":"Polifarma Benessere","offers":[{"title":"Default Title","offer_id":51131205583175,"sku":"008883035","price":11.07,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/polifarma-benessere-srl-tiocalmina-1-2g-100ml-0-1g-100ml-sciroppo-200g-farmacia-dottor-tili-1213792379.jpg?v=1767133031"},{"product_id":"fluifort-2-7g-10ml-sciroppo-12-bustine-10ml","title":"Fluifort 2.7g\/10ml syrup 12 sachets 10ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMucolytic, fluidifying in acute and chronic respiratory system diseases.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA 10 ml sachet of 27% syrup contains: active ingredient: carbocysteine lysine salt monohydrate equal to 2.7 g of carbocysteine lysine salt. Excipients with known effect: methyl parahydroxybenzoate, propyl parahydroxybenzoate, sorbitol, sodium carmellose, ethanol (contained in cherry flavouring). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSorbitol (70% solution); xylitol; ammonium glycyrrhizinate; carmellose sodium; glycerol; cherry flavoring (containing ethanol); methyl parahydroxybenzoate; propyl parahydroxybenzoate; purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Gastroduodenal ulcer. Pregnancy and breastfeeding. The drug is contraindicated in pediatric patients under 11 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e1 sachet per day. Fluifort 2.7 g\/10 ml syrup, due to its innovative packaging, ensures precision in dosage, hygiene, practicality and ease of intake and is particularly suitable for conditions in the acute phase for which short-term treatment is envisaged. In consideration of the pharmacokinetic characteristics, the recommended dosage can be maintained even in patients with renal and hepatic insufficiency. The maximum duration of therapy is up to 14 days. However, carbocysteine ​​lysine salt monohydrate can also be used for prolonged periods, according to the doctor's opinion.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore below 25°C. If stored correctly, any change in color of the preparation does not affect the therapeutic activity of the specialty which remains valid until the indicated expiry date.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eGastrointestinal bleeding\u003c\/u\u003e Cases of gastrointestinal bleeding have been reported with the use of carbocysteine. Caution is advised in the elderly, in patients with a history of gastroduodenal ulcers, or in patients taking concomitant medications known to increase the risk of gastrointestinal bleeding. In case of gastrointestinal bleeding, the patient should discontinue treatment with carbocysteine. \u003cu\u003eAsthmatic and debilitated patients\u003c\/u\u003e It is recommended to take specific precautions in patients with severe respiratory failure, in patients with asthma and a history of bronchospasm, as well as in debilitated patients. The use of carbocysteine ​​causes a decrease in mucus viscosity and an increase in mucus removal, both through the ciliary activity of the epithelium and through the cough reflex. Therefore, increased cough and sputum is expected. The use of antitussive medicines inhibits the cough reflex and increases the risk of airway obstruction, due to an increase in the accumulation of mucus in the airways. The concomitant use of this medicinal product with cough suppressants and\/or medicinal products that inhibit bronchial secretion (e.g. anti-muscarinic medicinal products) is not recommended. There are no known phenomena of habituation or dependence. This medicine contains methyl parahydroxybenzoate and propyl parahydroxybenzoate, which are known to cause urticaria. In general, parahydroxybenzoates can cause delayed reactions, such as contact dermatitis, and rarely immediate reactions with manifestations of urticaria and bronchospasm. This medicine contains sorbitol, patients suffering from rare hereditary problems of fructose intolerance should not take this medicine. Fluifort 2.7 g \/10 ml syrup contains ethanol This medicine contains 15.2 mg of alcohol (ethanol) in each dose (10 ml). The amount in 10 ml of this medicine is equivalent to less than 4 ml of beer or 2 ml of wine. The small amount of alcohol in this medicine will not produce any noticeable effects. Fluifort 2.7 g \/10 ml syrup contains less than 1 mmol (23 mg) sodium per dose, i.e. essentially 'sodium-free'. Fluifort 2.7 g \/10 ml syrup does not contain aspartame; therefore it can be administered to patients suffering from phenylketonuria. Fluifort 2.7 g\/10 ml syrup does not affect low-calorie or controlled diets and can also be administered to diabetic patients. Fluifort 2.7 g\/10 ml syrup does not contain gluten; therefore it can be administered to patients suffering from celiac disease. Open the sachet following the dotted line and ingest the contents.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn controlled clinical studies, no interactions were highlighted with the most common drugs used in the treatment of upper and lower airway diseases, nor with foods or laboratory tests.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects are described according to system organ class according to MedDRA and on the basis of the frequency estimated from post-marketing experience. Frequencies are defined as follows: very common (≥1\/10); common (≥1\/100, \u003c1\/10); uncommon: (≥1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1000); very rare (\u003c1\/10,000); not known (frequency cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Not known. Adverse reaction: Skin rash, urticaria, erythema, exanthema, exanthema\/bullous erythema, pruritus, angioedema, dermatitis Stevens-Johnson syndrome, bullous dermatitis, erythema multiforme, toxic skin rash.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Not known. Adverse reaction: Abdominal pain, nausea, vomiting, diarrhea Gastrointestinal bleeding.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Not known. Adverse reaction: Dizziness.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Not known. Adverse reaction: Dyspnea.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Frequency: Not known. Adverse reaction: Redness.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e \u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptoms reported in case of overdose are: headache, nausea, vomiting, diarrhea, gastralgia, skin reactions, alteration of sensory systems. There is no specific antidote; it is advisable to induce vomiting and possibly perform gastric lavage followed by specific support therapy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAlthough the active ingredient is neither teratogenic nor mutagenic and has not shown negative effects on the reproductive function in animals, Fluifort must not be administered during pregnancy (see 4.3). Since no data are available regarding the passage of carbocysteine ​​lysine salt monohydrate into breast milk, use during breastfeeding is contraindicated (see 4.3).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo adverse effects of the drug on the ability to drive or use machinery have been reported.\u003c\/p\u003e","brand":"Dompé","offers":[{"title":"Default Title","offer_id":51131208040775,"sku":"023834144","price":13.49,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/dompe-farmaceutici-spa-fluifort-2-7g-10ml-sciroppo-12-bustine-10ml-farmacia-dottor-tili-1213792367.jpg?v=1767142409"},{"product_id":"grintuss-adulti-sciroppo-180g","title":"Grintuss Adults Syrup 180g","description":"\u003cp\u003eThe \u003cstrong\u003eGrintuss Adults syrup 180g\u003c\/strong\u003e is an innovative medical device, designed to offer effective treatment of \u003cstrong\u003edry, oily cough\u003c\/strong\u003e. Formulated with the plant complex \u003cstrong\u003ePolyresin\u003c\/strong\u003e and enriched with \u003cstrong\u003ehoney\u003c\/strong\u003e, this syrup is ideal for adults and children aged 12 and over. Its action is based on a natural approach, free of preservatives, synthetic substances or artificial sweeteners, guaranteeing a safe and healthy product.\u003c\/p\u003e\n\n\u003cp\u003eThanks to the combination of \u003cstrong\u003epolysaccharides, resins and flavonoids\u003c\/strong\u003e extracted from plants such as plantain, grindelia and helichrysum, Grintuss Adult syrup creates a \u003cstrong\u003eprotective barrier\u003c\/strong\u003e on the respiratory tract, reducing irritation and promoting mucus hydration. This soothing effect is enhanced by the presence of \u003cstrong\u003eessential oils\u003c\/strong\u003e of eucalyptus, star anise and lemon, which contribute to an action \u003cstrong\u003eanti-inflammatory\u003c\/strong\u003e e \u003cstrong\u003emucoregulator\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eGrintuss Adult Syrup is made with ingredients sourced from \u003cstrong\u003eorganic farming\u003c\/strong\u003e, ensuring a high quality and environmentally friendly product. Its formulation without \u003cstrong\u003egluten\u003c\/strong\u003e e \u003cstrong\u003elactose\u003c\/strong\u003e It also makes it suitable for those with food intolerances. This syrup not only relieves cough symptoms but also promotes action \u003cstrong\u003elubricant\u003c\/strong\u003e e \u003cstrong\u003ehydrating\u003c\/strong\u003e, improving the well-being of the respiratory tract during the acute and persistent phases of cough.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy should Grintuss Adulti syrup 180g be used? What is it for?\u003c\/h3\u003e\u003cp\u003eSyrup based on the Poliresin plant complex and honey, indicated in case of dry and oily cough in adults and children aged 12 and over; creates a protective and soothing barrier on the respiratory tract which promotes the hydration of mucus and reduces irritation.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Grintuss Adulti syrup 180g contain?\u003c\/h3\u003e\u003cp\u003e10 ml of product contains: Poliresin plant complex 159 mg, based on polysaccharides, resins and flavonoids (LPME extractive fraction of plantain*, grindelia* and helichrysum*), honey* 3.4 g, cane sugar*, water, essential oils of eucalyptus, star anise and lemon, natural lemon flavour, gum arabic and xanthan.\u003cbr\u003e*Ingredient from organic farming\u003cbr\u003eIt does not contain preservatives and artificial sweeteners\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Grintuss Adult syrup 180g?\u003c\/h3\u003e\u003cp\u003e10 ml of syrup (two teaspoons) two to four times a day, carrying out the last administration before bedtime. Shake before use. After use, close the bottle tightly. The product can also be taken for prolonged periods. If after 14 days of treatment the symptoms do not resolve, it is still recommended to consult a doctor.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Grintuss Adulti syrup 180g?\u003c\/h3\u003e\u003cp\u003eDo not use if there is individual hypersensitivity or allergy to one or more components.\u003cbr\u003eKeep out of reach of children.\u003cbr\u003eIf you notice the appearance of an undesirable effect attributable to the product or its use, inform your doctor and\/or pharmacist and the Aboca manufacturer at the contact details listed on the package leaflet. In the event of a serious accident, also inform the competent authority of your country.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Grintuss Adulti syrup 180g stored?\u003c\/h3\u003e\u003cp\u003eStore at room temperature even after opening.\u003cbr\u003eValidity after first opening: 3 months.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Grintuss Adult syrup 180g?\u003c\/h3\u003e\u003cp\u003e180 g bottle.\u003c\/p\u003e","brand":"Aboca","offers":[{"title":"Default Title","offer_id":51131221573959,"sku":"927091227","price":15.16,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/aboca-spa-societa-agricola-grintuss-adulti-sciroppo-180g-farmacia-dottor-tili-1213792347.jpg?v=1767142689"},{"product_id":"bronchenolo-sedativo-e-fluidificante-1-5mg-ml-10mg-ml-sciroppo-150ml","title":"Bronchenolo Sedative and Fluidifying 1.5mg\/ml + 10mg\/ml syrup 150ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic treatment of cough.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 ml of syrup contains: • \u003cu\u003eactive ingredients\u003c\/u\u003e: dextromethorphan hydrobromide 0.15 g and guaifenesin 1.00 g. \u003cu\u003eExcipients with known effects\u003c\/u\u003e: sucrose 73.50 g, propyl parahydroxybenzoate 0.025 g, methyl parahydroxybenzoate 0.075g, ethyl alcohol 5.00 g. One tablet contains: • \u003cu\u003eactive ingredients\u003c\/u\u003e: dextromethorphan hydrobromide 7.5 mg and guaifenesin 55 mg. \u003cu\u003eExcipients with known effects\u003c\/u\u003e: sucrose 2080.92 mg, aspartame (E951) 23 mg. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eBRONCHENOL SEDATIVE AND FLUIDIFYING syrup\u003c\/u\u003e 100 ml of syrup contains: mountain pine essential oil; citric acid monohydrate; alcohol; glycerol; sucrose; sweet orange essence; propyl parahydroxybenzoate; methyl parahydroxybenzoate; sodium saccharin; purified water. \u003cu\u003eBRONCHENOL SEDATIVE AND FLUIDIFIER mint flavored tablets\u003c\/u\u003e A 2.3 g tablet of BRONCHENOL SEDATIVE AND FLUIDIFYER mint flavor contains: mountain pine essential oil; magnesium trisilicate; aspartame; magnesium stearate; sucrose; mint flavour.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Children under 6 years of age. Patients who are taking or have taken in the last two weeks monoamine oxidase inhibitor (MAOI) antidepressants (see section 4.5). Patients with respiratory failure or at risk of developing respiratory failure (for example patients with chronic obstructive airway disease or pneumonia, patients with a current asthma attack or an exacerbation of asthma).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e \u003cu\u003eSyrup\u003c\/u\u003e \u003cb\u003eAdults\u003c\/b\u003e (including the elderly): 2 teaspoons (10 ml) 2-4 times a day, up to a maximum of 8 teaspoons (40 ml) per day. \u003ci\u003ePediatric population\u003c\/i\u003e \u003cb\u003eChildren over 12 years old\u003c\/b\u003e: 2 teaspoons (10 ml) 2-4 times a day, up to a maximum of 8 teaspoons (40 ml) per day. \u003cb\u003eChildren from 6 to 12 years\u003c\/b\u003e: 1 teaspoon (5 ml) 3-4 times a day, up to a maximum of 4 teaspoons (20 ml) per day. Administer the medicine every 4-6 hours as needed. \u003cu\u003ePads\u003c\/u\u003e \u003cb\u003eAdults\u003c\/b\u003e (including the elderly): 3-6 lozenges per day to dissolve in the mouth, up to a maximum of 6 lozenges per day. \u003ci\u003ePediatric population\u003c\/i\u003e \u003cb\u003eChildren over 12 years old\u003c\/b\u003e: 3-6 lozenges per day to dissolve in the mouth, up to a maximum of 6 lozenges per day. \u003cb\u003eChildren from 6 to 12 years\u003c\/b\u003e: 2-3 tablets per day to dissolve in the mouth, up to a maximum of 3 tablets per day. Administer the medicine every 4-6 hours as needed. \u003cu\u003eMethod of administration\u003c\/u\u003e To be administered orally only. Do not exceed the recommended doses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNone\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn the following cases BRONCHENOL SEDATIVE AND FLUIDIFYER must be used only after careful medical evaluation: - chronic or persistent cough, such as that which occurs in cases of asthma or emphysema; - severe liver failure; - severe renal failure; - concomitant use of selective serotonin re-uptake inhibitor antidepressants or tricyclic antidepressants (see section 4.5). The patient should be advised to consult a doctor if the cough persists, or if it is accompanied by high fever, skin rash or persistent headache. Do not exceed the maximum recommended dose or frequency of administration. After 5-7 days of treatment without appreciable results, a clinical evaluation is necessary. The simultaneous use of other cough and cold medicines should be avoided. The concomitant use of alcohol during therapy with SEDATIVE AND FLUIDIFYING BRONCHENOL must be avoided. Cases of abuse and dependence of dextromethorphan have been reported. Particular caution is recommended with adolescents and young adults, as well as with patients with a history of drug or psychoactive substance abuse. Dextromethorphan is metabolised by hepatic cytochrome P450 2D6. The activity of this enzyme is genetically determined. Approximately 10% of the population slowly metabolizes CYP2D6. Exaggerated and\/or prolonged effects of dextromethorphan may occur in poor metabolizers and patients with concomitant use of CYP2D6 inhibitors. Caution is therefore necessary in patients who are poor metabolisers of CYP2D6 or who use CYP2D6 inhibitors (see also section 4.5). \u003ci\u003eRisks deriving from the concomitant use of sedative medicines such as benzodiazepines or related drugs.\u003c\/i\u003e The concomitant use of BRONCHENOL SEDATIVE AND FLUIDIFYER and sedative medicines such as benzodiazepines, or related drugs, may cause sedation, respiratory depression, such as and death. Because of these risks, concomitant prescribing with sedative medicinal products should be reserved for patients for whom no alternative treatment options are available. If BRONCHENOL SEDATIVE AND FLUIDICANT is prescribed concomitantly with sedative medicinal products, the lowest effective dose should be used and the duration of treatment should be as short as possible. Patients should be carefully monitored for signs and symptoms of respiratory depression and sedation. In this regard, it is strongly recommended to inform patients and anyone caring for them to make them aware of these symptoms (see section 4.5). \u003cb\u003eSeratonin syndrome\u003c\/b\u003e Serotonergic effects, including the development of life-threatening serotonin syndrome, have been reported for dextromethorphan with concomitant administration of serotonergic agents, such as selective serotonin reuptake inhibitors (SSRIs), drugs that alter serotonin metabolism (including monoamine oxidase inhibitors [MAOIs]), and CYP2D6 inhibitors. Serotonin syndrome may include mental status changes, autonomic instability, neuromuscular abnormalities, and\/or gastrointestinal symptoms. If serotonin syndrome is suspected, treatment with SEDATIVE AND FLUIDIFYING BRONCHENOL must be discontinued. \u003cb\u003ePediatric population\u003c\/b\u003e Serious adverse events, including neurological disorders, may occur in children in case of overdose. Persons caring for patients should be advised not to exceed the recommended dose. \u003cu\u003eInformation on excipients with known effects\u003c\/u\u003e \u003cb\u003eBRONCHENOL SEDATIVE AND FLUIDIFIER syrup contains: \u003c\/b\u003e • sucrose. Contains 7.35 g of sucrose (sugar) per 10 ml dose. This should be taken into consideration in patients with diabetes mellitus. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine; • ethyl alcohol. This medicine contains 480 mg of alcohol (ethanol) in each 10 ml dose. The quantity in 10 ml of this medicine is equivalent to 12 ml of beer and 5 ml of wine. It can be harmful to alcoholics. To be taken into consideration in pregnant or breastfeeding women, children and high-risk groups such as people with liver disease or epilepsy. A 10ml dose of this medicine administered to a child aged 12 years and weighing less than or equal to 32kg would result in an exposure of 15 mg which may cause an increase in blood alcohol concentration (BAC) of approximately 2.5 mg\/100ml. Co-administration with medicines containing e.g. propylene glycol or ethanol may lead to ethanol accumulation and induce adverse effects, particularly in young children with low or immature metabolic activity. • propyl and methyl para-hydroxybenzoates, which can cause allergic reactions (even delayed); • Sodium. This medicinal product contains less than 1 mmol sodium (23 mg), i.e. essentially sodium-free. \u003cb\u003eBRONCHENOL SEDATIVE AND FLUIDIFIER mint flavor tablets contains: \u003c\/b\u003e • sucrose. contains 2.08 g of sucrose per dose. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine; • aspartame. This medicine contains 23 mg of aspartame per tablet. Aspartame is a source of phenylalanine. It may be harmful to you if you suffer from phenylketonuria, a rare genetic disease that causes the accumulation of phenylalanine because the body is unable to dispose of it correctly.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicine must not be used simultaneously with or within 2 weeks of treatment with monoamine oxidase inhibitor (MAOI) antidepressants, as serious adverse reactions, including serotonin syndrome, have been reported (see section 4.3). Patients should be informed to consult their doctor before taking dextromethorphan in combination with the following drugs: - concomitant use of dextromethorphan with selective serotonin reuptake inhibitor antidepressants or tricyclic antidepressants may cause serotonin syndrome with changes in mental status, hypertension, agitation, myoclonus, hyperreflexia, diaphoresis, chills and tremors (see section 4.4); - the concomitant use of dextromethorphan and alcohol can increase the depressant effects on the Central Nervous System of both substances. CYP2D6 inhibitors Dextromethorphan is metabolised by CYP2D6 and has extensive first pass metabolism. Concomitant use of strong inhibitors of the CYP2D6 enzyme can increase dextromethorphan concentrations in the body to levels many times higher than the normal value. This increases the patient's risk for toxic effects of dextromethorphan (agitation, confusion, tremor, insomnia, diarrhea, and respiratory depression) and for the development of serotonin syndrome. Potent inhibitors of CYP2D6 are fluoxetine, paroxetine, quinidine and terbinafine. In concomitant use with quinidine, plasma concentrations of dextromethorphan are increased up to 20-fold, resulting in increased adverse central nervous system effects of the agent. Amiodarone, flecainide and propafenone, sertraline, bupropion, methadone, cinacalcet, haloperidol, perphenazine and thioridazine also have similar effects on the metabolism of dextromethorphan. If concomitant use of CYP2D6 inhibitors and dextromethorphan is necessary, the patient should be monitored and the dose of dextromethorphan may need to be reduced. The association with phenylpropanolamine should be used with caution in subjects with hypertension, heart disease, diabetes, peripheral vascular disease, prostatic hypertrophy and glaucoma. Treatment with guaifenesin can cause false positive results in the measurement of urinary vanillylmandelic acid. Sedative medicines such as benzodiazepines or related medicines Concomitant use of opioids and sedative medicines such as benzodiazepines or related medicines increases the risk of sedation, respiratory depression, coma and death due to additive CNS depressant effect. The dosage and duration of concomitant treatment should be limited (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eData from clinical studies\u003c\/u\u003e The adverse events reported below were observed in clinical studies and are considered uncommon adverse reactions (i.e. found in a percentage between ≥1\/1000 and \u003c1\/100 patients). Adverse reactions are listed according to MedDRA classification. \u003cb\u003eNervous system disorders\u003c\/b\u003e • drowsiness. \u003cb\u003eEar and labyrinth disorders\u003c\/b\u003e • dizziness. \u003cb\u003eGastrointestinal disorders\u003c\/b\u003e • gastrointestinal disorder; • nausea; • vomit; • abdominal discomfort. \u003cu\u003ePost marketing data\u003c\/u\u003e Adverse reactions identified during post-marketing use are listed below. Since these reactions are reported voluntarily from a population of uncertain size, their frequency is not known, but is probably very rare (occurring in \u003c1\/10,000 patients). \u003cb\u003eNervous system disorders\u003c\/b\u003e • serotonin syndrome. Serotonin syndrome (with mental status changes, agitation, myoclonus, hyperreflexia, diaphoresis, chills, tremors and hypertension) has been reported in case of concomitant use of dextromethorphan with antidepressants (monoamine oxidase inhibitors or serotonin reuptake inhibitors) (see sections 4.3 and 4.5). \u003cb\u003eImmune system disorders \u003c\/b\u003e • hypersensitivity (e.g. rash, urticaria, angioedema). \u003cu\u003eReporting of suspected adverse reactions \u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at - www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSigns and symptoms\u003c\/u\u003e Dextromethorphan overdose may be associated with nausea, vomiting, dystonia, agitation, confusion, drowsiness, stupor, nystagmus, cardiotoxicity (tachycardia, abnormal ECG including QTc interval prolongation), ataxia, toxic psychosis with visual hallucinations, hyperexcitability. In case of taking massive overdose, the following symptoms may be observed: coma, respiratory depression and convulsions. If taken in excessive quantities, guaifenesin can cause kidney stones. \u003cu\u003eManagement:\u003c\/u\u003e Activated charcoal may be administered to asymptomatic patients who have ingested overdoses of dextromethorphan within the previous hour. Emergency interventions include emptying the stomach and supporting vital functions, particularly in order to control respiratory depression and other disorders affecting the Central Nervous System. For patients who have ingested dextromethorphan and are sedated or comatose, naloxone, in usual doses, may be considered for treatment of opioid overdose. Benzodiazepines may be used for seizures and benzodiazepines and external cooling measures for serotonin syndrome hyperthermia.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo data regarding pregnancy and breastfeeding are available. In pregnant and breastfeeding women, the medicine must be administered only if clearly necessary and under the direct supervision of a doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBRONCHENOL SEDATIVE AND FLUIDIFIER can alter the ability to drive vehicles and use machinery as it can induce drowsiness or dizziness, this must be taken into account by those who may drive motor vehicles or carry out operations requiring an intact level of vigilance.\u003c\/p\u003e","brand":"Perrigo","offers":[{"title":"Default Title","offer_id":51131250999623,"sku":"026564070","price":13.94,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/perrigo-italia-srl-bronchenolo-sedativo-e-fluidificante-1-5mg-ml-10mg-ml-sciroppo-150ml-farmacia-dottor-tili-1213792301.jpg?v=1767143548"},{"product_id":"vicks-flu-tripla-azione-500mg-200mg-10mg-10-bustine-polvere-per-soluzione-orale","title":"Vicks Flu Triple Action 500mg\/200mg\/10mg 10 sachets powder for oral solution","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term symptomatic treatment of mild to moderate pain, fever, nasal congestion with expectorant effect in case of wet cough, associated with colds, chills and flu.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne sachet contains: 500 mg of paracetamol 200 mg of guaifenesin 10 mg of phenylephrine hydrochloride Excipients: Sucrose 2000 mg Aspartame 6 mg Sodium 157 mg For the complete list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSucrose Citric acid Tartaric acid Sodium cyclamate Sodium citrate Aspartame (E951) Acesulfame potassium (E950) Menthol powder Lemon flavor Lemon juice flavor Quinoline yellow (E104)\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to paracetamol, guaifenesin, phenylephrine hydrochloride or to any of the excipients. Severe hepatic or renal impairment Hypertension Hyperthyroidism Diabetes Heart disease. Angle-closure glaucoma Porphyria Use in patients who are taking tricyclic antidepressants Use in patients who are taking, or who have taken in the previous 2 weeks, monoamine oxidase inhibitors (MAOIs). Use in patients who are taking beta-blocking drugs. Use in patients who are taking other sympathomimetic drugs. Children under 12 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDissolve the contents of one sachet in a medium-sized cup and add hot, non-boiling water (approximately 250 ml). Allow to cool to a drinkable temperature. Adults and children from 12 years of age: one sachetRepeat every four hours according to the indications, without exceeding four doses (sachets) within 24 hours. Do not administer to children under 12 years of age without medical advice. Do not administer to patients with hepatic impairment or severe renal impairment (see section 4.3). Consult your doctor if symptoms persist for more than 3 days.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store above 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eProlonged use of the product is not recommended. Patients should be advised not to take other products containing paracetamol or containing the same active ingredients as this preparation. Patients should also be advised to avoid the concomitant use of alcohol, other decongestant products or cough or cold products. The doctor or pharmacist is required to verify that preparations containing sympathomimetics are not administered simultaneously through multiple routes, i.e. orally and topically (nasal, auricular and ocular preparations). This medicine should only be recommended in the presence of all symptoms (pain and\/or fever, nasal congestion and bronchial cough). The risks related to overdose are greater in patients with non-cirrhotic alcoholic liver disease. Use with caution in patients taking digitalis, beta-adrenergic blockers, methyldopa or other antihypertensive agents (see section 4.5). Use with caution in patients with prostatic hypertrophy as they are potentially subject to urinary retention. Products containing sympathomimetics should be used with great care in patients taking phenothiazines. Use in patients with Raynaud's phenomenon. Consult your doctor before use in case of persistent or chronic cough such as that manifested by smoking, asthma, chronic bronchitis or emphysema. Contains sucrose. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrasisomaltase insufficiency should not take this medicine. Contains 157 mg sodium per dose. To be taken into consideration in people with reduced kidney function or who follow a low sodium diet. Contains aspartame (E951). This medicine contains a source of phenylalanine. It may be harmful to you if you suffer from phenylketonuria.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe hepatotoxicity of paracetamol can be potentiated by excessive alcohol intake. The rate of absorption of paracetamol can be increased with metoclopramide or domperidone and the absorption reduced with cholestyramine. Substances that induce hepatic microsomal enzymes, such as alcohol, barbiturates, monoamine oxidase inhibitors and tricyclic antidepressants, may increase the hepatotoxicity of paracetamol, particularly following overdosage. Isoniazid reduces the elimination of paracetamol, with possible enhancement of its activity and\/or toxicity, through the inhibition of its metabolism in the liver. Probenecid causes a halving of the elimination of paracetamol, inhibiting its binding with glucuronic acid. A reduction in paracetamol should be considered if probenecid is being taken. Regular use of paracetamol may reduce the metabolism of Zidovudine (increasing the risk of neutropenia). Interactions between sympathomimetic amines, such as phenylephrine, and monoamine oxidase inhibitors cause hypertensive effects. Phenylephrine may interact negatively with sympathomimetic agents and may reduce the effectiveness of beta-blocking drugs, methyldopa and other antihypertensive drugs (see section 4.4). The conditions in which these drugs are taken constitute contraindications to the use of the product. The anticoagulant effect of warfarin and other coumarin drugs can be enhanced by regular and prolonged intake of paracetamol, with an increased risk of bleeding; doses taken occasionally have no significant effects. Drug interactions have been reported between acetaminophen and several other drugs. Such interactions are considered unlikely to be clinically significant in temporary use and in accordance with the suggested dosing regimen. Salicylates\/aspirin can prolong the elimination (t ½) of paracetamol. Paracetamol may decrease the bioequivalence of lamotrigine, with a possible decrease in its effect, due to a possible increase in its metabolism in the liver. It is possible that digitalis may sensitize the myocardium to sympathomimetic-like effects. Paracetamol can alter the uric acid phosphotungstate test and the blood sugar test.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe incidence of side effects is usually classified as follows: Very common (\u003e10) Common (\u003e1\/100 to \u003c1\/10) Uncommon (\u003e1\/1000 to \u003c1\/100) Rare (\u003e1\/10,000 to \u003c1\/1000) Very rare (\u003c1\/10,000) Not known (the incidence cannot be classified from the available data) Cardiac disorders: Phenylephrine may be rarely associated with tachycardia (≥1\/10,000 to ≤1 in 1000). Blood and lymphatic system disorders: very rarely (\u003c1 in 10,000) blood dyscrasias such as thrombocytopenia, agranulocytosis, hemolytic anemia, neutropenia, leukopenia and pancytopenia have been reported following the intake of paracetamol, although there may not be a causal relationship. Nervous system disorders: As with other sympathomimetic amines, insomnia, nervousness, tremor, anxiety, restlessness, confusion, irritability and headache may occur rarely (≥1\/10,000 to ≤1 in 1000). It is also known that guaifenesin can rarely (≥1\/10,000 to ≤1 in 1000) cause headache and dizziness. Gastrointestinal disorders: Anorexia, nausea and vomiting are common with sympathomimetics (≥1 in 100 to ≤1 in 10) and may occur with phenylephrine. Gastrointestinal disorders, nausea, vomiting, and diarrhea are the most common side effects associated with guaifenesin, but occur rarely (≥1\/10,000 to ≤1 in 1000). The gastrointestinal effects of paracetamol are very rare but cases of acute pancreatitis have been reported following ingestion of higher than normal doses. Renal and urinary disorders: Interstitial nephritis has been reported randomly after prolonged use of high doses of paracetamol. Skin and subcutaneous tissue disorders: hypersensitivity, including skin rash, and urticaria may rarely occur following the intake of paracetamol (from ≥1\/10,000 to ≤1 in 1000). Vascular disorders: following the intake of phenylephrine, increased blood pressure associated with headache, vomiting and palpitations may rarely occur (from ≥1\/10,000 to ≤1 in 1000). Immune system disorders: Rare cases (≥1\/10,000 to ≤1 in 1000) of allergic or hypersensitivity reactions have been reported following intake of both phenylephrine and paracetamol, including skin rashes, urticaria, anaphylaxis and bronchospasm. Hepatobiliary disorders: rarely (≥ 1\/10,000 to ≤ 1\/1000), abnormalities in liver function tests (increased liver transaminases).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePARACETAMOL There is a risk of poisoning particularly in elderly patients, young children, in patients with liver disease, in chronic alcoholics, in patients with chronic malnutrition. In these cases, an overdose can be fatal. In adults, a quantity of paracetamol equal to or greater than 10 g can cause liver damage. If the patient has one of the risk factors (see below), ingesting 5 g or more of paracetamol may cause liver damage. Risk factors If the patient: a) is on prolonged therapy with carbamazepine, phenobarbital, phenytoin, primidone, rifampicin, St. John's wort or other liver enzyme-inducing drugs, or b) regularly takes ethanol in excess of recommended amounts, or c) has a glutathione deficiency, e.g. in case of eating disorders, cystic fibrosis, HIV infection, inanition, cachexia. Symptoms The symptoms of paracetamol overdose that appear in the first 24 hours are paleness, nausea, vomiting, anorexia and abdominal pain. Liver damage may appear 12–48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. In cases of severe poisoning, liver failure may progress to encephalopathy, hemorrhage, hypoglycemia, brain edema, and death. Even in the absence of severe liver damage, acute renal failure with acute tubular necrosis may occur, which is highly likely if accompanied by low back pain, hematuria, and proteinuria. Cases of cardiac arrhythmia and pancreatitis have been reported. Treatment In case of paracetamol overdose it is essential to treat the patient immediately. Even in the absence of significant initial symptoms, the patient must be urgently transferred to hospital. Symptoms may be limited to nausea or vomiting and may not reflect the severity of the overdose or the risk of organ damage. Patient treatment must be carried out in compliance with current guidelines. If no more than an hour has passed since the overdose was taken, treatment with activated charcoal may be considered. The plasma concentration of paracetamol must be measured no earlier than 4 hours after ingestion (plasma concentrations measured at earlier times are not reliable). Within 24 hours of ingesting paracetamol the patient can be treated with N-acetylcysteine; however, the maximum protective effect is obtained within 8 hours of ingestion. After this time, the effectiveness of the antidote decreases drastically. If necessary, the patient should be administered N-acetylcysteine ​​intravenously, in line with the established dosing schedule. If vomiting is not a problem and the patient is away from the hospital, taking oral methionine can be a valid alternative. Treatment of patients with severe hepatic dysfunction presenting within 24 hours of ingestion should be discussed with the poison control center or hepatology department. Phenylephrine hydrochloride Symptoms of phenylephrine overdose include irritability, headache, arterial hypertension, reflex bradycardia and arrhythmias. Hypertension must be treated with an alpha-blocker such as phentolamine IV. The reduction in blood pressure can increase, as a reflex mechanism, the heart rate but, if necessary, this can be facilitated by taking atropine. GUAIFENESIN Mild to moderate overdose may cause dizziness and gastrointestinal disturbances. Very high doses can produce excitation, confusion and respiratory depression. Urinary stones have been reported in patients consuming large quantities of guaifenesin-containing preparations. Treatment is symptomatic and includes gastric lavage and general supportive measures.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEpidemiological studies on pregnant women have demonstrated the absence of negative effects due to the use of paracetamol in the recommended dosages; however, pregnant patients are required to follow their doctor's instructions regarding the use of the drug. Paracetamol is excreted in breast milk, although not in clinically significant quantities. The available published data do not report contraindications regarding breastfeeding. Data on the use of phenylephrine in pregnancy are limited. Vasoconstriction of the uterine vessels and reduction in uterine blood flow associated with the use of phenylephrine may cause fetal hypoxia. Until further information is available, taking phenylephrine during pregnancy should be avoided, except when your doctor deems it essential. There are no data available regarding the possible release of phenylephrine into breast milk nor are there any reports regarding the effects of phenylephrine on breast-fed infants. Until further data become available, taking phenylephrine during breastfeeding should be avoided, except when your doctor deems it essential. The safety of guaifenesin during pregnancy and breastfeeding has not yet been fully defined. During pregnancy, the product must be taken only when the doctor deems it essential.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo studies on the effects on the ability to drive and use machines have been performed. When carrying out these activities, the possibility of adverse events, such as dizziness and confusion, must be considered.\u003c\/p\u003e","brand":"Procter \u0026 Gamble","offers":[{"title":"Default Title","offer_id":51131272331591,"sku":"039773027","price":9.43,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/procter-gamble-srl-vicks-flu-tripla-azione-500mg-200mg-10mg-10-bustine-polvere-per-soluzione-orale-farmacia-dottor-tili-1213792260.jpg?v=1767133270"},{"product_id":"fomentil-10-compresse-per-suffumigi","title":"Fomentil 10 tablets for fumigations","description":"\u003cp\u003eFomentil 10 fumigation tablets is a \u003cstrong\u003emedical device\u003c\/strong\u003e Class I, designed to provide relief to the respiratory tract through inhalation of vapors. These non-sterile tablets are ideal for those suffering from \u003cstrong\u003esore throat\u003c\/strong\u003e, \u003cstrong\u003ecold\u003c\/strong\u003e, \u003cstrong\u003esinusitis\u003c\/strong\u003e, \u003cstrong\u003ebronchitis\u003c\/strong\u003e and other inflammations of the respiratory system. Thanks to their formulation, Fomentil acts as an effective \u003cstrong\u003edecongestant\u003c\/strong\u003e, helping to clear the airways and fluidize catarrhal secretions, which are then naturally expelled through coughing.\u003c\/p\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Fomentil 10 fumigation tablets used? What is it for?\u003c\/h3\u003e\u003cp\u003eFomentil 10 fumigation tablets is a \u003cstrong\u003emedical device\u003c\/strong\u003e Class I, designed to provide relief to the respiratory tract through inhalation of vapors. These non-sterile tablets are ideal for those suffering from \u003cstrong\u003esore throat\u003c\/strong\u003e, \u003cstrong\u003ecold\u003c\/strong\u003e, \u003cstrong\u003esinusitis\u003c\/strong\u003e, \u003cstrong\u003ebronchitis\u003c\/strong\u003e and other inflammations of the respiratory system. Thanks to their formulation, Fomentil acts as an effective \u003cstrong\u003edecongestant\u003c\/strong\u003e, helping to clear the airways and fluidize catarrhal secretions, which are then naturally expelled through coughing.\u003c\/p\u003e\u003cp\u003eThe product exploits the beneficial properties of \u003cstrong\u003ementhol\u003c\/strong\u003e and of the\u003cstrong\u003eeucalyptus\u003c\/strong\u003e, which, combined with water vapor, help to decongest the respiratory tract, offering an immediate sense of relief. Fomentil is particularly useful in the presence of \u003cstrong\u003emucosal hypersecretion\u003c\/strong\u003e, acting as an adjuvant in treatments aimed at restoring the normal functioning of the respiratory tract. Its action is also indicated for conditions of \u003cstrong\u003erhinitis\u003c\/strong\u003e, \u003cstrong\u003epharyngitis\u003c\/strong\u003e e \u003cstrong\u003elaryngitis\u003c\/strong\u003e, protecting the nasal and oropharyngeal mucosa.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Fomentil 10 fumigation tablets contain?\u003c\/h3\u003e\u003cp\u003eSodium Bicarbonate, Tartaric Acid, Microcrystalline Cellulose, Bentonite, Glyceryl Distearate, Silica Colloidal Hydrated, Polyvinylpyrrolidone, Talc, Magnesium Stearate, Flavor (Eucaliptus Globulus Leaf Oil, Lavandula Angustifolia Oil, Thymus Vulgaris Flower\/Leaf Oil, Menthol).\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Fomentil 10 fumigation tablets?\u003c\/h3\u003e\u003cp\u003eDissolve 1-2 tablets in approximately half a liter of boiling water and breathe the vapors for 3-4 minutes, collecting them using a special vapor inhaler or with your hands. Repeat this operation 3-4 times a day.\u003cbr\u003eThe water must be boiling for the tablet to dissolve completely. Break the tablets to facilitate their dissolution.\u003cbr\u003eDo not cover your head with a cloth while inhaling and be careful to keep your face at a distance of about 40 cm to prevent the hot water vapor from irritating the skin.\u003cbr\u003eFor children over 30 months: place a basin with boiling water near the child's bed and dissolve 3-4 tablets in it, one at a time. The duration of fumigation treatment should not exceed 3 days.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Fomentil 10 fumigation tablets?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWarnings\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eRead the leaflet carefully. Do not use if package is open or damaged. The product should not be used for children under 30 months of age. Do not administer in case of already known hypersensitivity to the components. For external use, do not swallow the tablets or drink the solution. Use only for fumigations and inhalations. Avoid contact with eyes. There are no known interactions with other products and\/or medicines, however in case of concomitant therapy for the respiratory tract, wait at least 30 minutes between the use of Fomentil and the other treatment. Fomentil is not recommended during pregnancy and in women of childbearing potential who are not using contraceptive measures. Fomentil should not be used during breastfeeding. It is important to report the appearance of side effects to your doctor or pharmacist. Keep out of the sight and reach of children and anyone who may accidentally ingest the tablet or solution. A higher dose than recommended should not be used. Consult your doctor if you suffer from chronic respiratory diseases.\u003cbr\u003eDo not use the product after the expiry date indicated on the package. Do not dispose of in the environment after use.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Fomentil 10 fumigation tablets stored?\u003c\/h3\u003e\u003cp\u003eStore the product in the original packaging, away from direct light and heat, at room temperature.\u003cbr\u003eThe expiry date refers to the intact product, correctly stored.\u003cbr\u003eValidity with intact packaging: 36 months.\u003cbr\u003eValidity after first opening: 18 months.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Fomentil 10 fumigation tablets?\u003c\/h3\u003e\u003cp\u003eTube of 10 tablets.\u003c\/p\u003e","brand":"Sit Laboratorio Farmaceutico","offers":[{"title":"Default Title","offer_id":51131304640839,"sku":"935558039","price":8.84,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sit-laboratorio-farmac-srl-fomentil-10-compresse-per-suffumigi-farmacia-dottor-tili-1213792163.jpg?v=1767134710"},{"product_id":"licky-caramelle-baby-tosse-gola-fragola","title":"Licky baby cough\/throat strawberry sweets","description":"\u003cp\u003eLe \u003cstrong\u003eLicky baby cough\/throat strawberry sweets\u003c\/strong\u003e they are the ideal solution for the well-being of the throat of the little ones. These candies are formulated with a combination of \u003cstrong\u003emedicinal herbs\u003c\/strong\u003e e \u003cstrong\u003eIcelandic lichen\u003c\/strong\u003e, known for their soothing and emollient properties. The delicious \u003cstrong\u003estrawberry flavour\u003c\/strong\u003e makes these sweets particularly appreciated by children, transforming the moment of relief into a pleasant experience.\u003c\/p\u003e\n\u003cp\u003eThanks to their composition, Licky baby candies are perfect for alleviating discomfort related to \u003cstrong\u003ecough\u003c\/strong\u003e and to \u003cstrong\u003esore throat\u003c\/strong\u003e, offering natural and delicate support. The practical format of 24 sweets is ideal for always carrying with you, guaranteeing immediate relief at any time of the day.\u003c\/p\u003e\n\u003cp\u003eLicky candies are a \u003cstrong\u003esupplement for children\u003c\/strong\u003e which combines effectiveness and taste, making them a precious ally for parents looking for a safe and natural product for the well-being of their children.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy should you use Licky baby cough\/throat strawberry sweets? What is it for?\u003c\/h3\u003e\u003cp\u003eStrawberry flavored sweets based on medicinal herbs and Icelandic lichen, with soothing and emollient properties, designed for the well-being of children's throats in case of irritated throats.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings for Licky baby strawberry cough\/throat sweets?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eLegal warnings\u003c\/strong\u003e\u003cbr\u003eDo not exceed the recommended daily dose.\u003cbr\u003eKeep out of reach of children under three years of age.\u003cbr\u003eSupplements are not intended as substitutes for a varied and balanced diet and a healthy lifestyle.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Licky baby cough\/throat strawberry sweets?\u003c\/h3\u003e\u003cp\u003eCase of 24 candies.\u003c\/p\u003e","brand":"Fitobucaneve","offers":[{"title":"Default Title","offer_id":51131314405703,"sku":"930366137","price":6.7,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/fitobucaneve-srl-licky-caramelle-baby-tosse-gola-fragola-farmacia-dottor-tili-1213792122.jpg?v=1767135869"},{"product_id":"mucosolvan-15mg-5ml-sciroppo-gusto-frutti-di-bosco-200ml","title":"Mucosolvan 15mg\/5ml syrup wild berries flavour 200ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTreatment of secretion disorders in acute and chronic bronchopulmonary diseases.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e5 ml of syrup contains: active ingredient: ambroxol hydrochloride 15 mg. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenzoic acid, hydroxyethyl cellulose, sucralose, berry flavor, vanilla flavor, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients. Severe hepatic and renal alterations. The drug is contraindicated in children under 2 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following dosages are recommended unless otherwise prescribed by a doctor: Adults: 10 ml 3 times a day. Children from 2 to 5 years: 3 ml 3 times a day. Children over 5 years: 3 ml 4 times a day. Can be administered to patients with diabetes. Mucosolvan can be taken regardless of meals. In acute respiratory conditions, contact your doctor if symptoms do not improve or worsen during treatment with Mucosolvan.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any particular storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAmbroxol hydrochloride should be administered with caution to patients with peptic ulcers. Cases of serious skin reactions such as erythema multiforme, Stevens-Johnson syndrome (SJS)\/toxic epidermal necrolysis (TEN) and acute generalized exanthematous pustulosis (AGEP) have been reported in association with the administration of ambroxol hydrochloride. If symptoms or signs of progressive skin rash (sometimes associated with blisters or mucosal lesions) are present, treatment with ambroxol hydrochloride should be stopped immediately and a doctor should be consulted. Most of these reactions could be explained by the severity of underlying diseases or other concomitant medications. Furthermore, in the initial phase of Stevens Johnson syndrome or toxic epidermal necrolysis (TEN), patients may initially experience non-specific symptoms similar to those of the flu, such as fever, chills, rhinitis, cough and sore throat. Because of these misleading symptoms, symptomatic treatment with cough and cold therapy may be undertaken. In case of impaired kidney function, Mucosolvan can only be used after consulting your doctor. Mucolytics can induce bronchial obstruction in children under 2 years of age. In fact, the drainage capacity of bronchial mucus is limited in this age group, due to the physiological characteristics of the respiratory tract. They should therefore not be used in children under 2 years of age (see section 4.3).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFollowing the administration of ambroxol, the concentrations of antibiotics (amoxicillin, cefuroxime, erythromycin) in bronchopulmonary secretions and saliva are increased. No interactions with other medicinal products have been reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions are listed below by system organ class and frequency, according to the following categories: Very common ≥ 1\/10 Common ≥ 1\/100, \u003c 1\/10 Uncommon ≥ 1\/1,000, \u003c 1\/100 Rare ≥ 1\/10,000, \u003c 1\/1,000 Very rare \u003c 1\/10,000 Not known frequency cannot be defined on the basis of available data. \u003ci\u003e \u003cu\u003eImmune system disorders:\u003c\/u\u003e \u003c\/i\u003e Rare: hypersensitivity reactions. Not known: anaphylactic reactions including anaphylactic shock, angioedema and pruritus. \u003ci\u003e \u003cu\u003eSkin and subcutaneous tissue disorders:\u003c\/u\u003e \u003c\/i\u003eRare: rash, urticaria. Not known: serious cutaneous adverse reactions (including erythema multiforme, Stevens-Johnson syndrome\/toxic epidermal necrolysis and acute generalized exanthematous pustulosis). \u003ci\u003e \u003cu\u003eNervous system disorders:\u003c\/u\u003e \u003c\/i\u003e Common: dysgeusia. \u003ci\u003e \u003cu\u003eGastrointestinal disorders:\u003c\/u\u003e \u003c\/i\u003e Common: nausea, oral hypoesthesia. Uncommon: vomiting, diarrhoea, dyspepsia, abdominal pain, dry mouth. Rare: dry throat. Heartburn has also been reported. \u003ci\u003e \u003cu\u003eRespiratory, thoracic and mediastinal disorders:\u003c\/u\u003e \u003c\/i\u003e Common: Pharyngeal hypoesthesia. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSo far, no specific symptoms of overdose have been reported in humans. Symptoms observed in cases of accidental overdose and\/or in cases of medication errors are consistent with the expected side effects of Mucosolvan at recommended doses and may require symptomatic treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Ambroxol hydrochloride crosses the placental barrier. Preclinical studies have not shown any directly or indirectly harmful effects on pregnancy, embryonic\/foetal development, birth or postnatal development. Although preclinical studies and extensive clinical experience have not shown any harmful effects on the fetus after 28\u003csup\u003ea\u003c\/sup\u003e week of gestation, it is advisable to take normal precautions when taking medications during pregnancy. Especially during the first trimester, taking Mucosolvan is not recommended. \u003cu\u003eBreastfeeding\u003c\/u\u003e Ambroxol hydrochloride is excreted in breast milk. Although no side effects are expected in breastfed infants, the use of Mucosolvan is not recommended during breastfeeding. \u003cu\u003eFertility\u003c\/u\u003e Preclinical studies have not shown any directly or indirectly harmful effects on fertility.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFrom post-marketing experience there is no evidence of an effect on the ability to drive vehicles and use machinery. No studies on the effects on the ability to drive and use machines have been performed.\u003c\/p\u003e","brand":"Opella Healthcare","offers":[{"title":"Default Title","offer_id":51131324399943,"sku":"024428272","price":12.93,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/opella-healthcare-italy-srl-mucosolvan-15mg-5ml-sciroppo-gusto-frutti-di-bosco-200ml-farmacia-dottor-tili-1213792079.jpg?v=1767136531"},{"product_id":"breathe-right-balsamici-10-pezzi","title":"Breathe Right balsamic 10 pieces","description":"\u003cp\u003eI \u003cstrong\u003eBreathe Right balsamics 10 pieces\u003c\/strong\u003e are innovative nasal patches designed to offer immediate relief from nasal congestion. Thanks to \u003cstrong\u003ebalsamic aromas\u003c\/strong\u003e, these patches help open the nasal passages without the use of medications, making them ideal for those looking for a natural alternative to relieve a stuffy nose. Perfect for those who suffer from \u003cstrong\u003ecold\u003c\/strong\u003e, \u003cstrong\u003eallergies\u003c\/strong\u003e or has a \u003cstrong\u003edeviated nasal septum\u003c\/strong\u003e, Breathe Right patches improve airflow, making breathing easier.\u003c\/p\u003e\n\n\u003cp\u003eTheirs \u003cstrong\u003eanatomical shape\u003c\/strong\u003e and the special adhesive guarantee optimal adhesion, while the disposable design ensures impeccable hygiene. Can also be used to reduce \u003cstrong\u003esnore\u003c\/strong\u003e, these patches are a \u003cstrong\u003emedical device\u003c\/strong\u003e safe and practical for outdoor use. The package contains 10 pieces, offering a convenient option for those who need quick and effective relief from nasal congestion.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy do you use Breathe Right balsamic 10 pieces? What is it for?\u003c\/h3\u003e\u003cp\u003eNasal patch medical device with balsamic aromas, indicated for the relief of nasal congestion linked to colds, allergies or deviated nasal septum; improves airflow and can also be used to reduce snoring.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Breathe Right balsamic 10 pieces contain?\u003c\/h3\u003e\u003cp\u003eBreathe Right balsamic patches are made with hypoallergenic materials and contain balsamic aromas for a refreshing effect. They do not contain medicines.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Breathe Right balsamic 10 pieces?\u003c\/h3\u003e\u003cp\u003eApply the nasal patch to the clean, dry skin of the nose. Make sure the ends of the patch are positioned correctly to ensure optimal adhesion. Use one patch nightly or as needed to relieve nasal congestion.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Breathe Right balsamic 10 pieces?\u003c\/h3\u003e\u003cp\u003eDo not use on irritated or injured skin. If irritation or allergic reaction occurs, discontinue use and consult a doctor. Keep out of reach of children. Store in a cool, dry place.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Breathe Right balsamic 10 pieces?\u003c\/h3\u003e\u003cp\u003ePack of 10 pieces\u003c\/p\u003e","brand":"Efas","offers":[{"title":"Default Title","offer_id":51131334033735,"sku":"982483529","price":9.03,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/e-fa-s-spa-breathe-right-balsamici-10-pezzi-farmacia-dottor-tili-1213792053.jpg?v=1767137291"},{"product_id":"neo-borocillina-tosse-10mg-1-2mg-20-pastiglie","title":"Neo Borocillina Cough 10mg + 1.2mg 20 tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCough sedative and oropharyngeal antiseptic.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEvery \u003ci\u003etablet\u003c\/i\u003e contains: - DEXTROMETHORPHAN BROMYDRATE 10 mg (adsorbed on magnesium trisilicate) - 2,4-DICHLOROBENZYL ALCOHOL 1.2 mg \u003ci\u003eExcipients with known effects\u003c\/i\u003e: aspartame (E 951), compressible sugar For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFreshflavor aroma, ammonium glycyrrhizinate, magnesium stearate, aspartame (E 951), copovidone, compressible sugar.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients. Bronchial asthma, COPD, pneumonia, breathing difficulties, respiratory depression, cardiovascular diseases, hypertension, hyperthyroidism, diabetes, glaucoma, prostatic hypertrophy, gastrointestinal and urogenital stenosis, epilepsy, serious liver diseases. Do not administer to children under 12 years of age. Do not use at the same time as or in the two weeks following treatment with MAO inhibitor antidepressant drugs. Pregnancy, particularly in the first trimester, breastfeeding (see section 4.6).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdults and children over 12 years of age: slowly dissolve one tablet in the mouth every 2-3 hours, up to a daily maximum of 8 tablets. Do not exceed the recommended doses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore below 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn case of irritating cough with significant mucus production (e.g. in patients suffering from pathologies such as bronchiectasis and cystic fibrosis) or in patients suffering from neurological diseases associated with a marked reduction of the cough reflex (such as stroke, Parkinson's disease and dementia), treatment with Neo Borocillin Cough Lozenges as a cough sedative should be administered with particular caution and only on medical advice after a careful risk-benefit assessment (see section 4.5). There is limited information on the use of dextromethorphan in patients with impaired hepatic or renal function. Therefore, Neo Borocillin Cough Lozenges should be administered with caution in such patients, especially in patients with severe impairment. Dextromethorphan is metabolised by hepatic cytochrome P450 2D6. The activity of this enzyme is genetically determined. Approximately 10% of the population slowly metabolizes CYP2D6. Exaggerated and\/or prolonged effects of dextromethorphan may occur in poor metabolizers and patients with concomitant use of CYP2D6 inhibitors. Caution is therefore necessary in patients who are poor metabolisers of CYP2D6 or who use CYP2D6 inhibitors (see also section 4.5). Due to the potential release of histamine, the use of Neo Borocillin Cough Lozenges should be avoided in case of mastocytosis. A chronic cough can be an early symptom of asthma and therefore Neo Borocillin Cough Lozenges is not indicated for the suppression of chronic cough, particularly in children. Neo Borocillin Cough Lozenges should be used with caution in patients taking serotonergic drugs (other than MAO inhibitor drugs), such as selective serotonin reuptake inhibitors (SSRIs) (e.g. fluoxetine, paroxetine) or tricyclic antidepressant drugs (see section 4.5). The use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. In this case it is necessary to interrupt the treatment and consult the doctor for the purposes of instituting any suitable therapy. After 5-7 days of treatment, without appreciable results, consult your doctor. \u003cu\u003eImportant information about some excipients\u003c\/u\u003e Contains 1.386 g of sucrose (sugar) per tablet. To be taken into consideration in people suffering from diabetes mellitus. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. The product contains aspartame, a source of phenylalanine (see paragraph 4.3). It is inadvisable to consume alcohol during therapy. Dextromethorphan may be slightly habit-forming. Following prolonged use (e.g. exceeding the recommended treatment period), patients may develop tolerance to the medicine, as well as mental and physical dependence. Cases of abuse of dextromethorphan have been reported. Particular caution is recommended with adolescents and young adults, as well as with patients with a history of drug or psychoactive substance abuse. Patients with a tendency towards abuse or dependence must take Neo Borocillin Cough for short periods and under close medical supervision.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDextromethorphan has weak serotonergic properties. Dextromethorphan may therefore lead to an increased risk of serotonin toxicity (serotonin syndrome), especially when taken together with other serotonergic agents, such as MAO inhibitor drugs or SSRIs or tricyclic antidepressants. Especially pre-treatment or concomitant treatment with drugs that compromise the metabolism of serotonin, such as antidepressant drugs of the MAO inhibitor type, can induce the development of a serotonin syndrome with the following characteristic symptoms: neuromuscular hyperactivity (e.g. tremor, clonic spasm, myoclonus, increased reflex response and rigidity of pyramidal origin), hyperactivity of the autonomic nervous system (e.g. diaphoresis, fever, tachycardia, tachypnoea, mydriasis) and altered mental status (e.g. agitation, excitation, confusion) (see section 4.3 (MAO inhibitor drugs) and 4.4). Concomitant administration of drugs with an inhibitory effect on the central nervous system such as hypnotics, sedatives or anxiolytics, or the intake of alcohol, may lead to additive effects. If dextromethorphan is used in combination with mucolytics in patients with pre-existing respiratory tract diseases, such as cystic fibrosis and bronchiectasis, suffering from mucus hypersecretion, the reduction of the cough reflex may lead to a (severe) accumulation of mucus. \u003cb\u003eCYP2D6 inhibitors\u003c\/b\u003e Dextromethorphan is metabolised by CYP2D6 and has extensive first pass metabolism. Concomitant use of strong inhibitors of the CYP2D6 enzyme can increase dextromethorphan concentrations in the body to levels many times higher than the normal value. This increases the patient's risk for toxic effects of dextromethorphan (agitation, confusion, tremor, insomnia, diarrhea, and respiratory depression) and for the development of serotonin syndrome. Potent inhibitors of CYP2D6 are fluoxetine, paroxetine, quinidine, terbinafine, cimetidine, ritonavir, berberine. In concomitant use with quinidine, plasma concentrations of dextromethorphan are increased up to 20-fold, resulting in increased adverse central nervous system effects of the agent. Amiodarone, flecainide and propafenone, sertraline, bupropion, methadone, cinacalcet, haloperidol, perphenazine and thioridazine also have similar effects on the metabolism of dextromethorphan. If concomitant use of CYP2D6 inhibitors and dextromethorphan is necessary, the patient should be monitored and the dose of dextromethorphan may need to be reduced.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eThere is insufficient data to establish the frequency of the listed effects\u003c\/u\u003e. \u003cb\u003e \u003ci\u003eImmune system disorders\u003c\/i\u003e \u003c\/b\u003e Hypersensitivity reactions (including anaphylactic reaction, angioedema, urticaria, pruritus, rash and erythema) \u003cb\u003e \u003ci\u003eMetabolism and nutrition disorders\u003c\/i\u003e \u003c\/b\u003e Reduced appetite \u003cb\u003e \u003ci\u003ePsychiatric disorders\u003c\/i\u003e \u003c\/b\u003e Hallucinations Dextromethorphan abuse and dependence \u003cb\u003e \u003ci\u003eNervous system disorders\u003c\/i\u003e \u003c\/b\u003e Drowsiness \u003cb\u003e \u003ci\u003eEar and labyrinth disorders\u003c\/i\u003e \u003c\/b\u003e Dizziness \u003cb\u003e \u003ci\u003eRespiratory, thoracic and mediastinal disorders\u003c\/i\u003e \u003c\/b\u003e Respiratory depression \u003cb\u003e \u003ci\u003eGastrointestinal disorders\u003c\/i\u003e \u003c\/b\u003e Nausea, vomiting, gastrointestinal disorders \u003cb\u003e \u003ci\u003eSystemic pathologies and conditions relating to the administration site\u003c\/i\u003e \u003c\/b\u003e Fatigue \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: http:\/\/www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSymptoms\u003c\/b\u003e In case of overdose, the known side effects may occur with greater frequency or severity: nausea, vomiting, visual disturbances and central nervous system disorders such as ataxia, dizziness, excitation, increased muscle tone, states of mental confusion, drowsiness, hypotension and tachycardia. In extreme cases, urinary retention and respiratory depression may occur. \u003cb\u003eTreatment\u003c\/b\u003e If necessary, resort to intensive medical care (in particular intubation, ventilation). Precautions may be necessary to safeguard heat loss and replenish fluids. Intravenous administration of naloxone can antagonize the effects of dextromethorphan on the central nervous system. If necessary, perform gastric lavage with \u003ci\u003estable circulation\u003c\/i\u003e. Do not administer centrally acting emetics.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNeo Borocillin Cough Lozenges should not be used during the first three months of pregnancy; in the following months the drug must be administered only in case of actual need and under the direct supervision of the doctor. Since the excretion of the drug in breast milk is not known and a respiratory depressive effect on the newborn cannot be excluded, Neo Borocillin Cough Lozenges is contraindicated during breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the product can cause drowsiness and\/or dizziness (especially in conjunction with the intake of alcohol or other medicines which can reduce reaction times), this must be taken into account by those who may drive motor vehicles or carry out operations requiring an intact level of vigilance.\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":51131342225735,"sku":"027081049","price":10.51,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-spa-neo-borocillina-tosse-10mg-1-2mg-20-pastiglie-farmacia-dottor-tili-1213792006.jpg?v=1767149267"},{"product_id":"fluibron-15mg-5ml-sciroppo-200ml","title":"Fluibron 15mg\/5ml syrup 200ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFluibron is indicated in the treatment of acute respiratory diseases characterized by dense and viscous hypersecretion.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eFluibron 15 mg\/5 ml syrup\u003c\/b\u003e 5 ml of syrup contains: Active ingredient: ambroxol hydrochloride 15 mg. Excipients: Sorbitol 1.5 g; Benzoic acid 6.5 mg. \u003cb\u003eFluibron Adults 30 mg granules for oral suspension \u003c\/b\u003e One sachet contains: Active ingredient: ambroxol hydrochloride 30 mg. Excipients: Orange granules on sorbitol 2998.0 mg (sorbitol: approximately 96%; Azo dye (E110 orange yellow S): approximately 0.02%-0.03%); Sodium saccharin 5 mg. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSyrup\u003c\/b\u003e: Sorbitol 70% non-crystallizable solution, Glycerol, Citric acid monohydrate, Sucralose, Benzoic acid, Natural raspberry flavour, Purified water. \u003cb\u003eGranules for oral suspension Adults\u003c\/b\u003e: Orange flavor granules on sorbitol (sorbitol, orange flavor, orange yellow (E110)), Mannitol, Citric acid monohydrate, Glycine, Gum arabic, Sodium saccharin, Colloidal anhydrous silica.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1; Severe hepatic and\/or renal alterations. Pediatric population The medicine is contraindicated in children under 2 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSyrup: Adults: initially 10 ml 3 times a day, subsequently 5 ml 3 times a day. Children from two to five years: 2.5 ml 3 times a day; over five years: 5 ml 3 times a day. At the beginning of treatment the dose can be increased or even doubled according to the doctor's opinion. 10ml = 30mg. The included measuring cup has graduated marks at 10 ml, 5 ml and 2.5 ml. Sachets Adults: initially 1 sachet Adults 3 times a day, in maintenance therapy 2 sachets Adults per day, dissolved in water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMucolytics can induce bronchial obstruction in children under 2 years of age. In fact, the drainage capacity of bronchial mucus is limited in this age group, due to the physiological characteristics of the respiratory tract. They should therefore not be used in children under 2 years of age (see section 4.3). Fluibron should be administered with caution in patients with peptic ulcers. Cases of serious skin reactions such as erythema multiforme, Stevens-Johnson syndrome (SJS)\/toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP) have been reported associated with the administration of ambroxol. If symptoms or signs of progressive skin rash are present (sometimes associated with blisters or mucosal lesions), treatment with ambroxol should be stopped immediately and a doctor should be consulted. The majority of these cases can be explained by the severity of the patient's underlying disease and\/or concomitant therapy. Additionally, during the early phase of Stevens-Johnson syndrome or TEN, patients may experience nonspecific flu-like prodromes such as fever, muscle aches, rhinitis, cough, and sore throat. Because of these misleading, nonspecific flu-like prodromes, symptomatic treatment with cough-and-cold medications may be instituted. Therefore, if new lesions of the skin or mucous membranes appear, it is necessary to immediately consult your doctor and discontinue treatment with ambroxol hydrochloride as a precaution. In the presence of mild or moderate renal insufficiency, Fluibron should be used only after consulting your doctor. As with any medicinal product with hepatic metabolism followed by renal elimination, accumulation of ambroxol metabolites generated in the liver may occur in severe renal insufficiency. \u003cu\u003eWarnings relating to some excipients of Fluibron\u003c\/u\u003e FLUIBRON granules for oral suspension contains: • sorbitol: this medicine contains 2,878.08 mg of sorbitol per sachet. Sorbitol is a source of fructose. This medicine must not be given to patients suffering from rare hereditary problems of fructose intolerance. It can cause gastrointestinal problems and have a mild laxative effect. • saccharin sodium: this medicine contains less than 1mmol (23mg) sodium per sachet, i.e. it is essentially sodium-free. • azo dye (E110 yellow orange S): may cause allergic reactions. FLUIBRON syrup contains: • sorbitol: this medicine contains 3,000 mg of sorbitol per 10 ml dose. Sorbitol is a source of fructose. This medicine must not be given to patients suffering from rare hereditary problems of fructose intolerance. It can cause gastrointestinal problems and have a mild laxative effect. This medicine contains 750 mg of sorbitol per 2.5 ml dose and 1,500 mg of sorbitol per 5 ml dose. Sorbitol is a source of fructose. This medicine must not be given to patients suffering from rare hereditary problems of fructose intolerance. It can cause gastrointestinal problems and have a mild laxative effect. • benzoic acid: this medicine contains 1.3mg\/ml benzoic acid.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFollowing the administration of ambroxol, the concentrations of antibiotics (amoxicillin, cefuroxime, erythromycin) in bronchopulmonary secretions and saliva are increased. No interactions with other medicinal products have been observed.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt the recommended doses the medicine is normally well tolerated. The following side effects were observed during therapy with ambroxol hydrochloride, with frequencies: Very common (≥1\/10); Common (≥1\/100 and \u003c1\/10); Uncommon (≥1\/1,000 and \u003c1\/100); Rare (≥1\/10,000 and \u003c1\/1,000); Very rare (\u003c1\/10,000); Not known (frequency cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003eImmune System Disorders - Adverse reaction: Hypersensitivity reactions. Frequency: Rare.\u003c\/p\u003e\n\u003cp\u003eImmune System Disorders - Adverse reaction: Anaphylactic reactions, including anaphylactic shock, angioedema and pruritus. Frequency: Not known.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Adverse reaction: Dysgeusia (e.g. alteration of the sense of taste). Frequency: Common.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Adverse reaction: Headache. Frequency: Rare.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Adverse reaction: Hypoesthesia of the oral cavity and pharynx. Frequency: Common.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Adverse reaction: Bronchial obstruction. Frequency: Not known.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Adverse reaction: Nausea. Frequency: Common.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Adverse reaction: Vomiting, diarrhea, dyspepsia and abdominal pain, dry mouth. Frequency: Uncommon.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Adverse reaction: Dry throat. Frequency: Not known.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Adverse reaction: Rash, urticaria Adverse skin reactions. Frequency: Rare.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Adverse reaction: serious (including erythema multiforme, Stevens-Johnson syndrome\/toxic epidermal necrolysis and acute generalized exanthematous pustulosis). Frequency: Not known.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e \u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reaction via the national reporting system at “https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse”.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known cases of overdose with Fluibron. The symptoms observed in cases of accidental overdose and\/or in cases of errors in administration of the medicinal product are consistent with the expected side effects of ambroxol hydrochloride at recommended doses and may require symptomatic treatment. Keep in mind that the patient has not ingested other medicines at the same time.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAmbroxol hydrochloride crosses the placental barrier. Animal studies have not shown any direct or indirect harmful effects on pregnancy, embryonic\/foetal development, parturition or postnatal development. Clinical studies and extensive clinical experience after the 28th week of pregnancy have shown no evidence of harmful effects on the fetus. However, it is recommended that you observe the usual precautions regarding the use of medicines during pregnancy. In particular, during the first trimester, the use of Fluibron is not recommended. Ambroxol hydrochloride is secreted into breast milk. Although no side effects on infants are expected, the use of Fluibron is not recommended in breastfeeding mothers.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere is no evidence of effects on the ability to drive or use machines.\u003c\/p\u003e","brand":"Chiesi","offers":[{"title":"Default Title","offer_id":51131377647943,"sku":"024596037","price":11.07,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/chiesi-farmaceutici-spa-fluibron-15mg-5ml-sciroppo-200ml-farmacia-dottor-tili-1213791851.jpg?v=1767140729"},{"product_id":"viscoflu-10-flaconcini-5ml","title":"Viscoflu 10 vials 5ml","description":"\u003cp\u003eThe \u003cstrong\u003eViscoflu 10 vials 5ml\u003c\/strong\u003e is a disposable medical device designed for the treatment of respiratory tract diseases characterized by dense and viscous hypersecretion. This sterile hypertonic saline solution is particularly suitable for conditions such as \u003cstrong\u003eacute bronchitis\u003c\/strong\u003e, \u003cstrong\u003echronic bronchitis\u003c\/strong\u003e and its exacerbations, \u003cstrong\u003epulmonary emphysema\u003c\/strong\u003e, \u003cstrong\u003emucoviscidosis\u003c\/strong\u003e, \u003cstrong\u003ebronchiectasis\u003c\/strong\u003e, \u003cstrong\u003erhinosinusitis\u003c\/strong\u003e e \u003cstrong\u003emidsecretory otitis\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThanks to its formulation, Viscoflu can be used in different ways to ensure effective therapeutic action. It can be \u003cstrong\u003enebulized\u003c\/strong\u003e with aerosol devices for inhalation, allowing the solution to directly reach the bronchial district. Furthermore, it is possible to instill it directly to wash the nasal and ear cavities, or at an endobronchial level via permanent tubes or a bronchoscope.\u003c\/p\u003e\n\n\u003cp\u003eThe composition of Viscoflu includes \u003cstrong\u003eN-acetylcysteine\u003c\/strong\u003e (300 mg) e \u003cstrong\u003esodium chloride\u003c\/strong\u003e (150 mg), supported by excipients such as sodium hydroxide, sodium edetate and water for injections. This combination of ingredients is designed to thin secretions, facilitating their expulsion and improving breathing.\u003c\/p\u003e\n\n\u003cp\u003eThe product is packaged in practical 5 ml vials, with a total of 10 vials per pack, ensuring simple and hygienic use. Viscoflu is an ideal solution for those looking for an effective and targeted treatment for respiratory problems, supported by the quality and reliability of \u003cstrong\u003ePharma Line Srl\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Viscoflu 10 vials 5ml used? What is it for?\u003c\/h3\u003e\u003cp\u003eDisposable sterile hypertonic saline solution (medical device), indicated as an adjuvant in respiratory tract diseases with dense and viscous hypersecretion (acute and chronic bronchitis, pulmonary emphysema, mucoviscidosis, bronchiectasis, rhinosinusitis, midsecretory otitis); it can be nebulized by aerosol or used for nasal and ear washes.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Viscoflu 10 vials 5ml contain?\u003c\/h3\u003e\u003cp\u003eN-acetylcysteine ​​(300 mg), Sodium chloride (150 mg).\u003cbr\u003eExcipients: sodium hydroxide, sodium edetate, water for injections.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Viscoflu 10 vials 5ml?\u003c\/h3\u003e\u003cp\u003eSterile solution which can be:\u003cbr\u003e- Nebulized with aerosol devices to be inhaled in order to reach the bronchial district.\u003cbr\u003e- Instilled directly for washing the nasal and ear cavities.\u003cbr\u003e- Instilled endobronchially via permanent tubes, bronchoscope, etc.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Viscoflu 10 vials 5ml?\u003c\/h3\u003e\u003cp\u003ePack containing 10 vials of 5 ml\u003c\/p\u003e","brand":"Pharma Line","offers":[{"title":"Default Title","offer_id":51131378368839,"sku":"934038276","price":14.06,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/pharma-line-srl-viscoflu-10-flaconcini-5ml-farmacia-dottor-tili-1213791721.jpg?v=1767140890"},{"product_id":"gastrotuss-sciroppo-500ml","title":"Gastrotuss syrup 500ml","description":"\u003cp\u003eThe \u003cstrong\u003eGastrotuss syrup 500ml\u003c\/strong\u003e is a CE medical device designed for the treatment of \u003cstrong\u003egastroesophageal reflux\u003c\/strong\u003e and\/or pharyngolaryngeal. This anti-reflux syrup is formulated to relieve symptoms associated with reflux, such as \u003cstrong\u003eacid or basic regurgitation\u003c\/strong\u003e, the \u003cstrong\u003eheartburn\u003c\/strong\u003e (heartburn), the feeling of \u003cstrong\u003ehypopharyngeal globe\u003c\/strong\u003e (foreign body in the throat), and the \u003cstrong\u003ecough\u003c\/strong\u003e. Furthermore, it is useful in cases of \u003cstrong\u003edysphonia\u003c\/strong\u003e (voice alteration) e \u003cstrong\u003enasopharyngeal inflammation\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThanks to its mechanical action, Gastrotuss helps to reduce the residence time of gastric contents in the stomach, favoring the re-epithelialization processes of the gastroesophageal and pharyngolaryngeal mucosa. Its formulation includes ingredients such as \u003cstrong\u003emagnesium alginate\u003c\/strong\u003e e \u003cstrong\u003esimethicone\u003c\/strong\u003e, known for their beneficial properties in treating reflux. The product is free of \u003cstrong\u003egluten and lactose\u003c\/strong\u003e, making it also suitable for those with food intolerances.\u003c\/p\u003e\n\n\u003cp\u003eGastrotuss syrup is available in a practical \u003cstrong\u003e500 ml bottle\u003c\/strong\u003e with measuring spoon, ideal for prolonged use and to ensure precise dosing. This product is particularly suitable for those looking for an effective and safe treatment for the symptoms of gastroesophageal reflux, improving the quality of daily life. Choose Gastrotuss for quick and long-lasting relief from the discomfort of reflux.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy use Gastrotuss syrup 500ml? What is it for?\u003c\/h3\u003e\u003cp\u003eThe \u003cstrong\u003eGastrotuss syrup 500ml\u003c\/strong\u003e is a CE medical device designed for the treatment of \u003cstrong\u003egastroesophageal reflux\u003c\/strong\u003e and\/or pharyngolaryngeal. This anti-reflux syrup is formulated to relieve symptoms associated with reflux, such as \u003cstrong\u003eacid or basic regurgitation\u003c\/strong\u003e, the \u003cstrong\u003eheartburn\u003c\/strong\u003e (heartburn), the feeling of \u003cstrong\u003ehypopharyngeal globe\u003c\/strong\u003e (foreign body in the throat), and the \u003cstrong\u003ecough\u003c\/strong\u003e. Furthermore, it is useful in cases of \u003cstrong\u003edysphonia\u003c\/strong\u003e (voice alteration) e \u003cstrong\u003enasopharyngeal inflammation\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Gastrotuss syrup 500ml contain?\u003c\/h3\u003e\u003cp\u003eMagnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis and Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, sodium methyl p-oxybenzoate, sodium propyl p-oxybenzoate, natural flavors, erythrosine (E127), purified water.\u003c\/p\u003e\u003cp\u003eWithout \u003cstrong\u003egluten and lactose\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Gastrotuss syrup 500ml?\u003c\/h3\u003e\u003cp\u003eShake vigorously before use. Adults and children over 12 years: 20 ml after main meals and at bedtime or according to different medical advice.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Gastrotuss syrup 500ml?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWarnings\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eDo not use the product in case of known hypersensitivity to the components of the product.\u003cbr\u003eTo take it during pregnancy or during the breastfeeding period, consult your doctor.\u003cbr\u003eThe product can be more or less viscous, without any deterioration in its quality.\u003cbr\u003eThe presence of natural substances can affect the organoleptic characteristics of the product; variations in color and\/or flavor can therefore be detected without any deterioration in its quality.\u003cbr\u003eIn case of adverse reactions, discontinue use of the product and consult your doctor.\u003cbr\u003eDo not exceed the recommended doses, follow the instructions for use.\u003cbr\u003eIt is advisable to leave an interval of at least one hour between taking Gastrotuss and taking medications.\u003cbr\u003eDo not use the product if the packaging is not intact or has been tampered with. Tampering and\/or lack of integrity of the packaging could compromise the safety requirements of the product itself.\u003cbr\u003eDo not use the product after the expiry date indicated on the package.\u003cbr\u003eKeep out of the sight and reach of children.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Gastrotuss syrup 500ml stored?\u003c\/h3\u003e\u003cp\u003eStore at temperatures not exceeding 30°C.\u003cbr\u003eClose the bottle tightly after use.\u003cbr\u003eThe expiry date refers to the product in intact packaging, correctly stored.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Gastrotuss syrup 500ml?\u003c\/h3\u003e\u003cp\u003e500 ml bottle with measuring spoon.\u003c\/p\u003e","brand":"Dmg Italia","offers":[{"title":"Default Title","offer_id":51131382923591,"sku":"900489360","price":18.1,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/d-m-g-italia-srl-gastrotuss-sciroppo-500ml-farmacia-dottor-tili-1213791701.png?v=1767144469"},{"product_id":"coryfin-2-8-mg-16-8-mg-24-pastiglie","title":"Coryfin 2.8 mg + 16.8 mg 24 tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic in the treatment of cough and hoarseness. Coryfin relieves local irritation and reduces phlegm, even in smokers.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eCoryfin 6.5 mg + 18 mg tablets\u003c\/u\u003e \u003cu\u003eActive ingredients\u003c\/u\u003e: menthol ethyl glycolate 6.5 mg; sodium ascorbate 18.0 mg equal to 16 mg of ascorbic acid (Vitamin C). \u003cu\u003eExcipients with known effects\u003c\/u\u003e: glucose 0.9 g, sucrose 1.1 g. \u003cu\u003eCoryfin 2.8 mg + 16.8 mg tablets\u003c\/u\u003e \u003cu\u003eActive ingredients\u003c\/u\u003e: menthol ethyl glycolate 2.8 mg; sodium ascorbate 16.8 mg equal to 15 mg of ascorbic acid (Vitamin C). \u003cu\u003eExcipients with known effects\u003c\/u\u003e: glucose 0.9 g, sucrose 1.1 g. \u003cu\u003eCoryfin 6.5 mg + 112.5 mg tablets\u003c\/u\u003e \u003cu\u003eActive ingredients\u003c\/u\u003e: menthol ethyl glycolate 6.5 mg; sodium ascorbate 112.5 mg equal to 100 mg of ascorbic acid (Vitamin C). \u003cu\u003eExcipients with known effects\u003c\/u\u003e: glucose 0.8 g, sucrose 1 g. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne tablet of Coryfin 6.5 mg + 18 mg contains: menthol-eucalyptol flavouring, citric acid, \u003cb\u003esucrose\u003c\/b\u003e, \u003cb\u003eglucose\u003c\/b\u003e. One tablet of Coryfin 2.8 mg + 16.8 mg contains: menthol, citric acid, lemon essence, \u003cb\u003esucrose\u003c\/b\u003e, \u003cb\u003eglucose\u003c\/b\u003e. One tablet of Coryfin 6.5 mg + 112.5 mg contains: menthol, mandarin flavour, citric acid, \u003cb\u003esucrose\u003c\/b\u003e, \u003cb\u003eglucose\u003c\/b\u003e.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e– Hypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. – Children up to 30 months of age. – Children with a history of epilepsy or febrile seizures.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e Coryfin 6.5 mg + 18 mg and Coryfin 2.8 mg + 16.8 mg: One tablet every 1–2 hours, up to a maximum of 8 tablets per day. Coryfin 6.5 mg + 112.5 mg: One tablet every 2–3 hours, up to a maximum of 6 tablets per day. \u003ci\u003ePediatric population\u003c\/i\u003e In children over 30 months halved doses. Do not exceed the indicated doses. The duration of treatment should not exceed 3 days.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis product contains terpene derivatives which, in excessive doses, can cause neurological disorders such as seizures in infants and children. Treatment must not be prolonged for more than 3 days due to the risks associated with the accumulation of terpene derivatives, such as camphor, cineole, niaouli, wild thyme, terpineol, terpine, citral, menthol and essential oils of pine needles, eucalyptus and turpentine (due to their lipophilic properties, the rate of metabolism and disposal is not known) in the tissues and brain, in particular neuropsychological disorders. A higher than recommended dose should not be used to avoid an increased risk of adverse drug reactions and disorders associated with overdose (see section 4.9). The product is flammable, it must not be brought near flames. \u003cb\u003eCoryfin contains glucose\u003c\/b\u003e. Patients suffering from rare problems of glucose-galactose malabsorption should not take this medicine. \u003cb\u003eCoryfin contains sucrose. \u003c\/b\u003ePatients suffering from rare problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. To be taken into consideration in people suffering from diabetes mellitus.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCoryfin must not be used concomitantly with other products (medicines or cosmetics) containing terpene derivatives, regardless of the route of administration (oral, rectal, cutaneous, nasal or inhalation).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn rare cases of sensitizing or irritating effects, suspend use and institute suitable therapy. \u003cu\u003ePediatric population\u003c\/u\u003e Due to the presence of menthol and in case of non-compliance with the recommended doses there may be a risk of convulsions in children and infants. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known effects of overdose. \u003cu\u003ePediatric population\u003c\/u\u003e In case of accidental oral intake or incorrect administration in newborns and children there may be a risk of neurological disorders. If necessary, administer appropriate symptomatic treatment in specialized treatment centers.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e There are no or limited data available on the use of menthol in pregnant women. Coryfin is not recommended during pregnancy and in women of childbearing potential who are not using contraceptive measures. \u003cb\u003eBreastfeeding\u003c\/b\u003e There is insufficient information on the excretion of menthol in breast milk. Coryfin should not be used during breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicine does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Sit Laboratorio Farmaceutico","offers":[{"title":"Default Title","offer_id":51730208260423,"sku":"012377089","price":7.35,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sit-laboratorio-farmac-srl-coryfin-2-8-mg-16-8-mg-24-pastiglie-farmacia-dottor-tili-1213791079.jpg?v=1767154308"},{"product_id":"vicks-medinait-0-5-0-25-20-mg-ml-180-ml-sciroppo","title":"Vicks Medinait 0.5 + 0.25 + 20 mg\/ml 180 ml syrup","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTreatment of cold and flu symptoms.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 ml of syrup contains: \u003cb\u003e \u003cu\u003eActive ingredients\u003c\/u\u003e \u003c\/b\u003e Dextromethorphan hydrobromide 0.05 g; Doxylamine succinate 0.025 g; Paracetamol 2 g. Excipients with known effects: sucrose, sodium, sodium benzoate, propylene glycol. For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePropylene glycol, sodium citrate, citric acid monohydrate, potassium sorbate, sodium benzoate, macrogol, sucrose, glycerol, anethole, quinoline yellow (E 104), brilliant blue FCF (E 133) and purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. - Children and adolescents under 12 years of age. - Asthma, diabetes, glaucoma, prostatic hypertrophy, stenosis of the gastrointestinal and urogenital system, epilepsy, severe liver disease or severe renal impairment. - Glucose-6-phosphate dehydrogenase deficiency and hemolytic anemia (due to the paracetamol content). - History of gastrointestinal haemorrhage or perforation due to previous treatment with medicinal products with anti-inflammatory, anti-pyretic and pain-relieving activity or history of recurrent peptic haemorrhage\/ulcer (two or more distinct episodes of demonstrated ulceration or bleeding). - Severe heart failure. Do not administer at the same time as or in the two weeks following therapy with MAO inhibitor antidepressant drugs.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003c\/i\u003e \u003cu\u003eAdults and adolescents over 12 years:\u003c\/u\u003e The recommended dose is 30 ml once a day. 30 ml contains 0.015 g of dextromethorphan hydrobromide, 0.0075 g of doxylamine succinate and 0.6 g of paracetamol. Do not exceed the recommended doses. \u003ci\u003eDuration of treatment\u003c\/i\u003e After 3 days of continuous use, in the absence of appreciable results, re-evaluate the clinical picture. \u003ci\u003eMethod of administration\u003c\/i\u003e Vicks MediNait should be taken before bedtime for a night's rest and on a full stomach. Use the measuring cup included in the package.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eKeep the bottle in the outer carton in order to protect the medicine from light. Any variation in the color of the syrup does not alter the quality of the product.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects can be minimized with the shortest possible treatment duration needed to control symptoms. Elderly people have a greater susceptibility to the onset of side effects. A chronic or persistent cough due to smoking, emphysema, asthma requires clinical evaluation. In case of irritating cough with significant mucus production, Vicks MediNait must be used with particular caution and after a careful risk-benefit assessment. High or prolonged doses of paracetamol, present in the product, can cause high-risk liver disease and even serious alterations to the kidney and blood. Paracetamol should be used with caution in subjects with renal or hepatic insufficiency, including those with non-cirrhotic alcoholic liver disease. The damage from overdose is greater in subjects suffering from alcoholic liver disease. Vicks MediNait must not be used with other products containing paracetamol or medicines with anti-inflammatory, anti-pyretic and pain-relieving properties. In the rare cases of allergic reactions, administration should be suspended and suitable treatment instituted. The use of antihistamines with ototoxic antibiotics can mask the first signs of ototoxicity, which can be perceived late, when the damage is irreversible. Vicks MediNait should be used with caution in patients with cardiovascular disease, hypertension and hyperthyroidism. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should only be treated with Vicks MediNait after careful consideration given the risk of fluid retention and edema. Alcohol intake during treatment should be avoided. \u003ci\u003eRisks arising from the concomitant use of sedative medicines such as benzodiazepines or related medicines\u003c\/i\u003e Concomitant use of Vicks MediNait and sedative medicines such as benzodiazepines, or related drugs, may cause sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing of sedative medicinal products should be limited to patients for whom alternative treatments are not possible. If the decision is made to prescribe Vicks MediNait together with sedative medicines, the duration of treatment should be as short as possible. Patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this regard, it is strongly recommended to inform patients and anyone caring for them (where applicable) so that they are aware of these symptoms (see section 4.5). Dextromethorphan can be habit-forming. Following prolonged use, patients may develop tolerance to the medicine, as well as mental and physical dependence. Patients with a tendency towards abuse or dependence should take Vicks MediNait for short periods and be carefully monitored. Cases of abuse and dependence on dextromethorphan have been reported. Caution is particularly recommended for adolescents and young adults, as well as in patients with a history of drug or psychoactive substance abuse. Serotonin syndrome Serotonergic effects, including the development of life-threatening serotonin syndrome, have been reported for dextromethorphan with concomitant administration of serotonergic agents, such as selective serotonin reuptake inhibitors (SSRIs), drugs that alter serotonin metabolism (including monoamine oxidase inhibitors [MAOIs]), and CYP2D6 inhibitors. Serotonin syndrome may include mental status changes, autonomic instability, neuromuscular abnormalities, and\/or gastrointestinal symptoms. If serotonin syndrome is suspected, treatment with Vicks Medinait should be discontinued. The concomitant use of medicinal products with anti-inflammatory, anti-pyretic and pain-relieving activity, including selective COX-2 inhibitors, should be avoided. Dextromethorphan is metabolised by hepatic cytochrome P450 2D6 (see section 5.2). The activity of this enzyme is genetically determined. Approximately 10% of the population slowly metabolizes CYP2D6. Exaggerated and\/or prolonged effects of dextromethorphan may occur in poor metabolizers and patients with concomitant use of CYP2D6 inhibitors. Caution is required in patients who are poor metabolisers of CYP2D6 or who use CYP2D6 inhibitors (see section 4.5). \u003cu\u003eElderly:\u003c\/u\u003e Elderly people have an increased frequency of adverse reactions to medicinal products with anti-inflammatory, anti-pyretic and pain-relieving activity, especially gastrointestinal bleeding and perforation, which can be fatal. \u003cu\u003eGastrointestinal bleeding, ulceration and perforation:\u003c\/u\u003e During treatment with all anti-inflammatory, anti-pyretic and pain-relieving medicinal products, gastrointestinal haemorrhage, ulceration and perforation, which may be fatal, have been reported at any time, with or without warning symptoms or previous history of serious gastrointestinal events. In patients with a history of ulcer, especially if complicated by haemorrhage or perforation (see section 4.3), the risk of gastrointestinal haemorrhage, ulceration or perforation is higher with increased doses of medicinal products with anti-inflammatory, anti-pyretic and pain-relieving activity. These patients should start treatment with the lowest available dose. The concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients and also for patients taking low doses of acetylsalicylic acid or other drugs that may increase the risk of gastrointestinal events (see below and section 4.5). Patients with a history of gastrointestinal toxicity, particularly the elderly, should report any gastrointestinal symptoms (especially gastrointestinal haemorrhage) even at the start of treatment. Caution should be exercised in patients taking concomitant medications that may increase the risk of ulceration or haemorrhage, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking Vicks MediNait, treatment should be discontinued. Medicines with anti-inflammatory, anti-pyretic and pain-relieving activity should be administered with caution in patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of medicinal products with anti-inflammatory, anti-pyretic and pain-relieving activity (see section 4.8). At the beginning of treatment patients appear to be at higher risk. Vicks MediNait should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. Invite the patient to contact the doctor before combining any other drug. Caution is advised if acetaminophen is administered concurrently with flucloxacillin due to the increased risk of high anion gap metabolic acidosis (HAGMA), particularly in patients with severe renal impairment, sepsis, malnutrition, and other sources of glutathione deficiency (e.g., chronic alcoholism), as well as in those using maximum daily doses of acetaminophen. Close monitoring, including measurement of urinary 5-oxoproline, is recommended. \u003cu\u003eImportant information about some excipients \u003c\/u\u003e Vicks MediNait contains 8.25 g of \u003cb\u003esucrose\u003c\/b\u003e per dose (equal to 30 ml). To be taken into consideration in people suffering from diabetes mellitus. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. This medicine contains approximately 75 mg of \u003cb\u003esodium\u003c\/b\u003e per dose (equal to 30 ml) equivalent to approximately 3.8% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult. Vicks MediNait contains 30 mg of \u003cb\u003esodium benzoate\u003c\/b\u003e per dose (equal to 30 ml). This medicine contains 3 g of \u003cb\u003epropylene glycol\u003c\/b\u003e per dose (equal to 30 ml). Clinical monitoring is required for patients with hepatic or renal insufficiency due to various adverse events attributed to propylene glycol such as renal dysfunction (acute tubular necrosis), acute kidney injury, and hepatic dysfunction. Although propylene glycol has not shown toxic effects on reproduction and development in animals or humans, it can reach the fetus and has been found in breast milk. As a consequence, the administration of propylene glycol to pregnant or breastfeeding patients should be considered on a case-by-case basis. Interference with serological tests The administration of paracetamol can interfere with the determination of uric acid (using the phosphotungstic acid method) and blood sugar (using the glucose-oxidase-peroxidase method).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eConcomitant administration with MAO inhibitor drugs is contraindicated (see section 4.3). Use with extreme caution and under strict control during chronic treatment with drugs that can cause the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example, rifampicin, cimetidine, antiepileptics such as glutethimide, phenobarbital, carbamazepine and alcohol) due to an increased risk of hepatotoxicity from paracetamol. The rate of absorption of paracetamol may be increased by metoclopramide or domperidone and the absorption may be reduced by cholestyramine. The anticoagulant effect of warfarin and other coumarin drugs can be strengthened by prolonged and regular use of paracetamol, increasing the risk of bleeding. Liver enzyme inducers (e.g. alcohol and antiepileptics) may increase the hepatotoxicity of paracetamol, particularly after an overdose. \u003ci\u003eCYP2D6 inhibitors\u003c\/i\u003e There is a possibility of interaction between dextromethorphan and medicinal products that inhibit the CYP2D6 isoenzyme such as SSRIs (e.g., fluoxetine, paroxetine). Dextromethorphan is metabolised by CYP2D6 and has extensive first pass metabolism. Concomitant use of strong inhibitors of the CYP2D6 enzyme can increase dextromethorphan concentrations in the body to levels many times higher than the normal value. This increases the patient's risk for toxic effects of dextromethorphan (agitation, confusion, tremor, insomnia, diarrhea, and respiratory depression) and for the development of serotonin syndrome. Potent inhibitors of CYP2D6 are fluoxetine, paroxetine, quinidine and terbinafine. During concomitant use with quinidine, plasma concentrations of dextromethorphan are increased up to 20-fold, resulting in increased adverse effects on the central nervous system of the agent. Amiodarone, flecainide and propafenone, sertraline, bupropion, methadone, cinacalcet, haloperidol, perphenazine and thioridazine also have similar effects on the metabolism of dextromethorphan. If concomitant use of CYP2D6 inhibitors and dextromethorphan is necessary, the patient should be monitored and the dose of dextromethorphan may need to be reduced. \u003ci\u003eDiuretics, ACE inhibitors and Angiotensin II antagonists:\u003c\/i\u003e Medicines with anti-inflammatory, anti-pyretic and pain-relieving activity can reduce the effect of diuretics and other antihypertensive drugs. In subjects with compromised renal function (for example dehydrated or elderly patients) co-administration with an ACE inhibitor or an angiotensin II antagonist may lead to a further deterioration of renal function. Hydration before initiating concomitant therapy and close monitoring of renal function after initiation of treatment are recommended. \u003ci\u003eCorticosteroids:\u003c\/i\u003e co-administration may increase the risk of gastrointestinal ulceration or haemorrhage (see section 4.4). \u003ci\u003eAnticoagulants:\u003c\/i\u003e Medicines with anti-inflammatory, anti-pyretic and pain-relieving activity may increase the effects of anticoagulants, such as warfarin (see section 4.4). \u003ci\u003eAntiplatelet agents and selective serotonin reuptake inhibitors (SSRIs):\u003c\/i\u003e co-administration may lead to an increased risk of gastrointestinal bleeding (see section 4.4). \u003ci\u003eMedicines with sedative action such as benzodiazepines or related medicines\u003c\/i\u003e The concomitant use of opioids and sedative medicines such as benzodiazepines, or related medicines, increases the risk of sedation, respiratory depression, coma and death due to additive CNS depressant effect. The dose and duration of concomitant use should be limited (see section 4.4). Caution should be exercised when paracetamol is used concomitantly with flucloxacillin as concomitant use has been associated with high anion gap metabolic acidosis, especially in patients with risk factors (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects are classified according to their frequency and listed in order of decreasing severity. The frequency of adverse reactions is defined using the following convention: Very common (≥1\/10); common (≥1\/100 to \u003c1\/10); uncommon (≥1\/1,000 to \u003c1\/100); rare (≥1\/10,000 to \u003c1\/1,000); very rare (\u003c1\/10,000), not known (frequency cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders - Frequency: Very rare. Side effects: thrombocytopenia, leukopenia, agranulocytosis, hemolytic anemia, neutropenia, pancytopenia, epistaxis, increased propensity for wound bleeding.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency: Rare. Side effects: hypersensitivity, anaphylactic shock, anaphylaxis, angioedema, laryngeal edema, bronchospasm.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Common. Side effects: drowsiness, headache, blurred vision, psychomotor impairment.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Rare. Side effects: dizziness, insomnia.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Not known. Side effects: psychomotor hyperactivity*.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Common. Side effects: dry mouth, constipation, gastric reflux.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Rare. Side effects: nausea, vomiting, abdominal pain, diarrhea.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Not known. Side effects: exacerbation of colitis and Crohn's disease (see section 4.4), peptic ulcer, gastrointestinal perforation or haemorrhage** (see section 4.4), gastritis, melena, haematemesis, ulcerative stomatitis, flatulence, dyspesia.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders - Frequency: Not known. Side effects: hepatitis, increased aminotransferases, jaundice, hepatic necrosis.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Rare. Side effects: skin rashes, urticaria, erythema, pruritus, fixed drug eruption.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Very Rare. Side effects: erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders - Frequency: Not known. Side effects: acute renal failure, interstitial nephritis, hematuria, anuria, urinary retention, dysuria.\u003c\/p\u003e\n\u003cp\u003e*Paradoxical stimulation of the central nervous system, especially in children **sometimes fatal, especially in elderly patients \u003cu\u003eClass side effects: \u003c\/u\u003e \u003ci\u003eAntihistamines\u003c\/i\u003e Asthenia, photosensitivity, convulsions (at high doses), breathing difficulties due to increased bronchial secretions, and, especially in the elderly, hypotension and rhythm disturbances (extrasystoles and tachycardia). \u003ci\u003eMedicines with anti-inflammatory, anti-pyretic and pain-relieving activity\u003c\/i\u003e Edema, hypertension and heart failure. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reaction via the national reporting system reported on the site https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn case of overdose, paracetamol can cause hepatic cytolysis, which can evolve towards massive and irreversible necrosis. \u003cu\u003eSymptoms and signs\u003c\/u\u003e \u003ci\u003eParacetamol:\u003c\/i\u003e Symptoms of paracetamol overdose in the first 24 hours are paleness, nausea, vomiting, anorexia and abdominal pain. Liver damage may occur 12 to 48 hours after ingestion. Abnormalities in glucose metabolism and metabolic acidosis may occur. In cases of severe poisoning, liver failure can progress to encephalopathy, coma and death. Acute renal failure with acute tubular necrosis can develop even in the absence of severe liver damage. Cardiac arrhythmias have been reported. Other symptoms may include CNS depression, cardiovascular effects, and kidney damage. \u003ci\u003eDextromethorphan or Doxylamine:\u003c\/i\u003e Symptoms such as excitation, mental confusion, convulsions and respiratory depression may occur following an overdose with doxylamine. Dextromethorphan overdose may be associated with nausea, vomiting, dystonia, agitation, confusion, drowsiness, stupor, nystagmus, cardiotoxicity (tachycardia, abnormal ECG including QTc interval prolongation), ataxia, toxic psychosis with visual hallucinations, hyperexcitability. In case of massive overdose, the following symptoms may be observed: coma, respiratory depression, convulsions. \u003cu\u003eManagement: \u003c\/u\u003e Immediate treatment is essential for the management of acetaminophen overdose. Despite the lack of significant early symptoms, patients should urgently go to hospital for immediate medical attention and any patient who has ingested approximately 7.5 g or more of paracetamol in the previous 4 hours should undergo gastric lavage. The administration of oral methionine or intravenous N-acetylcysteine ​​may be necessary, which may have a beneficial effect for up to at least 48 hours after the overdose. General supportive measures must be available. Activated charcoal may be administered to asymptomatic patients who have ingested overdoses of dextromethorphan within the previous hour. For patients who have ingested dextromethorphan and are sedated or comatose, naloxone, in doses usual for the treatment of opioid overdose, may be considered. Benzodiazepines may be used for seizures and benzodiazepines and external cooling measures for serotonin syndrome hyperthermia.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eData on the safety of use of Vicks MediNait during pregnancy and during breastfeeding are limited. Vicks MediNait during pregnancy and breastfeeding is not recommended. The use of should be considered only if the expected benefit to the mother outweighs the risk to the fetus or child. \u003ci\u003ePregnancy\u003c\/i\u003e The numerous data relating to the use of paracetamol during pregnancy do not indicate either malformative or fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used for as short a time as possible and as frequently as possible. Literature data do not show a proven increase in the frequency of malformations or other direct or indirect harmful effects on the fetus induced by dextromethorphan. Use during late pregnancy may expose the newborn to respiratory depression. Epidemiological studies do not indicate doxylamine-induced malformation toxicity. Given the anticholinergic and sedative activity of doxylamine, monitoring of the newborn is strongly recommended in case of use of Vicks MediNait close to birth. \u003ci\u003eBreastfeeding \u003c\/i\u003e Although it is excreted in breast milk, the use of paracetamol is compatible with breastfeeding. Dextromethorphan and doxylamine are not known to be excreted in breast milk.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVicks MediNait may affect the ability to drive and use machines. The product may cause drowsiness (especially in conjunction with the intake of alcohol or other medicines that can reduce reaction times), this must be taken into account by those who may drive motor vehicles or carry out operations requiring an intact level of vigilance, who will have to abstain from such tasks after taking the product.\u003c\/p\u003e","brand":"Procter \u0026 Gamble","offers":[{"title":"Default Title","offer_id":51730214027591,"sku":"024449062","price":14.56,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/procter-gamble-srl-vicks-medinait-0-5-0-25-20-mg-ml-180-ml-sciroppo-farmacia-dottor-tili-1213791347.jpg?v=1767156328"},{"product_id":"vicks-medinait-0-5-0-25-20-mg-ml-90-ml-sciroppo","title":"Vicks Medinait 0.5 + 0.25 + 20 mg\/ml 90 ml syrup","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTreatment of cold and flu symptoms.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 ml of syrup contains: \u003cb\u003e \u003cu\u003eActive ingredients\u003c\/u\u003e \u003c\/b\u003e Dextromethorphan hydrobromide 0.05 g; Doxylamine succinate 0.025 g; Paracetamol 2 g. Excipients with known effects: sucrose, sodium, sodium benzoate, propylene glycol. For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePropylene glycol, sodium citrate, citric acid monohydrate, potassium sorbate, sodium benzoate, macrogol, sucrose, glycerol, anethole, quinoline yellow (E 104), brilliant blue FCF (E 133) and purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. - Children and adolescents under 12 years of age. - Asthma, diabetes, glaucoma, prostatic hypertrophy, stenosis of the gastrointestinal and urogenital system, epilepsy, severe liver disease or severe renal impairment. - Glucose-6-phosphate dehydrogenase deficiency and hemolytic anemia (due to the paracetamol content). - History of gastrointestinal haemorrhage or perforation due to previous treatment with medicinal products with anti-inflammatory, anti-pyretic and pain-relieving activity or history of recurrent peptic haemorrhage\/ulcer (two or more distinct episodes of demonstrated ulceration or bleeding). - Severe heart failure. Do not administer at the same time as or in the two weeks following therapy with MAO inhibitor antidepressant drugs.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003c\/i\u003e \u003cu\u003eAdults and adolescents over 12 years:\u003c\/u\u003e The recommended dose is 30 ml once a day. 30 ml contains 0.015 g of dextromethorphan hydrobromide, 0.0075 g of doxylamine succinate and 0.6 g of paracetamol. Do not exceed the recommended doses. \u003ci\u003eDuration of treatment\u003c\/i\u003e After 3 days of continuous use, in the absence of appreciable results, re-evaluate the clinical picture. \u003ci\u003eMethod of administration\u003c\/i\u003e Vicks MediNait should be taken before bedtime for a night's rest and on a full stomach. Use the measuring cup included in the package.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eKeep the bottle in the outer carton in order to protect the medicine from light. Any variation in the color of the syrup does not alter the quality of the product.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects can be minimized with the shortest possible treatment duration needed to control symptoms. Elderly people have a greater susceptibility to the onset of side effects. A chronic or persistent cough due to smoking, emphysema, asthma requires clinical evaluation. In case of irritating cough with significant mucus production, Vicks MediNait must be used with particular caution and after a careful risk-benefit assessment. High or prolonged doses of paracetamol, present in the product, can cause high-risk liver disease and even serious alterations to the kidney and blood. Paracetamol should be used with caution in subjects with renal or hepatic insufficiency, including those with non-cirrhotic alcoholic liver disease. The damage from overdose is greater in subjects suffering from alcoholic liver disease. Vicks MediNait must not be used with other products containing paracetamol or medicines with anti-inflammatory, anti-pyretic and pain-relieving properties. In the rare cases of allergic reactions, administration should be suspended and suitable treatment instituted. The use of antihistamines with ototoxic antibiotics can mask the first signs of ototoxicity, which can be perceived late, when the damage is irreversible. Vicks MediNait should be used with caution in patients with cardiovascular disease, hypertension and hyperthyroidism. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should only be treated with Vicks MediNait after careful consideration given the risk of fluid retention and edema. Alcohol intake during treatment should be avoided. \u003ci\u003eRisks arising from the concomitant use of sedative medicines such as benzodiazepines or related medicines\u003c\/i\u003e Concomitant use of Vicks MediNait and sedative medicines such as benzodiazepines, or related drugs, may cause sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing of sedative medicinal products should be limited to patients for whom alternative treatments are not possible. If the decision is made to prescribe Vicks MediNait together with sedative medicines, the duration of treatment should be as short as possible. Patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this regard, it is strongly recommended to inform patients and anyone caring for them (where applicable) so that they are aware of these symptoms (see section 4.5). Dextromethorphan can be habit-forming. Following prolonged use, patients may develop tolerance to the medicine, as well as mental and physical dependence. Patients with a tendency towards abuse or dependence should take Vicks MediNait for short periods and be carefully monitored. Cases of abuse and dependence on dextromethorphan have been reported. Caution is particularly recommended for adolescents and young adults, as well as in patients with a history of drug or psychoactive substance abuse. Serotonin syndrome Serotonergic effects, including the development of life-threatening serotonin syndrome, have been reported for dextromethorphan with concomitant administration of serotonergic agents, such as selective serotonin reuptake inhibitors (SSRIs), drugs that alter serotonin metabolism (including monoamine oxidase inhibitors [MAOIs]), and CYP2D6 inhibitors. Serotonin syndrome may include mental status changes, autonomic instability, neuromuscular abnormalities, and\/or gastrointestinal symptoms. If serotonin syndrome is suspected, treatment with Vicks Medinait should be discontinued. The concomitant use of medicinal products with anti-inflammatory, anti-pyretic and pain-relieving activity, including selective COX-2 inhibitors, should be avoided. Dextromethorphan is metabolised by hepatic cytochrome P450 2D6 (see section 5.2). The activity of this enzyme is genetically determined. Approximately 10% of the population slowly metabolizes CYP2D6. Exaggerated and\/or prolonged effects of dextromethorphan may occur in poor metabolizers and patients with concomitant use of CYP2D6 inhibitors. Caution is required in patients who are poor metabolisers of CYP2D6 or who use CYP2D6 inhibitors (see section 4.5). \u003cu\u003eElderly:\u003c\/u\u003e Elderly people have an increased frequency of adverse reactions to medicinal products with anti-inflammatory, anti-pyretic and pain-relieving activity, especially gastrointestinal bleeding and perforation, which can be fatal. \u003cu\u003eGastrointestinal bleeding, ulceration and perforation:\u003c\/u\u003e During treatment with all anti-inflammatory, anti-pyretic and pain-relieving medicinal products, gastrointestinal haemorrhage, ulceration and perforation, which may be fatal, have been reported at any time, with or without warning symptoms or previous history of serious gastrointestinal events. In patients with a history of ulcer, especially if complicated by haemorrhage or perforation (see section 4.3), the risk of gastrointestinal haemorrhage, ulceration or perforation is higher with increased doses of medicinal products with anti-inflammatory, anti-pyretic and pain-relieving activity. These patients should start treatment with the lowest available dose. The concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients and also for patients taking low doses of acetylsalicylic acid or other drugs that may increase the risk of gastrointestinal events (see below and section 4.5). Patients with a history of gastrointestinal toxicity, particularly the elderly, should report any gastrointestinal symptoms (especially gastrointestinal haemorrhage) even at the start of treatment. Caution should be exercised in patients taking concomitant medications that may increase the risk of ulceration or haemorrhage, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking Vicks MediNait, treatment should be discontinued. Medicines with anti-inflammatory, anti-pyretic and pain-relieving activity should be administered with caution in patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of medicinal products with anti-inflammatory, anti-pyretic and pain-relieving activity (see section 4.8). At the beginning of treatment patients appear to be at higher risk. Vicks MediNait should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. Invite the patient to contact the doctor before combining any other drug. Caution is advised if acetaminophen is administered concurrently with flucloxacillin due to the increased risk of high anion gap metabolic acidosis (HAGMA), particularly in patients with severe renal impairment, sepsis, malnutrition, and other sources of glutathione deficiency (e.g., chronic alcoholism), as well as in those using maximum daily doses of acetaminophen. Close monitoring, including measurement of urinary 5-oxoproline, is recommended. \u003cu\u003eImportant information about some excipients \u003c\/u\u003e Vicks MediNait contains 8.25 g of \u003cb\u003esucrose\u003c\/b\u003e per dose (equal to 30 ml). To be taken into consideration in people suffering from diabetes mellitus. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. This medicine contains approximately 75 mg of \u003cb\u003esodium\u003c\/b\u003e per dose (equal to 30 ml) equivalent to approximately 3.8% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult. Vicks MediNait contains 30 mg of \u003cb\u003esodium benzoate\u003c\/b\u003e per dose (equal to 30 ml). This medicine contains 3 g of \u003cb\u003epropylene glycol\u003c\/b\u003e per dose (equal to 30 ml). Clinical monitoring is required for patients with hepatic or renal insufficiency due to various adverse events attributed to propylene glycol such as renal dysfunction (acute tubular necrosis), acute kidney injury, and hepatic dysfunction. Although propylene glycol has not shown toxic effects on reproduction and development in animals or humans, it can reach the fetus and has been found in breast milk. As a consequence, the administration of propylene glycol to pregnant or breastfeeding patients should be considered on a case-by-case basis. Interference with serological tests The administration of paracetamol can interfere with the determination of uric acid (using the phosphotungstic acid method) and blood sugar (using the glucose-oxidase-peroxidase method).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eConcomitant administration with MAO inhibitor drugs is contraindicated (see section 4.3). Use with extreme caution and under strict control during chronic treatment with drugs that can cause the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example, rifampicin, cimetidine, antiepileptics such as glutethimide, phenobarbital, carbamazepine and alcohol) due to an increased risk of hepatotoxicity from paracetamol. The rate of absorption of paracetamol may be increased by metoclopramide or domperidone and the absorption may be reduced by cholestyramine. The anticoagulant effect of warfarin and other coumarin drugs can be strengthened by prolonged and regular use of paracetamol, increasing the risk of bleeding. Liver enzyme inducers (e.g. alcohol and antiepileptics) may increase the hepatotoxicity of paracetamol, particularly after an overdose. \u003ci\u003eCYP2D6 inhibitors\u003c\/i\u003e There is a possibility of interaction between dextromethorphan and medicinal products that inhibit the CYP2D6 isoenzyme such as SSRIs (e.g., fluoxetine, paroxetine). Dextromethorphan is metabolised by CYP2D6 and has extensive first pass metabolism. Concomitant use of strong inhibitors of the CYP2D6 enzyme can increase dextromethorphan concentrations in the body to levels many times higher than the normal value. This increases the patient's risk for toxic effects of dextromethorphan (agitation, confusion, tremor, insomnia, diarrhea, and respiratory depression) and for the development of serotonin syndrome. Potent inhibitors of CYP2D6 are fluoxetine, paroxetine, quinidine and terbinafine. During concomitant use with quinidine, plasma concentrations of dextromethorphan are increased up to 20-fold, resulting in increased adverse effects on the central nervous system of the agent. Amiodarone, flecainide and propafenone, sertraline, bupropion, methadone, cinacalcet, haloperidol, perphenazine and thioridazine also have similar effects on the metabolism of dextromethorphan. If concomitant use of CYP2D6 inhibitors and dextromethorphan is necessary, the patient should be monitored and the dose of dextromethorphan may need to be reduced. \u003ci\u003eDiuretics, ACE inhibitors and Angiotensin II antagonists:\u003c\/i\u003e Medicines with anti-inflammatory, anti-pyretic and pain-relieving activity can reduce the effect of diuretics and other antihypertensive drugs. In subjects with compromised renal function (for example dehydrated or elderly patients) co-administration with an ACE inhibitor or an angiotensin II antagonist may lead to a further deterioration of renal function. Hydration before initiating concomitant therapy and close monitoring of renal function after initiation of treatment are recommended. \u003ci\u003eCorticosteroids:\u003c\/i\u003e co-administration may increase the risk of gastrointestinal ulceration or haemorrhage (see section 4.4). \u003ci\u003eAnticoagulants:\u003c\/i\u003e Medicines with anti-inflammatory, anti-pyretic and pain-relieving activity may increase the effects of anticoagulants, such as warfarin (see section 4.4). \u003ci\u003eAntiplatelet agents and selective serotonin reuptake inhibitors (SSRIs):\u003c\/i\u003e co-administration may lead to an increased risk of gastrointestinal bleeding (see section 4.4). \u003ci\u003eMedicines with sedative action such as benzodiazepines or related medicines\u003c\/i\u003e The concomitant use of opioids and sedative medicines such as benzodiazepines, or related medicines, increases the risk of sedation, respiratory depression, coma and death due to additive CNS depressant effect. The dose and duration of concomitant use should be limited (see section 4.4). Caution should be exercised when paracetamol is used concomitantly with flucloxacillin as concomitant use has been associated with high anion gap metabolic acidosis, especially in patients with risk factors (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects are classified according to their frequency and listed in order of decreasing severity. The frequency of adverse reactions is defined using the following convention: Very common (≥1\/10); common (≥1\/100 to \u003c1\/10); uncommon (≥1\/1,000 to \u003c1\/100); rare (≥1\/10,000 to \u003c1\/1,000); very rare (\u003c1\/10,000), not known (frequency cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders - Frequency: Very rare. Side effects: thrombocytopenia, leukopenia, agranulocytosis, hemolytic anemia, neutropenia, pancytopenia, epistaxis, increased propensity for wound bleeding.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency: Rare. Side effects: hypersensitivity, anaphylactic shock, anaphylaxis, angioedema, laryngeal edema, bronchospasm.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Common. Side effects: drowsiness, headache, blurred vision, psychomotor impairment.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Rare. Side effects: dizziness, insomnia.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Not known. Side effects: psychomotor hyperactivity*.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Common. Side effects: dry mouth, constipation, gastric reflux.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Rare. Side effects: nausea, vomiting, abdominal pain, diarrhea.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Not known. Side effects: exacerbation of colitis and Crohn's disease (see section 4.4), peptic ulcer, gastrointestinal perforation or haemorrhage** (see section 4.4), gastritis, melena, haematemesis, ulcerative stomatitis, flatulence, dyspesia.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders - Frequency: Not known. Side effects: hepatitis, increased aminotransferases, jaundice, hepatic necrosis.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Rare. Side effects: skin rashes, urticaria, erythema, pruritus, fixed drug eruption.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Very Rare. Side effects: erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders - Frequency: Not known. Side effects: acute renal failure, interstitial nephritis, hematuria, anuria, urinary retention, dysuria.\u003c\/p\u003e\n\u003cp\u003e*Paradoxical stimulation of the central nervous system, especially in children **sometimes fatal, especially in elderly patients \u003cu\u003eClass side effects: \u003c\/u\u003e \u003ci\u003eAntihistamines\u003c\/i\u003e Asthenia, photosensitivity, convulsions (at high doses), breathing difficulties due to increased bronchial secretions, and, especially in the elderly, hypotension and rhythm disturbances (extrasystoles and tachycardia). \u003ci\u003eMedicines with anti-inflammatory, anti-pyretic and pain-relieving activity\u003c\/i\u003e Edema, hypertension and heart failure. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reaction via the national reporting system reported on the site https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn case of overdose, paracetamol can cause hepatic cytolysis, which can evolve towards massive and irreversible necrosis. \u003cu\u003eSymptoms and signs\u003c\/u\u003e \u003ci\u003eParacetamol:\u003c\/i\u003e Symptoms of paracetamol overdose in the first 24 hours are paleness, nausea, vomiting, anorexia and abdominal pain. Liver damage may occur 12 to 48 hours after ingestion. Abnormalities in glucose metabolism and metabolic acidosis may occur. In cases of severe poisoning, liver failure can progress to encephalopathy, coma and death. Acute renal failure with acute tubular necrosis can develop even in the absence of severe liver damage. Cardiac arrhythmias have been reported. Other symptoms may include CNS depression, cardiovascular effects, and kidney damage. \u003ci\u003eDextromethorphan or Doxylamine:\u003c\/i\u003e Symptoms such as excitation, mental confusion, convulsions and respiratory depression may occur following an overdose with doxylamine. Dextromethorphan overdose may be associated with nausea, vomiting, dystonia, agitation, confusion, drowsiness, stupor, nystagmus, cardiotoxicity (tachycardia, abnormal ECG including QTc interval prolongation), ataxia, toxic psychosis with visual hallucinations, hyperexcitability. In case of massive overdose, the following symptoms may be observed: coma, respiratory depression, convulsions. \u003cu\u003eManagement: \u003c\/u\u003e Immediate treatment is essential for the management of acetaminophen overdose. Despite the lack of significant early symptoms, patients should urgently go to hospital for immediate medical attention and any patient who has ingested approximately 7.5 g or more of paracetamol in the previous 4 hours should undergo gastric lavage. The administration of oral methionine or intravenous N-acetylcysteine ​​may be necessary, which may have a beneficial effect for up to at least 48 hours after the overdose. General supportive measures must be available. Activated charcoal may be administered to asymptomatic patients who have ingested overdoses of dextromethorphan within the previous hour. For patients who have ingested dextromethorphan and are sedated or comatose, naloxone, in doses usual for the treatment of opioid overdose, may be considered. Benzodiazepines may be used for seizures and benzodiazepines and external cooling measures for serotonin syndrome hyperthermia.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eData on the safety of use of Vicks MediNait during pregnancy and during breastfeeding are limited. Vicks MediNait during pregnancy and breastfeeding is not recommended. The use of should be considered only if the expected benefit to the mother outweighs the risk to the fetus or child. \u003ci\u003ePregnancy\u003c\/i\u003e The numerous data relating to the use of paracetamol during pregnancy do not indicate either malformative or fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used for as short a time as possible and as frequently as possible. Literature data do not show a proven increase in the frequency of malformations or other direct or indirect harmful effects on the fetus induced by dextromethorphan. Use during late pregnancy may expose the newborn to respiratory depression. Epidemiological studies do not indicate doxylamine-induced malformation toxicity. Given the anticholinergic and sedative activity of doxylamine, monitoring of the newborn is strongly recommended in case of use of Vicks MediNait close to birth. \u003ci\u003eBreastfeeding \u003c\/i\u003e Although it is excreted in breast milk, the use of paracetamol is compatible with breastfeeding. Dextromethorphan and doxylamine are not known to be excreted in breast milk.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVicks MediNait may affect the ability to drive and use machines. The product may cause drowsiness (especially in conjunction with the intake of alcohol or other medicines that can reduce reaction times), this must be taken into account by those who may drive motor vehicles or carry out operations requiring an intact level of vigilance, who will have to abstain from such tasks after taking the product.\u003c\/p\u003e","brand":"Procter \u0026 Gamble","offers":[{"title":"Default Title","offer_id":51730214060359,"sku":"024449050","price":9.02,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/procter-gamble-srl-vicks-medinait-0-5-0-25-20-mg-ml-90-ml-sciroppo-farmacia-dottor-tili-1213791346.jpg?v=1767156310"},{"product_id":"vicks-vaporub-100-g-unguento-inalatorio","title":"Vicks Vaporub 100 g inhalation ointment","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBalsamic treatment for diseases of the upper respiratory tract.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of ointment contains: \u003ci\u003eactive ingredients\u003c\/i\u003e: camphor 5 g; turpentine essential oil 5 g; menthol 2.75 g; eucalyptus essential oil 1.5 g. For the complete list of excipients see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThymol, cedarwood essential oil, white petrolatum.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Children up to 30 months of age. Administration through steam inhalation is contraindicated in children under 12 years of age. Children with a history of epilepsy or febrile convulsions. Generally contraindicated during pregnancy and breastfeeding (see section 4.6).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVicks Vaporub is contraindicated in children up to 30 months of age and vapor inhalation is contraindicated in children under 12 years (see section 4.3). Children must always be supervised. Vicks Vaporub ointment can be used in two ways: \u003cb\u003e1) Topical use (\u003cu\u003eadults and children over 30 months of age\u003c\/u\u003e)\u003c\/b\u003e Apply externally by first rubbing the chest, throat and back for 3 - 5 minutes and then spreading a thick layer on the chest. Repeat the treatment 2 times a day, one in the evening before going to sleep. Do not rub more than twice a day on the front of the chest, neck and back. Wear loose clothing to facilitate inhalation of vapours. \u003cb\u003e2) Inhalations (\u003cu\u003eadults and children over 12 years of age\u003c\/u\u003e)\u003c\/b\u003e Dissolve 2 teaspoons (2x5 ml) in half a liter of hot (not boiling) water and aspirate the released steam for a time not exceeding 10 minutes. To avoid the risk of serious burns, do not heat the mixture a second time or heat the mixture during inhalation (see section 4.4). Do not heat in the microwave. Do not exceed the recommended doses. The duration of treatment should not exceed 3 days. \u003ci\u003eTHE PRODUCT MUST NOT BE INGESTED\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUse the product according to the instructions. For external use only. Do not apply on wounds, abrasions and mucous membranes. Do not ingest or apply directly into the nostrils, eyes, mouth or face. Do not make a tight bandage. Do not use with hot compress or any type of heat. This product contains terpene derivatives which, in excessive doses, can cause neurological disorders such as seizures in infants and children. If symptoms persist, consult your doctor. The product should be used with caution or under medical suggestion by patients who present: • hypersensitivity reactions to perfumes or solvents; • convulsions or epilepsy (it is contraindicated in children with a history of epilepsy or febrile convulsions, see section 4.3); • Marked hypersensitivity of the respiratory tract including those conditions such as asthma and chronic obstructive pulmonary disease (COPD) as it can cause bronchospasm in these patients Inhalations: In order to avoid the risk of serious burns, do not use boiling water to prepare inhalations. Do not heat the mixture in the microwave and do not heat it again during and after use (see also section 6.6). The treatment must not be prolonged for more than 3 days due to the risks associated with the accumulation of terpene derivatives, such as \u003ci\u003ecamphor, cineol, niaouli, wild thyme, terpineol, terpine, citral, menthol and essential oils of pine needle, eucalyptus and turpentine\u003c\/i\u003e (due to their lipophilic properties the rate of metabolism and disposal is not known) in tissues and the brain, in particular neuropsychological disorders. A higher than recommended dose should not be used to avoid an increased risk of adverse drug reactions and disorders associated with overdose (see section 4.9). The product is flammable, it must not be brought near flames.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVicks Vaporub must not be used concomitantly with other products (medicines or cosmetics) containing terpene derivatives, regardless of the route of administration (oral, rectal, cutaneous, nasal or inhalation).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects may occur with the use of the medicine. Such effects may occur with the following frequency categories: Very common (≥1\/10) Common (≥1\/100; \u003c1\/10) Uncommon (≥1\/1,000; \u003c1\/100) Rare (≥1\/10,000; \u003c1\/1,000) Very rare (\u003c1\/10,000) Not known (frequency cannot be predicted from the available data). \u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e Not known: erythema or heat erythema (redness and sensation of heat in the skin caused by camphor and menthol, which have rubefacient effects), skin irritation, allergic dermatitis, itching. \u003cb\u003eImmune system disorders\u003c\/b\u003e Not known: hypersensitivity, symptom of respiratory allergy (dyspnea and cough). If such events occur, treatment should be suspended and the necessary clinical measures adopted. \u003cb\u003eEye pathologies\u003c\/b\u003e Not known: eye irritation (following topical use or inhalation). \u003ci\u003eSystemic pathologies and conditions relating to the administration site\u003c\/i\u003e: Due to the recommended route of administration, systemic exposure is very low and no undesirable effects due to systemic exposure have been observed. Not known: burns at the application site. Other adverse events may be linked to improper use of the product (ingestion), in this regard see paragraph 4.9. \u003cb\u003e \u003cu\u003ePediatric population\u003c\/u\u003e \u003c\/b\u003e Due to the presence of camphor, turpentine essential oil, menthol and eucalyptus essential oil and in case of non-compliance with the recommended doses there may be a risk of convulsions in children and infants. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: http:\/\/www.agenziafarmaco.gov.it\/content\/comesegnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn case of accidental oral intake or incorrect administration in newborns and children there may be a risk of neurological disorders. If necessary, administer appropriate symptomatic treatment in specialized treatment centers. Overdose can cause skin irritation. \u003cu\u003eImproper use\u003c\/u\u003e: Ingestion of the ointment may cause gastrointestinal symptoms such as vomiting and diarrhea. Treatment is symptomatic. Acute poisoning has been observed following significant accidental intake with nausea, vomiting, abdominal pain, headache, dizziness, feeling hot\/hot flashes, convulsions, respiratory depression and coma. Patients with severe gastrointestinal or neurologic symptoms of poisoning should be observed and treated symptomatically. Do not induce vomiting. A) Topical administration: in the event of application of an excessive dose topically, skin irritation reactions may rarely occur. In this case, remove the excess product with a paper towel and administer, if necessary, an adequate therapy for such reactions. B) Inhalation: the symptoms and treatment are the same as in case of accidental ingestion. C) Accidental ingestion: the symptoms are mainly due to the presence of camphor. These include gastrointestinal problems such as nausea, vomiting and diarrhea. In the event of significant overdose, effects on the central nervous system are possible, such as ataxia, convulsions and respiratory depression. Treatment must be symptomatic and gastric lavage can be performed if necessary. In the presence of serious symptoms of poisoning at a gastrointestinal or neurological level, the patient must immediately consult his doctor for appropriate therapeutic measures.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003cu\u003ePregnancy\u003c\/u\u003e \u003c\/b\u003e There are no or limited data available on the use of camphor, turpentine essential oil, menthol, eucalyptus essential oil in pregnant women. There are no clinical data relating to the use of the components of Vicks Vaporub during pregnancy. Camphor is able to cross the placenta but there is no data on the other components. Animal studies do not indicate harmful effects, direct or indirect, on pregnancy, embryonic\/foetal development, parturition or postnatal development (see section 5.3). However, Vicks Vaporub is not recommended during pregnancy and in women of childbearing potential who are not using contraceptive measures. The use of the drug during pregnancy should only take place after consulting your doctor. \u003cb\u003e \u003cu\u003eBreastfeeding\u003c\/u\u003e \u003c\/b\u003e There is insufficient information on the excretion of camphor, turpentine essential oil, menthol, eucalyptus essential oil in breast milk. There are no clinical data relating to the use of the components of Vicks Vaporub during breastfeeding. Vicks Vaporub should not be used during breastfeeding. The product, applied to the mother's chest during breastfeeding, poses a potential risk of apneic reflex in the breast-fed infant.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVicks Vaporub does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Procter \u0026 Gamble","offers":[{"title":"Default Title","offer_id":51730214125895,"sku":"021625076","price":16.67,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/procter-gamble-srl-vicks-vaporub-100-g-unguento-inalatorio-farmacia-dottor-tili-1213791344.jpg?v=1767156388"},{"product_id":"pino-caramelle-balsamiche-60-g-tosse","title":"Pine balsamic cough sweets 60 g","description":"\u003cp\u003e\n\u003cstrong\u003ePino balsamic sweets 60 g cough\u003c\/strong\u003e they are the ideal solution for those looking for a \u003cstrong\u003equick relief from cough\u003c\/strong\u003e and come on \u003cstrong\u003ecooling disorders\u003c\/strong\u003e. These \u003cstrong\u003ebalsamic candies\u003c\/strong\u003e are formulated with a mixture of \u003cstrong\u003eherbal extracts\u003c\/strong\u003e e \u003cstrong\u003enatural flavours\u003c\/strong\u003e, including essential oil of pumilio pine, myrtle, hyssop, juniper, eucalyptus, chamomile, menthol, benzoin and hawthorn. Theirs \u003cstrong\u003enormalizing functionality\u003c\/strong\u003e helps soothe irritated throat and promote the well-being of the respiratory tract, offering a \u003cstrong\u003eintense balsamic taste\u003c\/strong\u003e which gives a pleasant sensation of freshness.\n\u003c\/p\u003e\n\u003cp\u003e\nIdeal in case of \u003cstrong\u003ecold\u003c\/strong\u003e, \u003cstrong\u003esore throat\u003c\/strong\u003e, \u003cstrong\u003ebronchitis\u003c\/strong\u003e e \u003cstrong\u003einfluence\u003c\/strong\u003e, Pino balsamic sweets are suitable for both adults and teenagers and children, thanks to their natural composition and no colourings. Perfect to always carry with you, these sweets represent a valid help for \u003cstrong\u003erelieve cough\u003c\/strong\u003e and donate \u003cstrong\u003eimmediate throat relief\u003c\/strong\u003e during the cold season or in the presence of temperature changes. Choose Pino balsamic sweets to take care of your throat in a natural and tasty way.\n\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Pino balsamic sweets 60 g cough contain?\u003c\/h3\u003e\u003cp\u003esugar, glucose syrup, flavourings: essential oil of pumilio pine, myrtle, hyssop, juniper, eucalyptus, chamomile, menthol, benzoin tincture, hawthorn extract, natural flavourings, without colourings.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Pino balsamic sweets 60 g cough?\u003c\/h3\u003e\u003cp\u003eadults: 4-8 tablets per day;\u003cbr\u003eboys: 3-6 tablets per day;\u003cbr\u003echildren: 2-4 tablets per day.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Pino balsamic sweets 60 g cough?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eLegal warnings\u003c\/strong\u003e\u003cbr\u003eDo not exceed the recommended daily dose.\u003cbr\u003eKeep out of reach of children under three years of age.\u003cbr\u003eSupplements are not intended as substitutes for a varied and balanced diet and a healthy lifestyle.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Pino balsamic sweets 60 g cough?\u003c\/h3\u003e\u003cp\u003e60 g\u003c\/p\u003e","brand":"Fitobucaneve","offers":[{"title":"Default Title","offer_id":51749064212807,"sku":"900596432","price":6.88,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/fitobucaneve-srl-pino-caramelle-balsamiche-60-g-tosse-farmacia-dottor-tili-1213791120.jpg?v=1767161509"},{"product_id":"bisolvon-linctus-sciroppo-8-mg-5-ml-gusto-cioccolato-e-ciliegia-200-ml","title":"Bisolvon Linctus Syrup 8 mg\/5 ml Chocolate and Cherry Flavor 200 ml","description":"\u003cp\u003e\u003cstrong\u003eBisolvon Linctus 8 mg\/5 ml syrup\u003c\/strong\u003e it's a \u003cstrong\u003emucolytic drug based on bromhexine hydrochloride\u003c\/strong\u003e, indicated for the treatment of wet cough and catarrh in acute and chronic respiratory diseases. It works by thinning mucus deposits in the respiratory tract and facilitating expectoration, offering quick and effective relief.\u003c\/p\u003e\n\u003cp\u003eThe taste \u003cstrong\u003echocolate and cherry\u003c\/strong\u003e makes intake pleasant, facilitating therapeutic compliance even in children. The bottle gives \u003cstrong\u003e200ml\u003c\/strong\u003e it is suitable for \u003cstrong\u003eadults, adolescents and children aged 6 and over\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Bisolvon Linctus Syrup 8 mg\/5 ml Chocolate and Cherry Flavor 200 ml used? What is it for?\u003c\/h3\u003e\u003cp\u003eBisolvon contains bromhexine hydrochloride. Bisolvon is used in adults, adolescents and children aged 6 and over suffering from acute and chronic respiratory diseases, with cough and phlegm production. It acts as a mucolytic, i.e. it thins the mucus deposits in the respiratory tract and thus facilitates their elimination.\u003c\/p\u003e\n\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Bisolvon Linctus Syrup 8 mg\/5 ml Chocolate and Cherry Flavor 200 ml not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp\u003eDo not take\/give your child Bisolvon:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eif you\/your child is allergic to bromhexine or any of the other ingredients of this medicine (listed in section 6);\u003c\/li\u003e\n\u003cli\u003eif you are breastfeeding (see section 2. \"Pregnancy, breastfeeding and fertility\").\u003c\/li\u003e\n\u003c\/ul\u003e\u003cbr\u003e\u003cbr\u003e\u003cp\u003eLike all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may occur following the use of Bisolvon:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eUncommon\u003c\/strong\u003e (may affect up to 1 in 100 people): nausea, vomiting, diarrhea and upper abdominal pain.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRare\u003c\/strong\u003e (may affect up to 1 in 1,000 people): hypersensitivity reactions, rash (skin rash), urticaria (appearance of red spots on the skin).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNot known\u003c\/strong\u003e (frequency cannot be estimated from the available data): anaphylactic reactions, including anaphylactic shock, angioedema (rapidly developing swelling of the skin, subcutaneous tissues, mucosa and submucosal tissues) and pruritus; serious cutaneous adverse reactions (including erythema multiforme, Stevens-Johnson syndrome\/toxic epidermal necrolysis, and acute generalized exanthematous pustulosis); narrowing of the bronchi which makes breathing difficult (bronchospasm).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eThese side effects are generally temporary. When they occur, consult your doctor or pharmacist.\u003c\/p\u003e\u003cp\u003eIf you get any side effects, talk to your doctor or pharmacist, including any not listed in this leaflet. You can also report side effects directly via the national reporting system at: \u003ca href=\"https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\" target=\"_blank\"\u003ehttps:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/a\u003e.\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Bisolvon Linctus Syrup 8 mg\/5 ml Chocolate and Cherry Flavor 200 ml?\u003c\/h3\u003e\u003cp\u003e200ml\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Opella Healthcare","offers":[{"title":"Default Title","offer_id":54074594427207,"sku":"021004179","price":13.49,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/opella-healthcare-italy-srl-8-mg-5-ml-sciroppo-flacone-200-ml-farmacia-dottor-tili-1241421755.jpg?v=1780549632"},{"product_id":"fluimucil-300-mg-3-ml-soluzione-per-nebulizzatore-20-fiale","title":"Fluimucil 300 mg\/3 ml Nebulizer Solution 20 Vials","description":"\u003cp\u003e\u003cstrong\u003eFluimucil 300 mg\/3 ml solution for nebulizer\u003c\/strong\u003e it's a \u003cstrong\u003emucolytic drug based on N-acetylcysteine\u003c\/strong\u003e, produced by Zambon, indicated to facilitate the elimination of thick and viscous mucus from the respiratory tract. It is used in the treatment of acute and chronic bronchitis, pulmonary emphysema, cystic fibrosis and bronchiectasis.\u003c\/p\u003e\n\u003cp\u003eThe wording in \u003cstrong\u003enebulizer solution\u003c\/strong\u003e allows direct administration by inhalation through the aerosol, ensuring localized and rapid action on the respiratory tract. The package contains \u003cstrong\u003e20 single-dose vials of 3 ml\u003c\/strong\u003e, practices for continuous home therapy.\u003c\/p\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Fluimucil 300 mg\/3 ml Nebulizer Solution 20 Vials used? What is it for?\u003c\/h3\u003e\u003cp\u003eFluimucil contains the active ingredient N-acetylcysteine, which belongs to a group of medicines called mucolytics, used to facilitate the elimination of mucus from the respiratory tract.\u003c\/p\u003e\u003cp\u003eFluimucil is indicated for the treatment of respiratory system diseases characterized by an increase in the production of thick and viscous mucus (thick and viscous hypersecretion) such as:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003einflammation of the bronchi (acute bronchitis, chronic bronchitis and its exacerbations);\u003c\/li\u003e\n\u003cli\u003epathology of the pulmonary alveoli (pulmonary emphysema);\u003c\/li\u003e\n\u003cli\u003ecystic fibrosis (mucoviscidosis);\u003c\/li\u003e\n\u003cli\u003edilation of the bronchi (bronchiectasis).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eTalk to your doctor if you do not feel better or if you feel worse after 10 days.\u003c\/p\u003e\n\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Fluimucil 300 mg\/3 ml Nebulizer Solution 20 Vials not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp\u003eDo not take Fluimucil:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eif you are allergic to N-acetylcysteine, or any of the other ingredients of this medicine (listed in section 6);\u003c\/li\u003e\n\u003cli\u003eif the patient is a child under 2 years of age.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cbr\u003e\u003cbr\u003e\u003cp\u003eLike all medicines, this medicine can cause side effects, although not everybody gets them.\u003c\/p\u003e\u003cp\u003eFrequency not known (frequency of which cannot be established from the available data):\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eallergic reactions (hypersensitivity);\u003c\/li\u003e\n\u003cli\u003econtraction of bronchial muscles (bronchospasm);\u003c\/li\u003e\n\u003cli\u003erunny nose (rhinorrhea);\u003c\/li\u003e\n\u003cli\u003ebreathing difficulties (bronchial obstruction);\u003c\/li\u003e\n\u003cli\u003einflammation of the mouth (stomatitis);\u003c\/li\u003e\n\u003cli\u003evomit;\u003c\/li\u003e\n\u003cli\u003enausea;\u003c\/li\u003e\n\u003cli\u003eurticaria;\u003c\/li\u003e\n\u003cli\u003erash;\u003c\/li\u003e\n\u003cli\u003eitching.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eIn very rare cases, serious skin reactions have occurred (Stevens Johnson syndrome or Lyell syndrome). If you have changes in the mucous membranes or skin, stop taking the medicine and contact your doctor. Furthermore, a reduction in platelet aggregation (prolongation of bleeding time) is possible.\u003c\/p\u003e\u003cp\u003eIf you get any side effects, talk to your doctor or pharmacist, including any not listed in this leaflet. You can also report side effects directly via the national reporting system at: \u003ca href=\"https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\" target=\"_blank\"\u003ehttps:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/a\u003e.\u003c\/p\u003e\n\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Fluimucil 300 mg\/3 ml Nebulizer Solution 20 Vials?\u003c\/h3\u003e\u003cp\u003eTalk to your doctor or pharmacist before taking Fluimucil. Take this medicine with caution and always under your doctor's supervision in the following cases:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eif you suffer from an inflammatory disease of the bronchi called bronchial asthma. Stop taking Fluimucil immediately if you have contraction of the bronchial muscles (bronchospasm);\u003c\/li\u003e\n\u003cli\u003eif you have suffered from atopy and asthma in the past as you may develop allergic reactions;\u003c\/li\u003e\n\u003cli\u003eif you are intolerant to histamine as you may develop allergic reactions;\u003c\/li\u003e\n\u003cli\u003eif you suffer or have suffered from a stomach or intestinal problem called peptic ulcer, especially if you are taking other medicines that cause stomach problems (gastroinjurious medicines) together with Fluimucil.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eThis medicine may increase the volume of bronchial mucus (bronchial secretions), especially at the beginning of treatment. Therefore, if this occurs and you are unable to eliminate the bronchial secretions by coughing (expectorate), contact your doctor who will show you a method to eliminate the mucus (postural drainage or bronchoaspiration).\u003c\/p\u003e\u003cp\u003eAllergic (hypersensitivity\/anaphylactoid) reactions may occur with N-acetylcysteine. Checking for signs of an allergic reaction may be necessary.\u003c\/p\u003e\u003cp\u003eIf you notice a sulfur smell when you open the vial, or the solution turns pink in the opened vial or when you transfer the solution into the aerosol machine, do not worry because this does not indicate any alteration of the medicine.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eLaboratory tests:\u003c\/strong\u003e N-acetylcysteine can interfere with some blood and urine tests (colorimetric assay for the determination of salicylates and tests for determining ketones). Tell your doctor that you are taking this medicine before having these tests.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eChildren:\u003c\/strong\u003e Fluimucil should not be administered to children under 2 years of age, as it can block the bronchi and prevent normal breathing. The same warnings and precautions reported for adults apply to children and adolescents.\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Fluimucil 300 mg\/3 ml Nebulizer Solution 20 Vials?\u003c\/h3\u003e\u003cp\u003e20 vials of 3 ml\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Zambon","offers":[{"title":"Default Title","offer_id":54074594525511,"sku":"020582300","price":20.37,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/zambon-italia-srl-fluimucil-300-mg-3-ml-soluzione-per-nebulizzatore-20-fiale-farmacia-dottor-tili-1242512807.jpg?v=1780572312"}],"url":"https:\/\/www.dottortili.com\/en\/collections\/farmaci-e-sciroppi-per-la-tosse-secca-e-grassa.oembed?page=2","provider":"Farmacia Dottor Tili","version":"1.0","type":"link"}